isr20180930_10q.htm

0001437749-20-002375.txt : 20200212 0001437749-20-002375.hdr.sgml : 20200212 20200212081615 ACCESSION NUMBER: 0001437749-20-002375 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200212 DATE AS OF CHANGE: 20200212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Isoray, Inc. CENTRAL INDEX KEY: 0000728387 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411458152 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33407 FILM NUMBER: 20600202 BUSINESS ADDRESS: STREET 1: 350 HILLS STREET, STREET 2: SUITE 106 CITY: RICHLAND STATE: WA ZIP: 99354 BUSINESS PHONE: (509) 375-1202 MAIL ADDRESS: STREET 1: 350 HILLS STREET, STREET 2: SUITE 106 CITY: RICHLAND STATE: WA ZIP: 99354 FORMER COMPANY: FORMER CONFORMED NAME: IsoRay, Inc. DATE OF NAME CHANGE: 20050805 FORMER COMPANY: FORMER CONFORMED NAME: CENTURY PARK PICTURES CORP DATE OF NAME CHANGE: 19920703 10-Q 1 isr20191231_10q.htm FORM 10-Q isr20180930_10q.htm

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

	☑	QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934
		For the quarterly period ended December 31, 2019

	☐	Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
		For the transition period from __________ to ____________

Commission File No. 001-33407

ISORAY, INC.

(Exact name of registrant as specified in its charter)

Delaware	41-1458152
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

350 Hills St., Suite 106, Richland, Washington	99354
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (509) 375-1202

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	ISR	NYSE American

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒

Number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date:

Class	Outstanding as of February 11, 2020
Common stock, $0.001 par value	67,650,547

Table of Contents

ISORAY, INC.

Table of Contents

PART I	FINANCIAL INFORMATION

Item 1	Consolidated Unaudited Financial Statements	1

	Consolidated Balance Sheets (Unaudited)	1

	Consolidated Statements of Operations (Unaudited)	2

	Consolidated Statements of Cash Flows (Unaudited)	3

	Consolidated Statement of Changes in Shareholders' Equity (Unaudited)	4

	Notes to the Consolidated Unaudited Financial Statements	5

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3	Quantitative and Qualitative Disclosures About Market Risk	22

Item 4	Controls and Procedures	22

PART II	OTHER INFORMATION

Item 1	Legal Proceedings	22

Item 1A	Risk Factors	22

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3	Defaults Upon Senior Securities	23

Item 4	Mine Safety Disclosures	23

Item 5	Other Information	23

Item 6	Exhibits	23

Signatures		25

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1 – FINANCIAL STATEMENTS

Isoray, Inc. and Subsidiaries

Consolidated Balance Sheets (Unaudited)

(In thousands, except shares)

	December 31,			June 30,
	2019			2019
ASSETS
Current assets:
Cash and cash equivalents	$	3,180		$	5,326
Accounts receivable, net		1,409			1,154
Inventory		545			530
Prepaid expenses and other current assets		497			305

Total current assets		5,631			7,315

Property and equipment, net		1,736			1,609
Right of use asset, net (Note 9)		1,116			-
Restricted cash		181			181
Inventory, non-current		127			155
Other assets, net of accumulated amortization		142			162

Total assets	$	8,933		$	9,422

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
Accounts payable and accrued expenses	$	632		$	683
Lease liability (Note 9)		229			-
Accrued protocol expense		24			133
Accrued radioactive waste disposal		89			74
Accrued payroll and related taxes		203			89
Accrued vacation		163			142

Total current liabilities		1,340			1,121
Long-term liabilities:
Lease liability, non-current (Note 9)		889			-
Asset retirement obligation		563			621

Total liabilities		2,792			1,742
Commitments and contingencies (Note 7)

Shareholders' equity:
Preferred stock, $.001 par value; 7,000,000 shares authorized:
Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding		-			-
Common stock, $.001 par value; 200,000,000 shares authorized; 67,388,047 shares issued and outstanding		67			67
Additional paid-in capital		92,279			92,105
Accumulated deficit		(86,205	)		(84,492	)

Total shareholders' equity		6,141			7,680

Total liabilities and shareholders' equity	$	8,933		$	9,422

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Isoray, Inc. and Subsidiaries

Consolidated Statements of Operations (Unaudited)

(Dollars and shares in thousands, except for per-share amounts)

	Three months ended						Six months ended
	December 31,						December 31,
	2019			2018			2019			2018

Sales, net	$	2,206		$	1,904		$	4,521		$	3,466
Cost of sales		1,095			1,139			2,174			2,177
Gross profit		1,111			765			2,347			1,289

Operating expenses:
Research and development:
Proprietary research and development		277			395			510			789
Collaboration arrangement, net of reimbursement		-			19			-			45
Total research and development		277			414			510			834
Sales and marketing		666			702			1,481			1,351
(Gain) on equipment disposal		-			(23	)		-			(23	)
General and administrative		1,071			1,101			2,168			2,074
(Gain) on change in estimate of asset retirement obligation (Note 9)		-			-			(73	)		-
Total operating expenses		2,014			2,194			4,086			4,236

Operating loss		(903	)		(1,429	)		(1,739	)		(2,947	)

Non-operating income:
Interest income, net		6			15			26			25
Non-operating income		6			15			26			25

Net loss		(897	)		(1,414	)		(1,713	)		(2,922	)
Preferred stock dividends		(2	)		(2	)		(5	)		(5	)

Net loss applicable to common shareholders	$	(899	)	$	(1,416	)	$	(1,718	)	$	(2,927	)

Basic and diluted loss per share	$	(0.01	)	$	(0.02	)	$	(0.03	)	$	(0.04	)

Weighted average shares used in computing net loss per share:
Basic and diluted		67,388			67,331			67,388			66,743

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Isoray, Inc. and Subsidiaries

Consolidated Statements of Cash Flows (Unaudited)

(In thousands)

	Six months ended December 31,
	2019			2018

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,713	)	$	(2,922	)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense		77			65
Gain on equipment disposals		-			(23	)
Amortization of other assets		20			25
Accretion of asset retirement obligation		15			16
Gain on change in estimate of asset retirement obligation		(73	)		-
Share-based compensation		185			190
Changes in operating assets and liabilities:
Accounts receivable, net		(255	)		85
Inventory		13			53
Prepaid expenses and other current assets		(190	)		(20	)
Accounts payable and accrued expenses		(51	)		(195	)
Accrued protocol expense		(109	)		36
Accrued radioactive waste disposal		15			18
Accrued payroll and related taxes		114			(35	)
Accrued vacation		21			(19	)

Net cash used by operating activities		(1,931	)		(2,726	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment		(204	)		(225	)
Proceeds from sale of equipment		-			23
Proceeds from maturity of certificates of deposit		-			4,418
Purchases of and interest from U.S. Treasury Securities		-			(8,259	)

Net cash used by investing activities		(204	)		(4,043	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid		(11	)		(11	)
Proceeds from sales of common stock, pursuant to registered direct offering, net		-			7,381

Net cash (used) provided by financing activities		(11	)		7,370

Net increase (decrease) in cash, cash equivalents, and restricted cash		(2,146	)		601
Cash, cash equivalents, and restricted cash beginning of period		5,507			2,781
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD	$	3,361		$	3,382

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	$	3,180		$	3,201
Restricted cash	$	181		$	181
Total cash, cash equivalents, and restricted cash shown on the consolidated statements of cash flows	$	3,361		$	3,382

Non-cash investing and financing activities:
Recognition of operating lease liability and right of use asset	$	1,228		$	-
Warrants issued to placement agent of registered direct offering	$	-		$	163

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Isoray, Inc. and Subsidiaries

Consolidated Statement of Changes in Shareholders' Equity (Unaudited)

(In thousands, except shares)

	Series B Preferred Stock				Common Stock
	Shares		Amount		Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Total

Balances at June 30, 2018		59,065	$	-		56,331,147	$	56	$	84,322		$	(79,348	)	$	5,030

Issuance of common stock pursuant to registered direct offering, net						11,000,000		11		7,483						7,494
Share-based compensation										93						93
Net Loss													(1,508	)		(1,508	)

Balances at September 30, 2018		59,065	$	-		67,331,147	$	67	$	91,898		$	(80,856	)	$	11,109

Offering costs pursuant to registered direct offering, net										(116	)					(116	)
Payment of dividend to preferred shareholders										(11	)					(11	)
Share-based compensation										97						97
Net Loss													(1,414	)		(1,414	)

Balances at December 31, 2018		59,065	$	-		67,331,147	$	67	$	91,868		$	(82,270	)	$	9,665

	Series B Preferred Stock				Common Stock
	Shares		Amount		Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Total

Balances at June 30, 2019		59,065	$	-		67,388,047	$	67	$	92,105		$	(84,492	)	$	7,680

Share-based compensation										91						91
Net Loss													(816	)		(816	)

Balances at September 30, 2019		59,065	$	-		67,388,047	$	67	$	92,196		$	(85,308	)	$	6,955

Payment of dividend to preferred shareholders										(11	)					(11	)
Share-based compensation										94						94
Net Loss													(897	)		(897	)

Balances at December 31, 2019		59,065	$	-		67,388,047	$	67	$	92,279		$	(86,205	)	$	6,141

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Isoray, Inc.

Notes to the Unaudited Consolidated Financial Statements

1.	Basis of Presentation

The accompanying unaudited interim consolidated financial statements are those of Isoray, Inc., and its wholly-owned subsidiaries, referred to herein as “Isoray” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10-K for the year ended June 30, 2019.

The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading.

Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not be indicative of those which may be expected for a full year. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2020 will be 0%.

2.	New Accounting Standards

Accounting Standards Updates Adopted

In February 2016, the FASB issued ASU 2016-02 Leases (Subtopic 842), which requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update was effective for annual and interim reporting periods beginning after December 15, 2018 and early adoption was permitted. The ASU became effective for, and was adopted by, the Company in the first quarter of the fiscal year ending June 30, 2020. The Company elected the transition option to apply the new guidance at the effective date without adjusting comparative periods presented.

Accounting Standards Updates to Become Effective in Future Periods

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company is in the process of evaluating the impact the standard will have on its financial statements.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Table of Contents

3.	Loss per Share

Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding and does not include the impact of any potentially dilutive common stock equivalents. At December 31, 2019 and 2018, the calculation of diluted weighted average shares did not include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company’s net loss position.

Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of December 31, 2019 and 2018, were as follows (in thousands):

	December 31,
	2019		2018
Series B preferred stock		59		59
Common stock warrants		6,080		6,080
Common stock options		4,651		3,917
Total potential dilutive securities		10,790		10,056

Table of Contents

4.	Inventory

Inventory consisted of the following at December 31, 2019 and June 30, 2019 (in thousands):

	December 31,		June 30,
	2019		2019
Raw materials	$	372	$	333
Work in process		166		166
Finished goods		7		31
Total inventory, current	$	545	$	530

	December 31,		June 30,
	2019		2019
Enriched barium, non-current	$	116	$	117
Raw materials, non-current		11		38
Total inventory, non-current	$	127	$	155

Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not be consumed within an operating cycle. On August 25, 2017, the Company entered into a Consignment Agreement and related Services Agreement with MedikorPharma-Ural LLC to begin utilizing our enriched barium-130 carbonate inventory. The Company originally anticipated obtaining enough Cesium-131 under this arrangement to obtain over 4,000 curies of Cesium-131. During the three and six months ended December 31, 2019, the Company obtained no and 31 curies, respectively, of Cesium-131 under this agreement which has been used in production. At December 31, 2019, the Company estimates that the remaining enriched barium will result in 894 curies; approximately 60 of which will be obtained in the next twelve months and 834 will be obtained after December 31, 2020. There is no assurance as to whether the agreement will be terminated before this full amount is obtained and other supply sources are used.

5.	Property and Equipment

Property and equipment consisted of the following at December 31, 2019 and June 30, 2019 (in thousands):

	December 31,			June 30,
	2019			2019
Land	$	366		$	366
Equipment		3,873			3,825
Leasehold improvements		4,143			4,143
Other¹		801			645
Property and equipment		9,183			8,979
Less accumulated depreciation		(7,447	)		(7,370	)
Property and equipment, net	$	1,736		$	1,609

¹ Includes plant and equipment not placed in service which are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at December 31, 2019 and June 30, 2019 are costs associated with advance planning and design work on the Company’s new production facility of $207,000.

Table of Contents

6.	Share-Based Compensation

The following table presents the share-based compensation expense recognized for stock-based options during the three months ended December 31, 2019 and 2018 (in thousands):

	Three Months ended December 31,
	2019		2018
Cost of sales	$	8	$	10
Research and development expenses		19		18
Sales and marketing expenses		24		22
General and administrative expenses		43		47
Total share-based compensation	$	94	$	97

Table of Contents

The following table presents the share-based compensation expense recognized for stock-based options during the six months ended December 31, 2019 and 2018 (in thousands):

	Six Months ended December 31,
	2019		2018
Cost of sales	$	16	$	20
Research and development expenses		38		36
Sales and marketing expenses		49		44
General and administrative expenses		82		90
Total share-based compensation	$	185	$	190

As of December 31, 2019, total unrecognized compensation expense related to stock-based options was approximately $454,000 and the related weighted-average period over which it is expected to be recognized is approximately .91 years.

A summary of stock options within the Company’s share-based compensation plans as of December 31, 2019 was as follows (in thousands except for exercise prices and terms):

Weighted

Average

Number of

Exercise

Contractual

Intrinsic

As of December 31, 2019

Options

Price

Term (Years)

Value

Outstanding

4,651

.64

7.46

418

Vested and expected to vest

4,651

.64

7.46

418

Vested and exercisable

2,956

.74

6.71

172

There were no stock options exercised during the three months ended December 31, 2019 and 2018, respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.

There were 30,000 and 155,000 option awards granted with a fair value of approximately $11,000 and $52,000 during the three months ended December 31, 2019 and 2018, respectively.

There were no stock option awards which expired during the three months ended December 31, 2019 and 2018, respectively.

There were no and 32,000 stock option awards forfeited during the three months ended December 31, 2019 and 2018, respectively.

There were no stock options exercised during the six months ended December 31, 2019 and 2018, respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.

There were 40,000 and 237,500 option awards granted with a fair value of approximately $14,000 and $87,000 during the six months ended December 31, 2019 and 2018, respectively.

There were 8,250 and 10,000 stock option awards which expired during the six months ended December 31, 2019 and 2018, respectively.

There were 26,250 and 70,750 stock option awards forfeited during the six months ended December 31, 2019 and 2018, respectively.

Table of Contents

7.	Commitments and Contingencies

Isotope Purchase Agreement

In December 2015, the Company completed negotiations with The Open Joint Stock Company (located in Russia) for the purchase of Cesium-131 manufactured by the Institute of Nuclear Materials. The purchase agreement provided the Company with one year’s supply of Cesium-131. The original agreement was due to expire on March 31, 2017, but in December 2016 an addendum was signed extending it until December 31, 2017. On October 23, 2017, the Company, together with The Open Joint Stock Company, signed an addendum to the contract to include Cesium-131 manufactured at RIAR and extending it until December 31, 2018. On December 24, 2018, an addendum was signed extending the term of the supply contract through December 31, 2019 and modifying the volume of additional shipments of Cesium-131. Under the addendum, current pricing and volumes for Cesium-131 purchases remained in place until May 31, 2019. On July 11, 2019, another addendum was signed extending the pricing terms until August 4, 2019. On July 30, 2019, a new supply contract was signed with The Open Joint Stock Company for a term of August 2019 to December 2020 as the Company had purchased the maximum amount of Cesium-131 permitted under the prior agreement.

Table of Contents

8.	Fair Value Measurements

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands):

	Fair Value at December 31, 2019
	Total		Level 1		Level 2		Level 3
Cash and cash equivalents	$	3,180	$	3,180	$	-	$	-

	Fair Value at June 30, 2019
	Total		Level 1		Level 2		Level 3
Cash and cash equivalents	$	5,326	$	5,326	$	-	$	-

The Company’s cash and cash equivalent instruments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

9.	Leases

The Company maintains a production facility located at Applied Process Engineering Laboratory (APEL) in Richland, Washington. The APEL facility became operational in September 2007. The production facility has over 15,000 square feet and includes space for isotope separation, seed production, order dispensing, a clean room for assembly of our product offerings, and a dedicated shipping area. In 2015, the Company entered into a modification to the production facility lease that modified the requirement to return the facility to ground at the time of exit at Company discretion, exercised an extension in 2017 to increase the lease term to April 30, 2021, and reduced the required notice to terminate the lease early from twelve months to six months. In July 2019, the Company entered into another modification of the production facility lease that extends the term to April 20, 2026, maintains the current rental rate through April 2020, and provides for an eighteen month termination notice with an early termination penalty of up to $40,000 which decreases in the future beginning May 1, 2022.

Upon the adoption of Topic 842 on July 1, 2019, the Company recognized a right-of-use asset and lease liability of approximately $1.2 million. In determining the amount of the right-of-use asset and lease liability, we assumed the termination of the lease in April 2024 and incurring a termination penalty of $20,000. As of the date of adoption, the operating lease is included on the balance sheet at the present value of the future base payments discounted at a 6% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit discount rate. The weighted average remaining term and discount rate as of December 31, 2019 was 4.3 years and 6%, respectively.

For the three and six months ended December 31, 2019, our operating lease expense was approximately $73,000 and $147,000, respectively. Operating right-of-use asset amortization was approximately $56,000 and $111,000 during the three and six months ended December 31, 2019, respectively. Due to lease expense in excess of payments made, the lease liability decreased approximately $55,000 and $109,000 for the three and six months ended December 31, 2019.

The following table presents the future operating lease payments and lease liability included on the condensed balance sheet related to the Company’s operating lease as of December 31, 2019 (in thousands):

Year Ending June 30,
2020 (remaining nine months of the year)	$	145
2021		290
2022		290
2023		290
2024		237
Total		1,252
Less: Imputed Interest		(134	)
Total Lease Liability		1,118
Less current portion		(229	)
Non-current Lease Liability	$	889

Table of Contents

Asset Retirement Obligation

The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. In connection with the lease modification executed in July 2019, the ARO changed as follows (in thousands):

	Six months ended December 31,
	2019			2018
Beginning balance	$	621		$	590
Accretion of discount		15			16
Gain on change in ARO estimate due to lease modification		(73	)		-
Ending Balance	$	563		$	606

The original facility lease was scheduled to expire in the fourth quarter of fiscal year 2016. Upon the end of the original lease term, the initial asset retirement estimate was fully accreted and the related ARO asset was fully amortized. During the six months ended December 31, 2019, the Company extended the lease term an additional five years thus extending the time before asset retirement costs would be incurred. This resulted in a decrease in the ARO balance to a fair value of $555,000 and the Company recognized a gain on change in the estimate of $73,000 during the six months ended December 31, 2019. At the time of the lease extension, the undiscounted estimated asset retirement obligation was $704,000 discounted to fair value utilizing an interest rate of 5.1%.

10.	Shareholders’ Equity

On July 11, 2018, the Company completed the closing of a registered direct offering with several institutional and accredited investors (each an “Investor”) for the sale of a total of 11,000,000 shares of common stock of the Company (“Shares”) at a price per share of $0.75, for aggregate gross proceeds to the Company of $8.25 million. Cash expenses relating to this offering were approximately $0.75 million.

Table of Contents

In a concurrent private placement, the Company sold to each Investor, at no additional consideration, unregistered warrants to purchase up to the number of shares of common stock of the Company equal to 50% of such Investor’s Shares or a total of 5,500,000 shares, with an exercise price of $0.75 per share, exercisable from January 11, 2019 until January 11, 2024 (the “Investor Warrants”). The Company also issued warrants to purchase up to 330,000 shares of common stock of the Company, at an exercise price of $0.9375, exercisable from January 11, 2019 until July 10, 2023, to representatives of H.C. Wainwright & Co., LLC (“Wainwright”), the placement agent for the registered direct offering, as part of its compensation (the “Placement Agent Warrants” and together with the Investor Warrants, the “Warrants”).

The aggregate number of shares of our common stock issuable upon the exercise of the Warrants is 5,830,000 shares relating to this offering. We will receive gross proceeds from this offering solely to the extent any Warrants are exercised for cash.

11.

Contracts with Customers

We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms, and in most cases, prices for the products that we offer. However, these agreements do not obligate us to provide goods to the customer and there is no consideration promised to us at the onset of these arrangements. For customers without separate agreements, we have a standard list price established for all products and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is not controlling. Our performance obligations are established when a customer submits a purchase order or e-mail notification (in writing, electronically or verbally) for goods, and we accept the order. We identify performance obligations as the sale of our products and services as requested from our customers. We generally recognize revenue upon the satisfaction of these criteria when control of the product has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are not affected by contingent events that could impact the transaction price. We do not offer price concessions and do not accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do not have any material performance obligations where we are acting as an agent for another entity.

Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.

Sources of Revenue

We have identified the following revenues disaggregated by revenue source:

	1.	Domestic – direct sales of products and services.

	2.	International – direct sales of products and services.

During the three months ended December 31, 2019, the Company did not have any international revenue and had a nominal amount during the three months ended December 31, 2018.

During the six months ended December 31, 2019, the Company did not have any international revenue and had a nominal amount during the six months ended December 31, 2018.

For the three months ended December 31, 2019 and 2018, respectively, prostate brachytherapy comprised 89% of our revenue while other revenue comprised 11%.

For the six months ended December 31, 2019 and 2018, respectively, prostate brachytherapy comprised 89% of our revenue while other revenue comprised 11%.

Contract Balances

We incur obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate.

Warranty

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

Returns

Generally, we allow returns if not implanted and we are notified within a few weeks after satisfying our performance obligations of a return. Returns after shipment may result in a 50% restocking fee.

Significant Judgments in the Application of the Guidance in ASC 606

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

Table of Contents

Commissions and Contract Costs

We expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.

Practical Expedients

Our payment terms for sales direct to customers and distributors are substantially less than the one year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Shipping and Handling Charges

Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of sales.

Taxes Collected from Customers

As our products are used in another service and are exempt, to this point we have not collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities.

Concentration of Customers

One group of customers, facilities or physician practices has revenues that aggregate to greater than 10% of total Company sales. While the aggregate members of the group aggregate to more than 10% of total Company sales, no single member of the group has revenues greater than 10% of total Company sales. These facilities are serviced by the same physician group, one of whom is our Medical Director:

Six Months Ended December 31,

Facility

2019
% of
total

revenue

2018
% of
total

revenue

El Camino, Los Gatos, & other facilities

23.60

22.26

Table of Contents

ITEM 2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Caution Regarding Forward-Looking Information

In addition to historical information, this Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA.

All statements contained in this Form 10-Q, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future revenue, economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under Item 1A - Risk Factors beginning on page 22 below that may cause actual results to differ materially.

Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company’s views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Table of Contents

Critical Accounting Policies and Estimates

The discussion and analysis of the Company’s financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, management evaluates past judgments and estimates, including those related to bad debts, inventories, accrued liabilities, derivative liabilities and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies and related risks described in the Company’s annual report on Form 10-K as filed with the SEC on September 27, 2019 are those that depend most heavily on these judgments and estimates. As of December 31, 2019, there had been no material changes to any of the critical accounting policies contained therein.

Overview

Isoray is a brachytherapy device manufacturer with FDA clearance for a single medical device that can be delivered to the physician in multiple configurations as prescribed for the treatment of cancers in multiple body sites. The Company manufactures and sells this product as the Cesium-131 brachytherapy seed.

The brachytherapy seed utilizes Cesium-131, with a 9.7 day half-life, as its radiation source. The Company believes that it is the unique combination of the short half-life and the energy of the Cesium-131 isotope that are yielding the beneficial treatment results that have been published in peer reviewed journal articles and presented in various forms at conferences and tradeshows.

The Company has distribution agreements outside of the United States. These distributors are responsible for obtaining regulatory clearance to sell the Company’s products in their territories, with the support of the Company. As of the date of this Report, the Company has distributors in the Russian Federation and Peru with no reported revenues in these locations during the six months ended December 31, 2019.

The Company has a supply agreement with The Open Joint Stock Company <<Isotope>>, a Russian company, for the supply of Cesium-131, which was extended by an addendum through December 31, 2019 and the volume was also modified. Under the addendum, current pricing and volumes for Cesium-131 purchases remained in place until May 31, 2019. On July 11, 2019, another addendum was signed extending the pricing terms until August 4, 2019. On July 30, 2019, a new supply contract was signed with The Open Joint Stock Company for a term of August 2019 to December 2020 as the Company had purchased the maximum amount of Cesium-131 permitted under the prior agreement. The Company also has a consignment inventory agreement with MedikorPharma-Ural LLC (“Medikor”) to process the Company’s enriched barium at another nuclear reactor in Russia. The term of this consignment agreement began in November 2017 and is for 10 years. Our source of supply of Cesium-131 from Russia is historically produced using one of two nuclear reactors which supply the irradiation needed for Cesium-131 production. One of the Russian nuclear reactors was shut down from December 2017 until August 2018, and the other Russian nuclear reactor shut down in August 2019 and continues to be shut down in 2020 for an indeterminate period. As a result of these scheduled shutdowns, only one of the Company's historic Russian suppliers of Cesium-131 is available during these periods.

Results of Operations

Three months ended December 31, 2019 and 2018 (in thousands):

	Three months ended December 31,
	2019						2018						2019 - 2018
	Amount			% (a)			Amount			% (a)			% Change
Sales, net	$	2,206			100		$	1,904			100			16
Cost of sales		1,095			50			1,139			60			(4	)
Gross profit / (loss)		1,111			50			765			40			45

Operating expenses:
Research and development expenses - proprietary		277			12			395			21			(30	)
Research and development expenses – collaboration agreement, net of reimbursement		-			-			19			1			(100	)
Sales and marketing expenses		666			30			702			37			(5	)
(Gain) on equipment disposal		-			-			(23	)		(1	)		100
General and administrative expenses		1,071			49			1,101			58			(3	)
Total operating expenses		2,014			91			2,194			115			(8	)
Operating loss		(903	)		(41	)		(1,429	)		(75	)		(37	)

(a)

Expressed as a percentage of sales, net

Table of Contents

Six months ended December 31, 2019 and 2018 (in thousands):

	Six months ended December 31,
	2019						2018						2019 - 2018
	Amount			% (a)			Amount			% (a)			% Change
Sales, net	$	4,521			100		$	3,466			100			30
Cost of sales		2,174			48			2,177			63			0
Gross profit / (loss)		2,347			52			1,289			37			82

Operating expenses:
Research and development expenses - proprietary		510			11			789			23			(35	)
Research and development expenses – collaboration agreement, net of reimbursement		-			-			45			1			(100	)
Sales and marketing expenses		1,481			33			1,351			39			10
(Gain) on equipment Disposal		-			-			(23	)		(1	)		100
General and administrative expenses		2,168			48			2,074			60			5
(Gain) on change in estimate of asset retirement obligation		(73	)		(2	)		-			-			(100	)
Total operating expenses		4,086			90			4,236			122			(4	)
Operating loss		(1,739	)		(38	)		(2,947	)		(85	)		(41	)

(a)

Expressed as a percentage of sales, net

Sales

Sales, net for the three months ended December 31, 2019 increased 16% compared to the three months ended December 31, 2018. Sales, net for the six months ended December 31, 2019 increased 30% compared to the six months ended December 31, 2018. The Company’s sales personnel continued to bring on new accounts while also working with existing customers to increase their order volumes. The Blu Build™ loader, while in a limited market release, also contributed nominally to revenues during the three and six months ended December 31, 2019.

The sales breakdown between prostate and non-prostate applications is set forth below.

Three months ended December 31, 2019 and 2018 (in thousands):

	Three months ended December 31,
	2019				2018				2019 - 2018
	Amount		% (a)		Amount		% (a)		% Change
Prostate brachytherapy	$	1,964		89	$	1,695		89		16
Other sales		242		11		209		11		16
Sales, net		2,206		100		1,904		100		16

(a) Expressed as a percentage of sales, net

Six months ended December 31, 2019 and 2018 (in thousands):

	Six months ended December 31,
	2019				2018				2019 - 2018
	Amount		% (a)		Amount		% (a)		% Change
Prostate brachytherapy	$	4,037		89	$	3,071		89		31
Other sales		484		11		395		11		23
Sales, net		4,521		100		3,466		100		30

(a) Expressed as a percentage of sales, net

Table of Contents

Prostate Brachytherapy

Prostate sales growth of approximately 16% during the three months ended December 31, 2019 compared to the three months ended December 31, 2018 and approximately 31% during the six months ended December 31, 2019 compared to the six months ended December 31, 2018 was achieved due to a sustained focus on acquiring new accounts through physician training programs and marketing campaigns along with continued support of existing customers to help them grow their business. While in a limited market release, the Blu Build™ loader also contributed to prostate revenue growth as it was sold to new customers that desired the intraoperative loader system. Management believes that the product's design is now complete and ready for broader market release but there is no assurance as to the exact timing of release. This broader market release should contribute to revenue in a more meaningful way in the second half of fiscal 2020 but there is no assurance that this will occur. Management believes the timing of the holidays in November and particularly in December resulted in fewer sales as many customers failed to order our product for use during the last two weeks of December. The Company continues to update its website and other marketing collateral as well as attending tradeshows to acquire new leads for our sales personnel. Also, the website along with some social media campaigns have been used to educate patients about the availability of Cesium-131 as a treatment option.

Management believes continued growth in prostate brachytherapy revenues will be the result of physicians, payors, and patients increasingly considering overall treatment advantages including costs compared with non-brachytherapy treatments, better treatment outcomes and improvement in the quality of life for patients. We believe the trend to use brachytherapy in lieu of other options is starting to improve our performance as for the twelve month period ended December 31, 2019 the net new physician customer count increased 39% over the same period ended December 31, 2018 but there is no assurance as to how long this trend will continue.

Management believes increased pressure to deliver effective healthcare in both terms of outcome and cost drove treatment options, and accordingly drove the Company’s prostate revenues, during the three and six months ended December 31, 2019.

Other Sales

Other sales includes, but is not limited to, brain, lung, head/neck, gynecological treatments, and services. Other sales, net increased by approximately 16% for the three months ended December 31, 2019 compared to the three months ended December 31, 2018, and approximately 23% for the six months ended December 31, 2019 compared to the six months ended December 31, 2018. Initial applications for these other brachytherapy treatments are primarily used in recurrent cancer treatments or salvage cases that are generally difficult to treat aggressive cancers where other treatment options are either ineffective or unavailable.

Other brachytherapy treatments are subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of physicians. This causes the revenue created by these types of treatment applications to be more volatile and vary significantly from year to year. Additionally, with other brachytherapy surgical procedures there remains inconsistency and uncertainty regarding reimbursement for the procedures. This uncertain reimbursement for these new procedures will remain until specific coding and coverage policies are established, which could take years. Individual centers weigh the value of the procedure with their other treatment priorities on a patient by patient basis. Isoray believes that additional clinical data will begin to build a compelling argument to support reimbursement and increased adoption of its procedures; however, any growth will be inconsistent in the near term.

GammaTile™

For several years the Company has focused on many different applications of its Cesium-131 brachytherapy seeds in the cranial cavity to target many forms of brain cancer. Most recently, the Company has focused on using braided strand configurations and on being a contract manufacturer of GammaTile™ Therapy which is owned by GT Medical Technologies, Inc. (GT Med Tech). GammaTile™ Therapy uses biodegradable “tiles” to deliver Cesium-131 brachytherapy seeds into contact with cancerous tumors in the brain.

GammaTile™ Therapy was originally cleared for treating recurrent brain cancers. GT Med Tech filed a 510k with the FDA on an expanded indication of GammaTile™ Therapy to include treatment of newly diagnosed brain tumors with an application of Cesium-131. On January 27, 2020, GT Med Tech announced that it had received clearance from the FDA for an expanded indication that will allow patients of newly diagnosed malignant brain tumors to be treated by GammaTile™ Therapy. For the three and six months ended December 31, 2019, total revenues from sales to GT Med Tech were nominal. There were no sales to GT Med Tech for the three and six months ended December 31, 2018 as GT Med Tech began the limited market release of GammaTile™ Therapy in January 2019. While GT Med Tech continues to assure Isoray that its sales and marketing efforts will show steady improvements in sales there is no assurance this will occur.

Cost of sales

Cost of sales consists primarily of the costs of manufacturing and distributing the Company’s products.

Contributing to the three and six months ended December 31, 2019 and 2018 comparison were increased other direct materials purchases as well as increased labor to meet production demand due to improved sales. Although sales improved dramatically, the increase in cost of sales was only nominal primarily as a result of cost savings in isotope due to the termination of our domestic isotope supplier that occurred in fiscal year 2019 which resulted in lower isotope unit costs compared to the three and six months ended December 31, 2018 and more efficient isotope usage driven by the increased revenue that led to lower losses of isotope due to decay.

Gross Profit

Gross profit increased 45% for the three month period ended December 31, 2019 when compared to the three month period ended December 31, 2018. Contributing to the three and six months ended December 31, 2019 and 2018 gross profit comparison were increased sales and significantly lower isotope unit costs compared to the prior year comparable period, continued leverage of the fixed cost components within costs of sales, and more efficient isotope usage. The lower isotope unit costs are related to the previously discussed change in our supply chain made at the end of calendar year 2018.

Research and development

Research and development – proprietary

Proprietary research and development consists primarily of employee and third-party costs related to research and development activities.

Contributing to the three and six months ended December 31, 2019 and 2018 proprietary research and development comparison were a decrease in protocol expense primarily relating to a mutually-agreed termination of a grant agreement which resulted in a reversal of the accrual and a reduction in investment in the development of the Blu Build™ delivery system for real-time prostate brachytherapy.

Research and development – collaborative arrangement

Collaboration arrangement related costs are incurred, shared, and separately stated in connection with a collaborative research and development project with

GT Medical Technologies, Inc. (formerly known as GammaTile, LLC).

Table of Contents

Contributing to the three and six months ended December 31, 2019 and 2018 comparison were decreased costs due to the fact that payments being made pursuant to the collaborative arrangement with GT Med Tech were no longer necessary at the same level, as the collaborative arrangement primarily related to work involved in obtaining 510(k) clearance, which has now been obtained.

Sales and marketing expenses

Sales and marketing expenses consist primarily of the costs related to the internal and external activities of the Company’s sales, marketing and customer service functions of the Company. As the Company increasingly focuses on improving sales, the cost associated with marketing and greater staffing continues to increase.

Contributing to the three months ended December 31, 2019 and 2018 comparison was a decrease in travel costs as a tradeshow that occurred in October 2018 occurred in September 2019. Incentive compensation increased for the quarter ended December 31, 2019 in connection with the increase in revenue.

Contributing to the six months ended December 31, 2019 and 2018 comparison were increased incentive compensation in connection with the increase in revenue.

General and administrative expenses

General and administrative expenses consist primarily of the costs related to the executive, human resources/training, quality assurance/regulatory affairs, finance, and information technology functions of the Company.

General and administrative expenses decreased 3% to $1.07 million in the second quarter of fiscal 2020 compared to the second quarter of fiscal 2019. Contributing to the three months ended December 31, 2019 and 2018 comparison were decreases in legal fees and proxy solicitation fees associated with redomiciling the Company to Delaware in December 2018 and renewal fees of our CE Mark. These cost decreases were partially offset in the three months ended December 31, 2019 by increases associated with payroll due to increased headcount and insurance premiums.

Contributing to the six months ended December 31, 2019 and 2018 comparison were cost increases associated with payroll due to increased headcount, insurance premiums, and employee hiring expense. These costs were partially offset in the six months ended December 31, 2019 by decreases in legal fees and proxy solicitation fees associated with redomiciling the Company to Delaware in December 2018.

Liquidity and capital resources

The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has historically financed its operations through selling equity to investors. During the six months ended December 31, 2019 and 2018, the Company used existing cash reserves to fund its operations and capital expenditures (in thousands except current ratio):

	Six months
	ended December 31,
	2019			2018
Net cash used by operating activities	$	(1,931	)	$	(2,726	)
Net cash used by investing activities		(204	)		(4,043	)
Net cash (used) provided by financing activities		(11	)		7,370
Net (decrease) increase in cash and cash equivalents	$	(2,146	)	$	601

Table of Contents

	As of
	December 31, 2019		June 30, 2019
Working capital	$	4,291	$	6,194
Current ratio		4.20		6.53

Cash flows from operating activities

Net cash used by operating activities in the six months ended December 31, 2019 was primarily due to a net loss of approximately $1.71 million, net of approximately $224,000 in adjustments for non-cash activity such as depreciation and amortization expense, asset retirement obligation accretion, change in estimate of asset retirement obligation, and share-based compensation. Changes in operating assets and liabilities used approximately $442,000 to fund operating activities; increases in accounts receivable and prepaid expenses and other current assets and decreases in accounts payable and other accrued expenses and accrued protocol expense were partially offset by increases in accrued payroll and related taxes, accrued vacation, accrued radioactive waste disposal, and inventory.

Net cash used by operating activities in the six months ended December 31, 2018 was primarily due to a net loss of approximately $2.92 million, net of approximately $273,000 in adjustments for non-cash activity such as depreciation and amortization expense, gain on equipment disposal, asset retirement obligation accretion, and share-based compensation. Changes in operating assets and liabilities used approximately $77,000 to fund operating activities; decreases in accounts payable and accrued expenses, accrued payroll and related taxes, accrued vacation and an increase in prepaid expenses and other current assets were partially offset by decreases in accounts receivable and inventory and increases in accrued protocol expense and accrued radioactive waste disposal.

Cash flows from investing activities

Investing activities for the six months ended December 31, 2019 consisted of transactions related to the purchase of fixed assets, including automation of production processes.

Investing activities for the six months ended December 31, 2018 consisted of transactions related to the purchase and sale of fixed assets, including automation of production processes, as well as the purchase and subsequent maturity of U.S. Treasury Bills.

Management will continue to invest in technology and machinery that improves and streamlines production processes and to invest maturing U.S. Treasury Bills in low-risk investment opportunities that safeguard assets and provide greater assurance those resources will be liquid and available for business needs as they arise.

Cash flows from financing activities

Financing activities in the six months ended December 31, 2019 included payment of preferred dividends.

Financing activities in the six months ended December 31, 2018 included payment of preferred dividends and proceeds from sale of common stock, pursuant to registered direct offering, net (see note 10 to the financial statements).

Projected 2020 Liquidity and Capital Resources

Operating activities

Assuming no extraordinary expenses occur (whether operating or capital), if management is successful at implementing its strategy of renewed emphasis on driving the consumer to the prostate market, meets or exceeds its annual growth targets of twenty-five percent increase in revenue in fiscal 2020 and this annual growth continues, the Company anticipates reaching cash flow break-even in three to four years. The Company exceeded that target of twenty-five percent increased revenue in the six months ended December 31, 2019. There is no assurance that targeted sales growth will continue over the next three to four years. However, management is encouraged by the results for the six months ended December 31, 2019.

Capital expenditures

Management has completed the design of a future production and administration facility but has not determined when or if it will move ahead with construction. If financing is obtained and the facility constructed, it is believed that the new facility will have non-cash depreciation cost equal to or greater than the monthly rental cost of the current facility.

Management is reviewing and implementing changes in all aspects of production operations (including process automation), research and development, sales and marketing, and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems, and personnel are available to support and drive sales.

During the six months ended December 31, 2019, the Company invested approximately $187,000 in the automation production processes. Beginning in fiscal 2017 and continuing through December 31, 2019, the Company has invested approximately $1,027,000 in the automation of five production processes, four of which have been placed in service as of the end of December 31, 2019. Management expects to invest approximately $30,000 more over the next three months on the remaining automation projects, but there is no assurance that this amount will not be revised. This investment is designed to allow the Company to significantly increase the output of Cesium-131 brachytherapy seeds, while allowing the Company to decrease the labor costs related to seed production and also improving the overall safety of our operations.

Table of Contents

Financing activities

On July 11, 2018, the Company sold 11,000,000 shares of its common stock at a price of $0.75 per share, for aggregate gross proceeds of $8.25 million, pursuant to the registration statement on Form S-3 that became effective on November 23, 2015. There was no material change in the use of proceeds from our public offering as described in our prospectus supplement filed with the SEC pursuant to Rule 424(b) on July 11, 2018. Through December 31, 2019, the Company had used the net proceeds raised through the July 11, 2018 offering as described in the prospectus supplement. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.

Additionally, the Company issued to the purchasers unregistered warrants to purchase up to 5,500,000 shares of common stock. The warrants have an exercise price of $0.75 per share common stock, are exercisable commencing six months following the issuance date, and expire five and one-half years from the issuance date. If exercised for cash, future exercises of these warrants will provide additional capital to the Company.

On October 19, 2018, the Company filed a Form S-1 registration statement for the registration of 5,830,000 shares of common stock to be received by the investors and representatives of Wainwright on exercise of warrants issued in connection with the registered direct offering completed on July 11, 2018. The Company may receive up to $4,434,375 in gross proceeds solely to the extent the warrants are exercised for cash. The registration statement became effective on December 14, 2018, and the SEC file number assigned to the registration statement is 333-207909.

On January 22, 2020, the Company filed a Form S-3 registration which became effective on February 4, 2020, with the potential to register up to $80 million of equity securities.

As of December 31, 2019, the Company had cash and cash equivalents that totaled $3.18 million compared to $5.33 million at the end of fiscal 2019 ended June 30, 2019. The Company has zero long-term debt. The relatively larger decrease in cash, cash equivalents, and certificates of deposit this quarter compared to recent quarters was attributed to an increase in prepaid expenses in the quarter primarily related to premium payments for Director & Officer insurance as well as a large decrease in accounts payable compared to the prior quarter due to the timing of payments made. Management remains comfortable that our cash reserves are sufficient to fund operating activities through the remainder of calendar year 2020. Shareholders’ equity at the end of fiscal second quarter 2020 totaled $6.14 million versus $7.68 million at the end of fiscal 2019 ended June 30, 2019.

The Company expects to finance its future cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing shareholders. Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to shareholders.

Other Commitments and Contingencies

The Company presented its other commitments and contingencies in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019. There have been no material changes outside of the ordinary course of business in those obligations during the quarter ended December 31, 2019 other than those previously disclosed in Note 7 of the interim financial statements contained in this Form 10-Q.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and on various other factors the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results could therefore differ materially from those estimates if actual conditions differ from our assumptions.

Table of Contents

During the quarter ended December 31, 2019, there have been no changes to the critical accounting policies and estimates, as discussed in Part II, Item 7 of our Form 10-K for the year ended June 30, 2019.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and co-principal financial officers, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-14(c) and 15d-14(c) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of December 31, 2019. Based on that evaluation, our principal executive officer and our co-principal financial officers concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures are designed to provide a reasonable level of assurance that the objectives of the system will be met.

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

Nothing to disclose.

ITEM 1A – RISK FACTORS

A description of the risk factors associated with our business is included under “Risk Factors” contained in Part I, Item 1A of our Form 10-K for the year ended June 30, 2019, and is incorporated herein by reference. There have been no material changes in our risk factors since such filing, except for the following:

We Rely Heavily On Three Customers

For the six months ended December 31, 2019 approximately 40% of the Company’s revenues were dependent on three customers with approximately 24% being generated by one customer. The loss of any of these customers would have a material adverse effect on the Company’s revenues which may not be replaced by other customers particularly as these customers are in the prostate sector which is facing substantial competition from other treatments.

We May Need Additional Capital In The Future To Maintain Our NYSE American Listing.

Our Common Stock is currently listed on the NYSE American stock exchange which will consider delisting a company’s securities if, among other things, the company fails to maintain minimum stockholder’s equity. With our stockholder's equity anticipated to fall below $6 million for the quarter ended March 31, 2020, we may not be able to maintain our listing on the NYSE American unless we raise capital in the next three to six months. In the event that our common stock is delisted from the NYSE American, trading, if any, in the common stock would be conducted in the over-the-counter market. As a result, our shareholders would likely find it more difficult to dispose of, or to obtain accurate quotations as to the market value of, our common stock.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Table of Contents

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5 – OTHER INFORMATION

None

ITEM 6. EXHIBITS

(Except as otherwise indicated (a) all exhibits were previously filed, (b) all omitted exhibits are intentionally omitted, and (c) all documents referenced below were filed under SEC file number 001-33407.)

Exhibits:

3(i)		Certificate of Incorporation, incorporated by reference to Exhibit A of the Form Def 14A filed on November 9, 2018.

3(ii)		Bylaws, incorporated by reference to Exhibit C of the Form Def 14A filed on November 9, 2018.

10.1		Form of Amendment to Employment Agreement, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on December 17, 2019.

31.1*		Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer

31.2*		Rule 13a-14(a)/15d-14(a) Certification of Co-Principal Financial Officer

31.3*		Rule 13a-14(a)/15d-14(a) Certification of Co-Principal Financial Officer

32.1**		Section 1350 Certifications

Table of Contents

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: February 12, 2020
		ISORAY, INC., a Delaware corporation
		/s/ Lori A. Woods
		Lori A. Woods
		Chief Executive Officer (Principal Executive Officer)



		/s/ Jonathan Hunt
		Jonathan Hunt
		Chief Financial Officer (Co-Principal Financial Officer)



		/s/ Mark J. Austin
		Mark J. Austin Controller (Co-Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 ex_170380.htm EXHIBIT 31.1 ex_143069.htm

Exhibit 31.1

CERTIFICATION

I, Lori A. Woods, certify that:

I have reviewed this quarterly report on Form 10-Q of Isoray, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 12, 2020

	/s/ Lori A. Woods
	Lori A. Woods
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 ex_170381.htm EXHIBIT 31.2 ex_143070.htm

Exhibit 31.2

CERTIFICATION

I, Jonathan Hunt, certify that:

I have reviewed this quarterly report on Form 10-Q of Isoray, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 12, 2020

	/s/ Jonathan Hunt
	Jonathan Hunt
	Chief Financial Officer
	(Co-Principal Financial Officer)

EX-31.3 4 ex_170383.htm EXHIBIT 31.3 ex_143071.htm

Exhibit 31.3

CERTIFICATION

I, Mark J. Austin, certify that:

I have reviewed this quarterly report on Form 10-Q of Isoray, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 12, 2020

	/s/ Mark J. Austin
	Mark J. Austin
	Controller
	(Co-Principal Financial and Principal Accounting Officer)

EX-32.1 5 ex_170384.htm EXHIBIT 32.1 ex_143072.htm

Exhibit 32.1

Section 1350 Certifications

Pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Isoray, Inc., a Delaware corporation (the "Company"), hereby certify that:

To my knowledge, the Quarterly Report on Form 10-Q of the Company for the quarterly period ended December 31, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 12, 2020

	/s/ Lori A. Woods
	Lori A. Woods
	Chief Executive Officer (Principal Executive Officer)



	/s/ Jonathan Hunt
	Jonathan Hunt
	Chief Financial Officer (Co-Principal Financial Officer)



	/s/ Mark J. Austin
	Mark J. Austin
	Controller (Co-Principal Financial and Principal Accounting Officer)

EX-101.INS 6 isr-20191231.xml XBRL INSTANCE DOCUMENT false --06-30 Q2 2020 2019-12-31 10-Q 0000728387 67650547 Yes Yes false Non-accelerated Filer IsoRay, Inc. false true Common stock, $0.001 isr 203000 89000 5.10 704000 555000 207000 207000 0.5 73000 114000 -35000 -109000 36000 21000 -19000 55000 109000 163000 40000 56000 111000 P1Y 19000 45000 277000 395000 510000 789000 0.5 11000 52000 14000 87000 20000

632000

683000

24000

133000

163000

142000

7447000

7370000

92279000

92105000

20000

25000

93000

97000

91000

94000

116000

8000

10000

19000

18000

24000

22000

43000

47000

94000

97000

16000

20000

38000

36000

49000

44000

82000

90000

185000

190000

59000

6080000

4651000

3917000

10790000

10056000

15000

621000

590000

563000

606000

15000

16000

563000

621000

8933000

9422000

5631000

7315000

3180000

5326000

3201000

3180000

5326000

5507000

2781000

3361000

3382000

-2146000

601000

0.75

0.9375

5500000

330000

5830000

0.001

200000000

67388047

67000

0.89

0.11

0.236

0.2226

1095000

1139000

2174000

2177000

77000

65000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table presents the share-based compensation expense recognized for stock-based options during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> (in thousands): </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 20%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months<br /> ended December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales and marketing expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">47</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">97</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table presents the share-based compensation expense recognized for stock-based options during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> (in thousands): </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 20%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six Months<br /> ended December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales and marketing expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">185</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">190</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>total unrecognized compensation expense related to stock-based options was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$454,000</div> and the related weighted-average period over which it is expected to be recognized is approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.91</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">A summary of stock options within the Company’s share-based compensation plans as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>was as follows (in thousands except for exercise prices and terms):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 10%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Weighted</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Average</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Number of</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Exercise</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Contractual</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Intrinsic</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As of December 31, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Options</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Price</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Term (Years)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Value</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,651</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.64</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.46</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,651</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.64</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.46</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and exercisable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,956</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.74</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.71</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> stock options exercised during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">155,000</div> option awards granted with a fair value of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$52,000</div> during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> stock option awards which expired during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,000</div> stock option awards forfeited during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> stock options exercised during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">237,500</div> option awards granted with a fair value of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$87,000</div> during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,250</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000</div> stock option awards which expired during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,250</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70,750</div> stock option awards forfeited during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div></div>

11000

-0.01

-0.02

-0.03

-0.04

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Loss per Share</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include the impact of any potentially dilutive common stock equivalents. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the calculation of diluted weighted average shares did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company’s net loss position.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> were as follows (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,080</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,080</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,651</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,917</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total potential dilutive securities</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,790</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,056</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div>

454000

P332D

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0px" cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div></div></div> </td> <td style="vertical-align: top; width: 92%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value at December 31, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,180</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,180</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"> </div></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value at June 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,326</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,326</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company’s cash and cash equivalent instruments are classified within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> of the fair value hierarchy because they are valued using quoted market prices.</div></div>

23000

1071000

1101000

2168000

2074000

1111000

765000

2347000

1289000

-51000

-195000

255000

-85000

-13000

-53000

15000

18000

190000

20000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt" border="0px"> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div></div></div> </td> <td style="vertical-align: top; width: 92%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Inventory</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Inventory consisted of the following at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 (</div>in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 63pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">372</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">333</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Work in process</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">166</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">166</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total inventory, current</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">545</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">530</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 63pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Enriched barium, non-current</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">116</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Raw materials, non-current</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total inventory, non-current</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">127</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">155</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be consumed within an operating cycle. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 25, 2017, </div>the Company entered into a Consignment Agreement and related Services Agreement with MedikorPharma-Ural LLC to begin utilizing our enriched barium-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">130</div> carbonate inventory. The Company originally anticipated obtaining enough Cesium-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">131</div> under this arrangement to obtain over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000</div> curies of Cesium-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">131.</div> During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company obtained <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31</div> curies, respectively, of Cesium-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">131</div> under this agreement which has been used in production. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company estimates that the remaining enriched barium will result in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">894</div> curies; approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div> of which will be obtained in the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">834</div> will be obtained after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2020. </div>There is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance as to whether the agreement will be terminated before this full amount is obtained and other supply sources are used, nor is there assurance that the agreements with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party Cesium-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">131</div> suppliers will be executed.</div></div>

7000

31000

545000

530000

116000

117000

11000

38000

127000

155000

372000

333000

166000

6000

15000

26000

25000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 85%;"><div style="display: inline; font-weight: bold;">Year Ending June 30,</div></td> <td> </td> <td><div style="display: inline; font-weight: bold;"> </div></td> <td><div style="display: inline; font-weight: bold;"> </div></td> <td><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>2020 (remaining nine months of the year)</td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">145</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>2021</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">290</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>2022</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">290</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>2023</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">290</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>2024</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">237</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>Total</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,252</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>Less: Imputed Interest</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(134</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>Total Lease Liability</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,118</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>Less current portion</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(229</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;">)</td> </tr> <tr> <td>Non-current Lease Liability</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: thin solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">889</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;"> </td> </tr> </table></div>

1252000

237000

290000

145000

134000

P5Y

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt" border="0px"> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></div></div> </td> <td style="vertical-align: top; width: 92%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Leases</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company maintains a production facility located at Applied Process Engineering Laboratory (APEL) in Richland, Washington. The APEL facility became operational in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2007. </div>The production facility has over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,000</div> square feet and includes space for isotope separation, seed production, order dispensing, a clean room for assembly of our product offerings, and a dedicated shipping area. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company entered into a modification to the production facility lease that modified the requirement to return the facility to ground at the time of exit at Company discretion, exercised an extension in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> to increase the lease term to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 30, 2021, </div>and reduced the required notice to terminate the lease early from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2019, </div>the Company entered into another modification of the production facility lease that extends the term to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 20, 2026, </div>maintains the current rental rate through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2020, </div>and provides for an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">eighteen</div> month termination notice with an early termination penalty of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$40,000</div> which decreases in the future beginning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 1, 2022. </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><br /> Upon the adoption of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 1, 2019, </div>the Company recognized a right-of-use asset and lease liability of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.2</div></div> million. In determining the amount of the right-of-use asset and lease liability, we assumed the termination of the lease in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2024 </div>and incurring a termination penalty of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$20,000.</div> As of the date of adoption, the operating lease is included on the balance sheet at the present value of the future base payments discounted at a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6%</div> discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> provide an implicit discount rate. The weighted average remaining term and discount rate as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.3</div> years and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6%,</div> respectively.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>our operating lease expense was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$73,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$147,000,</div> respectively. Operating right-of-use asset amortization was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$56,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$111,000</div> during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>respectively. Due to lease expense in excess of payments made, the lease liability decreased approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$55,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$109,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><br /> The following table presents the future operating lease payments and lease liability included on the condensed balance sheet related to the Company’s operating lease as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 (</div>in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 85%;"><div style="display: inline; font-weight: bold;">Year Ending June 30,</div></td> <td> </td> <td><div style="display: inline; font-weight: bold;"> </div></td> <td><div style="display: inline; font-weight: bold;"> </div></td> <td><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>2020 (remaining nine months of the year)</td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">145</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>2021</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">290</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>2022</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">290</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>2023</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">290</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>2024</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">237</div></td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>Total</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,252</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>Less: Imputed Interest</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(134</div></td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>Total Lease Liability</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,118</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>Less current portion</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(229</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr> <td>Non-current Lease Liability</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: thin solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">889</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div style="text-align: center; width: 100%"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div> </div> <div style="text-align: left; width: 100%"> <div style="display: inline;"></div> </div> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Asset Retirement Obligation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. In connection with the lease modification executed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2019, </div>the ARO changed as follows (in thousands):</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: -9pt;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="6" style="text-align: center; border-bottom: thin solid rgb(0, 0, 0);">Six months ended December 31,</td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2" style="text-align: center;">2019</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center;">2018</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%;">Beginning balance</td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">621</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">590</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>Accretion of discount</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>Gain on change in ARO estimate due to lease modification</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(73</div></td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>Ending Balance</td> <td style="width: 1%; padding-bottom: 3px;"> </td> <td style="width: 1%; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">563</div></td> <td style="width: 1%; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"> </td> <td style="width: 1%; padding-bottom: 3px;"> </td> <td style="width: 1%; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div></td> <td style="width: 1%; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The original facility lease was scheduled to expire in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Upon the end of the original lease term, the initial asset retirement estimate was fully accreted and the related ARO asset was fully amortized. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company extended the lease term an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years thus extending the time before asset retirement costs would be incurred. This resulted in a decrease in the ARO balance to a fair value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$555,000</div> and the Company recognized a gain on change in the estimate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$73,000</div> during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019. </div>At the time of the lease extension, the undiscounted estimated asset retirement obligation was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$704,000</div> discounted to fair value utilizing an interest rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.1%.</div></div></div>

2792000

1742000

8933000

9422000

1340000

1121000

-11000

7370000

-204000

-4043000

-1931000

-2726000

-1713000

-2922000

-1508000

-1414000

-816000

-897000

-899000

-1416000

-1718000

-2927000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 8%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline;"><div style="display: inline; font-weight: bold;">New Accounting </div><div style="display: inline; font-weight: bold;">Standards</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Accounting Standards Updates Adopted</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> Leases (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>), which requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update was effective for annual and interim reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018 </div>and early adoption was permitted. The ASU became effective for, and was adopted by, the Company in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of the fiscal year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2020. </div>The Company elected the transition option to apply the new guidance at the effective date without adjusting comparative periods presented.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Accounting Standards Updates to Become Effective in Future Periods</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> Collaborative Arrangements (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">808</div>): Clarifying the Interaction Between Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">808</div> and Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606.</div> The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019, </div>with early adoption permitted. The Company is in the process of evaluating the impact the standard will have on its financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Other accounting standards that have been issued or proposed by FASB that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> require adoption until a future date are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to have a material impact on the consolidated financial statements upon adoption. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> discuss recent pronouncements that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</div></div>

6000

15000

26000

25000

2014000

2194000

4086000

4236000

-903000

-1429000

-1739000

-2947000

73000

147000

1200000

1118000

229000

889000

1200000

1116000

0.06

P4Y109D

142000

162000

89000

74000

11000

750000

204000

225000

8259000

2000

5000

0.001

7000000

5000000

59065

497000

305000

8250000

7381000

23000

4418000

366000

3873000

3825000

4143000

801000

645000

9183000

8979000

1736000

1609000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 63pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Land</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">366</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">366</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,873</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,825</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,143</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,143</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other<div style="display: inline; font-family:Times New Roman;font-size:8pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">1</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">645</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,183</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,979</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,447</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,736</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,609</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

1409000

1154000

277000

414000

510000

834000

181000

-86205000

-84492000

2206000

1904000

4521000

3466000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt" border="0px"> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div></div></div> </td> <td style="vertical-align: top; width: 92%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Contracts with Customers</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms, and in most cases, prices for the products that we offer. However, these agreements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> obligate us to provide goods to the customer and there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> consideration promised to us at the onset of these arrangements. For customers without separate agreements, we have a standard list price established for all products and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> controlling. Our performance obligations are established when a customer submits a purchase order or e-mail notification (in writing, electronically or verbally) for goods, and we accept the order. We identify performance obligations as the sale of our products and services as requested from our customers. We generally recognize revenue upon the satisfaction of these criteria when control of the product has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> affected by contingent events that could impact the transaction price. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> offer price concessions and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any material performance obligations where we are acting as an agent for another entity.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> further performance obligations.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Sources of Revenue</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have identified the following revenues disaggregated by revenue source:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: middle; width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></td> <td style="vertical-align: top; width: 95%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Domestic – direct sales of products and services.</td> </tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: middle; width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: top; width: 95%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: middle; width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></td> <td style="vertical-align: top; width: 95%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">International – direct sales of products and services.</td> </tr> </table> <div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any international revenue and had a nominal amount during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any international revenue and had a nominal amount during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively, prostate brachytherapy comprised <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">89%</div></div> of our revenue while other revenue comprised <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11%</div>.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively, prostate brachytherapy comprised <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">89%</div></div> of our revenue while other revenue comprised <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11%</div>.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Contract Balances</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We incur obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Warranty</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our general product warranties do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> extend beyond an assurance that the product delivered will be consistent with stated specifications and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include separate performance obligations.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Returns</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Generally, we allow returns if <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> implanted and we are notified within a few weeks after satisfying our performance obligations of a return. Returns after shipment <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> restocking fee.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Significant Judgments in the Application of the Guidance in ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div></div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">There are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div style="text-align: center; width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div> </div> <div style="text-align: left; width: 100%"> <div style="display: inline;"></div> </div> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Commissions and Contract Costs</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Practical Expedients</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our payment terms for sales direct to customers and distributors are substantially less than the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year collection period that falls within the practical expedient in determination of whether a significant financing component exists.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Shipping and Handling Charges</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of sales.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Taxes Collected from Customers</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As our products are used in another service and are exempt, to this point we have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentration of Customers</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">One group of customers, facilities or physician practices has revenues that aggregate to greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total Company sales. While the aggregate members of the group aggregate to more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total Company sales, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> single member of the group has revenues greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total Company sales. These facilities are serviced by the same physician group, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of whom is our Medical Director:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table style="margin: 0pt; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: middle; width: 55%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td colspan="7" style="vertical-align: middle; width: 31%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Six Months Ended December 31,</div></div> </td> </tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: middle; width: 55%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Facility</div></div> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td colspan="2" style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2019<br /> % of<br /> total</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">revenue</div></div> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td colspan="2" style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2018<br /> % of<br /> total</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">revenue</div></div> </td> </tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="vertical-align: middle; width: 55%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">El Camino, Los Gatos, & other facilities</div> </td> <td style="vertical-align: middle; width: 1%; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: middle; width: 1%; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: middle; width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23.60</div></div> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">%</div> </td> <td style="vertical-align: middle; width: 1%; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: middle; width: 1%; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: middle; width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22.26</div></div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div style="text-align: center; width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div> </div> <div style="text-align: left; width: 100%"> <div style="display: inline;"></div> </div> </div></div>

1228000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 15%; margin-left: 36pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,080</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,080</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,651</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,917</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total potential dilutive securities</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,790</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,056</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="6" style="text-align: center; border-bottom: thin solid rgb(0, 0, 0);">Six months ended December 31,</td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2" style="text-align: center;">2019</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center;">2018</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%;">Beginning balance</td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">621</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">590</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>Accretion of discount</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="width: 1%; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>Gain on change in ARO estimate due to lease modification</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(73</div></td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>Ending Balance</td> <td style="width: 1%; padding-bottom: 3px;"> </td> <td style="width: 1%; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">563</div></td> <td style="width: 1%; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"> </td> <td style="width: 1%; padding-bottom: 3px;"> </td> <td style="width: 1%; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div></td> <td style="width: 1%; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months<br /> ended December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales and marketing expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 20%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six Months<br /> ended December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales and marketing expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">185</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">190</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value at December 31, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,180</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,180</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value at June 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,326</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,326</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 63pt; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">372</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">333</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Work in process</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">166</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">166</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total inventory, current</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">545</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">530</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Weighted</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Average</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Number of</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Exercise</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Contractual</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Intrinsic</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As of December 31, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Options</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Price</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Term (Years)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Value</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,651</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.64</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,651</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.64</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and exercisable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,956</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.71</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: middle; width: 55%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td colspan="7" style="vertical-align: middle; width: 31%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Six Months Ended December 31,</div></div> </td> </tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: middle; width: 55%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Facility</div></div> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td colspan="2" style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2019<br /> % of<br /> total</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">revenue</div></div> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td> <td colspan="2" style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2018<br /> % of<br /> total</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">revenue</div></div> </td> </tr> <tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="vertical-align: middle; width: 55%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">El Camino, Los Gatos, & other facilities</div> </td> <td style="vertical-align: middle; width: 1%; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: middle; width: 1%; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: middle; width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23.60</div></div> </td> <td style="vertical-align: middle; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">%</div> </td> <td style="vertical-align: middle; width: 1%; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: middle; width: 1%; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: middle; width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22.26</div></div> </td> </tr> </table></div>

666000

702000

1481000

1351000

185000

190000

2956000

0.74

8250

10000

32000

26250

70750

30000

155000

40000

237500

418000

4651000

0.64

172000

418000

4651000

0.64

P7Y167D

P6Y259D

P7Y167D

0.75

59065

56331147

59065

67331147

59065

67331147

59065

67388047

59065

67388047

59065

67388047

11000000

11000

7483000

7494000

6141000

7680000

56000

84322000

-79348000

5030000

67000

91898000

-80856000

11109000

67000

91868000

-82270000

9665000

67000

92105000

-84492000

67000

92196000

-85308000

6955000

67000

92279000

-86205000

67388000

67331000

67388000

66743000

Includes plant and equipment not placed in service which are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at December 31, 2019 and June 30, 2019 are costs associated with advance planning and design work on the Company’s new production facility of $207,000. xbrli:shares xbrli:pure utr:sqft iso4217:USD iso4217:USD xbrli:shares 0000728387 2015-12-01 2015-12-31 0000728387 2018-07-01 2018-09-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000728387 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000728387 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000728387 2018-07-01 2018-12-31 0000728387 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-12-31 0000728387 us-gaap:SeriesBPreferredStockMember 2018-07-01 2018-12-31 0000728387 us-gaap:WarrantMember 2018-07-01 2018-12-31 0000728387 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember isr:ElCaminoLosGatosOtherFacilitiesMember 2018-07-01 2018-12-31 0000728387 us-gaap:CostOfSalesMember 2018-07-01 2018-12-31 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-12-31 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-12-31 0000728387 us-gaap:SellingAndMarketingExpenseMember 2018-07-01 2018-12-31 0000728387 us-gaap:PrivatePlacementMember 2018-07-11 2018-07-11 0000728387 2018-10-01 2018-12-31 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ProductAndServiceOtherMember 2018-10-01 2018-12-31 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember isr:ProstateBrachytherapyMember 2018-10-01 2018-12-31 0000728387 us-gaap:CostOfSalesMember 2018-10-01 2018-12-31 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2018-10-01 2018-12-31 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2018-10-01 2018-12-31 0000728387 us-gaap:SellingAndMarketingExpenseMember 2018-10-01 2018-12-31 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-10-01 2018-12-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000728387 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000728387 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000728387 2019-07-01 2019-09-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000728387 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000728387 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000728387 2019-07-01 2019-12-31 0000728387 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-12-31 0000728387 us-gaap:SeriesBPreferredStockMember 2019-07-01 2019-12-31 0000728387 us-gaap:WarrantMember 2019-07-01 2019-12-31 0000728387 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember isr:ElCaminoLosGatosOtherFacilitiesMember 2019-07-01 2019-12-31 0000728387 us-gaap:GeographicDistributionForeignMember 2019-07-01 2019-12-31 0000728387 us-gaap:CostOfSalesMember 2019-07-01 2019-12-31 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-12-31 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-12-31 0000728387 us-gaap:SellingAndMarketingExpenseMember 2019-07-01 2019-12-31 0000728387 isr:OtherMember 2019-07-01 2019-12-31 0000728387 2019-10-01 2019-12-31 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ProductAndServiceOtherMember 2019-10-01 2019-12-31 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember isr:ProstateBrachytherapyMember 2019-10-01 2019-12-31 0000728387 us-gaap:GeographicDistributionForeignMember 2019-10-01 2019-12-31 0000728387 us-gaap:CostOfSalesMember 2019-10-01 2019-12-31 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2019-10-01 2019-12-31 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2019-10-01 2019-12-31 0000728387 us-gaap:SellingAndMarketingExpenseMember 2019-10-01 2019-12-31 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-10-01 2019-12-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000728387 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000728387 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000728387 srt:ScenarioForecastMember 2024-04-01 2024-04-30 0000728387 2018-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000728387 us-gaap:CommonStockMember 2018-06-30 0000728387 us-gaap:RetainedEarningsMember 2018-06-30 0000728387 2018-07-11 0000728387 isr:HCWainwrightCoLLCMember us-gaap:PrivatePlacementMember 2018-07-11 0000728387 us-gaap:PrivatePlacementMember 2018-07-11 0000728387 2018-09-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000728387 us-gaap:CommonStockMember 2018-09-30 0000728387 us-gaap:RetainedEarningsMember 2018-09-30 0000728387 2018-12-31 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000728387 us-gaap:CommonStockMember 2018-12-31 0000728387 us-gaap:RetainedEarningsMember 2018-12-31 0000728387 2019-06-30 0000728387 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000728387 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000728387 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000728387 us-gaap:ConstructionInProgressMember 2019-06-30 0000728387 us-gaap:EquipmentMember 2019-06-30 0000728387 us-gaap:LandMember 2019-06-30 0000728387 us-gaap:LeaseholdImprovementsMember 2019-06-30 0000728387 isr:OtherMember 2019-06-30 0000728387 isr:EnrichedBariumInventoryMember 2019-06-30 0000728387 isr:RawMaterialsMember 2019-06-30 0000728387 us-gaap:SeriesBPreferredStockMember 2019-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000728387 us-gaap:CommonStockMember 2019-06-30 0000728387 us-gaap:RetainedEarningsMember 2019-06-30 0000728387 us-gaap:AccountingStandardsUpdate201602Member 2019-07-01 0000728387 2019-07-31 0000728387 2019-09-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-09-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000728387 us-gaap:CommonStockMember 2019-09-30 0000728387 us-gaap:RetainedEarningsMember 2019-09-30 0000728387 2019-12-31 0000728387 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000728387 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000728387 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000728387 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000728387 us-gaap:ConstructionInProgressMember 2019-12-31 0000728387 us-gaap:EquipmentMember 2019-12-31 0000728387 us-gaap:LandMember 2019-12-31 0000728387 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000728387 isr:OtherMember 2019-12-31 0000728387 isr:EnrichedBariumInventoryMember 2019-12-31 0000728387 isr:RawMaterialsMember 2019-12-31 0000728387 srt:MaximumMember 2019-12-31 0000728387 isr:AppliedProcessEngineeringLaboratoryMember 2019-12-31 0000728387 us-gaap:SeriesBPreferredStockMember 2019-12-31 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000728387 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000728387 us-gaap:CommonStockMember 2019-12-31 0000728387 us-gaap:RetainedEarningsMember 2019-12-31 0000728387 2020-02-11

EX-101.SCH 7 isr-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statement of Changes in Shareholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - New Accounting Standards link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Inventory link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Share-Based Compensation link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Leases link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Contracts With Customers link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 4 - Inventory (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 5 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 6 - Share-Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 8 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 9 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 11 - Contracts With Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 1 - Basis of Presentation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 4 - Inventory - Current Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 4 - Inventory - Noncurrent Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 6 - Share-Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 6 - Share-Based Compensation - Share-Based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 6 - Share-Based Compensation - Summary of Stock Options (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 8 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 9 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 9 - Leases - Future Operating Lease Payments and Lease Liability (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 9 - Leases - Asset Retirement Obligation (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 10 - Shareholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 11 - Contracts With Customers (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 11 - Contracts With Customers - Concentration of Customers (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 isr-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 isr-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 isr-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Note 3 - Loss Per Share Note 4 - Inventory 2021 Note 5 - Property and Equipment Note 6 - Share-Based Compensation Note 8 - Fair Value Measurements Note 9 - Leases Note 11 - Contracts With Customers Note 3 - Loss Per Share - Antidilutive Securities (Details) Note 4 - Inventory - Current Inventory (Details) Note 4 - Inventory - Noncurrent Inventory (Details) Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Note 6 - Share-Based Compensation - Share-Based Compensation Expense (Details) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Other assets, net of accumulated amortization us-gaap_ShareBasedCompensation Share-based compensation Note 6 - Share-Based Compensation - Summary of Stock Options (Details) 2020 (remaining nine months of the year) Note 8 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 9 - Leases - Future Operating Lease Payments and Lease Liability (Details) Note 9 - Leases - Asset Retirement Obligation (Details) Note 11 - Contracts With Customers - Concentration of Customers (Details) Accrued radioactive waste disposal us-gaap_OtherLiabilitiesCurrent Notes To Financial Statements Notes To Financial Statements [Abstract] Amortization of other assets us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term Vested and exercisable, weighted average contractual term (Year) Depreciation expense Depreciation, Total Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Vested and expected to vest, weighted average contractual term (Year) Vested and exercisable, intrinsic value us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share Vested and expected to vest, Options (in shares) Total inventory, non-current Inventory, non-current Vested and expected to vest, weighted exercise price (in dollars per share) Vested and expected to vest, intrinsic value us-gaap_AssetsCurrent Total current assets Vested and exercisable, weighted exercise price (in dollars per share) Cash and cash equivalents Stockholders' Equity Note Disclosure [Text Block] Vested and exercisable (in shares) Outstanding, weighted average contractual term (Year) Outstanding, intrinsic value Proceeds from maturity of certificates of deposit Warrants issued to placement agent of registered direct offering The value of warrants issued in a non-cash financing activity Common stock, $.001 par value; 200,000,000 shares authorized; 67,388,047 shares issued and outstanding us-gaap_PaymentsToAcquireShortTermInvestments Purchases of and interest from U.S. Treasury Securities H.C. Wainwright & Co., LLC [Member] The entity H.C. Wainwright & Co., LLC. Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used by operating activities: Measurement Frequency [Domain] Outstanding, weighted exercise price (in dollars per share) Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Accrued protocol expense us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Accounts payable and accrued expenses us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Statistical Measurement [Domain] Maximum [Member] Non-cash investing and financing activities: Lessee, Operating Leases [Text Block] Product and Service [Axis] Outstanding (in shares) Product and Service [Domain] Statistical Measurement [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Proceeds from sale of equipment Preferred stock Preferred stock, shares issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Accrued vacation us-gaap_AccruedVacationCurrent Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Schedule of Change in Asset Retirement Obligation [Table Text Block] Preferred stock, shares authorized (in shares) isr_PurchaseAgreementPeriod Purchase Agreement Period This element represents the period of purchase for which the entity is enabled to purchase. Inventory Total inventory, current Preferred stock, par value (in dollars per share) Work in process Sales, net isr_GainLossOnChangeInAROEstimate Gain (Loss) on Change in ARO Estimate (Gain) on change in estimate of asset retirement obligation (Note 9) Gain on change in ARO estimate due to lease modification The amount of gain (loss) related to the change in ARO estimate. Fair Value, Inputs, Level 3 [Member] Accrued vacation The increase (decrease) during the reporting period in accrued vacation. isr_CapitalizedCostsRelatedToAdvancePlanningAndDesignWork Capitalized Costs Related to Advance Planning and Design Work The amount of costs capitalized related to advace planning and design work. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property and equipment El Camino, Los Gatos, & Other Facilities [Member] Represents the information pertaining to El Camino, Los Gatos, & other facilities. Finished goods Fair Value Hierarchy and NAV [Domain] Prostate Brachytherapy [Member] Prostate brachytherapy service. Customer [Axis] Fair Value, Inputs, Level 1 [Member] Customer [Domain] Accrued payroll and related taxes isr_AccruedPayrollAndRelatedTaxesCurrent Carrying value as of the balance sheet date of obligations incurred and payable for accrued payroll and related taxes. Fair Value, Inputs, Level 2 [Member] Accrued protocol expense The increase (decrease) during the reporting period in accrued protocol expense. Weighted average shares used in computing net loss per share: Product and Service, Other [Member] Fair Value Hierarchy and NAV [Axis] Current liabilities: Raw materials us-gaap_Assets Total assets Accounts receivable, net Construction in Progress [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_OperatingLeaseExpense Operating Lease, Expense CASH FLOWS FROM OPERATING ACTIVITIES: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net loss applicable to common shareholders Statement [Line Items] isr_TerminationOfLeasePenalty Termination of Lease, Penalty The penalty incurred for early termination of a lease arrangement. Applied Process Engineering Laboratory [Member] Information pertaining to the Applied Process Engineering Laboratory (APEL) in Richland, Washington. Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Additional paid-in capital Shareholders' equity: isr_IncreaseDecreaseInOperatingLeaseLiability Increase (Decrease) in Operating Lease Liability The increase (decrease) in the present value of lessee's discounted obligation for lease payments from operating lease. Land [Member] isr_OperatingLeaseRightOfUseAssetAmortization Operating Lease, Right-of-use Asset, Amortization Represents the amount of amortization of the lessee's right to use underlying asset under operating lease in the period. Leasehold Improvements [Member] Property, Plant and Equipment, Type [Axis] us-gaap_NonoperatingIncomeExpense Non-operating income Property, Plant and Equipment, Type [Domain] us-gaap_PreferredStockDividendsIncomeStatementImpact Preferred stock dividends Current assets: Fair Value Disclosures [Text Block] Net loss Net loss Total cash, cash equivalents, and restricted cash shown on the consolidated statements of cash flows Cash, cash equivalents, and restricted cash beginning of period CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD Private Placement [Member] Interest income, net us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash, cash equivalents, and restricted cash us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used) provided by financing activities isr_OperatingLeaseArrangementMaximumEarlyTerminationPenalty Operating Lease Arrangement, Maximum Early Termination Penalty The maximum penalty for the early termination of a lease agreement under the operating lease arrangement. Commitments and contingencies (Note 7) Sale of Stock [Axis] Sale of Stock [Domain] Asset retirement obligation us-gaap_OperatingIncomeLoss Operating loss Share-based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used by operating activities Non-operating income: Warrant [Member] Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used by investing activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Inventory [Axis] Inventory [Domain] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_GrossProfit Gross profit Cost of sales Counterparty Name [Axis] Counterparty Name [Domain] Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Property and equipment, net Property and equipment, net isr_RestockingFeePercentage Restocking Fee, Percentage Represents the percentage of the item price which will be used as a restocking fee in the case of a return after shipment. Accounting Standards Update 2016-02 [Member] Property and equipment, gross Type of Adoption [Domain] us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs Adjustments for New Accounting Pronouncements [Axis] us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock Preferred dividends paid Geographic Distribution, Foreign [Member] CASH FLOWS FROM INVESTING ACTIVITIES: Scenario [Domain] Forecast [Member] Geographic Distribution [Axis] Geographic Distribution [Domain] Retained Earnings [Member] Earnings Per Share [Text Block] us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax, Total Proceeds from sales of common stock, pursuant to registered direct offering, net Proceeds from Issuance of Common Stock Scenario [Axis] Accounts payable and accrued expenses Additional Paid-in Capital [Member] Common Stock [Member] Preferred Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights us-gaap_OperatingExpenses Total operating expenses Restricted cash Restricted cash General and administrative isr_AroDiscountAmountInterestRate ARO Discount Amount Interest Rate Represents ARO discount amount interest rate. EX-101.PRE 11 isr-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56	$ 84,322	$ (79,348)	$ 5,030
Issuance of common stock pursuant to registered direct offering, net (in shares)		11,000,000
Issuance of common stock pursuant to registered direct offering, net		$ 11	7,483		7,494
Share-based compensation			93		93
Net loss				(1,508)	(1,508)
Share-based compensation			93		93
Balances (in shares) at Sep. 30, 2018	59,065	67,331,147
Balances at Sep. 30, 2018		$ 67	91,898	(80,856)	11,109
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56	84,322	(79,348)	5,030
Net loss					(2,922)
Balances (in shares) at Dec. 31, 2018	59,065	67,331,147
Balances at Dec. 31, 2018		$ 67	91,868	(82,270)	9,665
Balances (in shares) at Sep. 30, 2018	59,065	67,331,147
Balances at Sep. 30, 2018		$ 67	91,898	(80,856)	11,109
Share-based compensation			97		97
Net loss				(1,414)	(1,414)
Offering costs pursuant to registered direct offering, net			(116)		(116)
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			97		97
Balances (in shares) at Dec. 31, 2018	59,065	67,331,147
Balances at Dec. 31, 2018		$ 67	91,868	(82,270)	9,665
Balances (in shares) at Jun. 30, 2019	59,065	67,388,047
Balances at Jun. 30, 2019		$ 67	92,105	(84,492)	7,680
Share-based compensation			91		91
Net loss				(816)	(816)
Share-based compensation			91		91
Balances (in shares) at Sep. 30, 2019	59,065	67,388,047
Balances at Sep. 30, 2019		$ 67	92,196	(85,308)	6,955
Balances (in shares) at Jun. 30, 2019	59,065	67,388,047
Balances at Jun. 30, 2019		$ 67	92,105	(84,492)	7,680
Net loss					(1,713)
Balances (in shares) at Dec. 31, 2019	59,065	67,388,047
Balances at Dec. 31, 2019		$ 67	92,279	(86,205)	6,141
Balances (in shares) at Sep. 30, 2019	59,065	67,388,047
Balances at Sep. 30, 2019		$ 67	92,196	(85,308)	6,955
Share-based compensation			94		94
Net loss				(897)	(897)
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			94		94
Balances (in shares) at Dec. 31, 2019	59,065	67,388,047
Balances at Dec. 31, 2019		$ 67	$ 92,279	$ (86,205)	$ 6,141

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 13 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment

6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

5.	Property and Equipment

Property and equipment consisted of the following at

December 31, 2019

and

June 30, 2019 (

in thousands):

	December 31,			June 30,
	2019			2019
Land	$	366		$	366
Equipment		3,873			3,825
Leasehold improvements		4,143			4,143
Other 1		801			645
Property and equipment		9,183			8,979
Less accumulated depreciation		(7,447	)		(7,370	)
Property and equipment, net	$	1,736		$	1,609

Includes plant and equipment

not

placed in service which are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore,

depreciation expense has been recognized. Also included at

December 31, 2019

and

June 30, 2019

are costs associated with advance planning and design work on the Company’s new production facility of

$207,000

XML 14 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Leases

6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

Leases

The Company maintains a production facility located at Applied Process Engineering Laboratory (APEL) in Richland, Washington. The APEL facility became operational in

September 2007.

The production facility has over

15,000

square feet and includes space for isotope separation, seed production, order dispensing, a clean room for assembly of our product offerings, and a dedicated shipping area. In

2015,

the Company entered into a modification to the production facility lease that modified the requirement to return the facility to ground at the time of exit at Company discretion, exercised an extension in

2017

to increase the lease term to

April 30, 2021,

and reduced the required notice to terminate the lease early from

twelve

months to

six

months. In

July 2019,

the Company entered into another modification of the production facility lease that extends the term to

April 20, 2026,

maintains the current rental rate through

April 2020,

and provides for an

eighteen

month termination notice with an early termination penalty of up to

$40,000

which decreases in the future beginning

May 1, 2022.

Upon the adoption of Topic

842

July 1, 2019,

the Company recognized a right-of-use asset and lease liability of approximately

1.2

million. In determining the amount of the right-of-use asset and lease liability, we assumed the termination of the lease in

April 2024

and incurring a termination penalty of

$20,000.

As of the date of adoption, the operating lease is included on the balance sheet at the present value of the future base payments discounted at a

discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does

not

provide an implicit discount rate. The weighted average remaining term and discount rate as of

December 31, 2019

was

4.3

years and

6%,

respectively.

For the

three

and

six

months ended

December 31, 2019,

our operating lease expense was approximately

$73,000

and

$147,000,

respectively. Operating right-of-use asset amortization was approximately

$56,000

and

$111,000

during the

three

and

six

months ended

December 31, 2019,

respectively. Due to lease expense in excess of payments made, the lease liability decreased approximately

$55,000

and

$109,000

for the

three

and

six

months ended

December 31, 2019.

The following table presents the future operating lease payments and lease liability included on the condensed balance sheet related to the Company’s operating lease as of

December 31, 2019 (

in thousands):

Year Ending June 30,
2020 (remaining nine months of the year)	$	145
2021		290
2022		290
2023		290
2024		237
Total		1,252
Less: Imputed Interest		(134	)
Total Lease Liability		1,118
Less current portion		(229	)
Non-current Lease Liability	$	889

Asset Retirement Obligation

The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. In connection with the lease modification executed in

July 2019,

the ARO changed as follows (in thousands):

	Six months ended December 31,
	2019			2018
Beginning balance	$	621		$	590
Accretion of discount		15			16
Gain on change in ARO estimate due to lease modification		(73	)		-
Ending Balance	$	563		$	606

The original facility lease was scheduled to expire in the

fourth

quarter of fiscal year

2016.

Upon the end of the original lease term, the initial asset retirement estimate was fully accreted and the related ARO asset was fully amortized. During the

six

months ended

December 31, 2019,

the Company extended the lease term an additional

five

years thus extending the time before asset retirement costs would be incurred. This resulted in a decrease in the ARO balance to a fair value of

$555,000

and the Company recognized a gain on change in the estimate of

$73,000

during the

six

months ended

December 31, 2019.

At the time of the lease extension, the undiscounted estimated asset retirement obligation was

$704,000

discounted to fair value utilizing an interest rate of

5.1%.

XML 15 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 3,180	$ 5,326
Accounts receivable, net	1,409	1,154
Inventory	545	530
Prepaid expenses and other current assets	497	305
Total current assets	5,631	7,315
Property and equipment, net	1,736	1,609
Right of use asset, net (Note 9)	1,116
Restricted cash	181	181
Inventory, non-current	127	155
Other assets, net of accumulated amortization	142	162
Total assets	8,933	9,422
Current liabilities:
Accounts payable and accrued expenses	632	683
Lease liability (Note 9)	229
Accrued protocol expense	24	133
Accrued radioactive waste disposal	89	74
Accrued payroll and related taxes	203	89
Accrued vacation	163	142
Total current liabilities	1,340	1,121
Long-term liabilities:
Non-current Lease Liability	889
Asset retirement obligation	563	621
Total liabilities	2,792	1,742
Commitments and contingencies (Note 7)
Shareholders' equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 67,388,047 shares issued and outstanding	67	67
Additional paid-in capital	92,279	92,105
Accumulated deficit	(86,205)	(84,492)
Total shareholders' equity	6,141	7,680
Total liabilities and shareholders' equity	8,933	9,422
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred stock

XML 16 R19.htm IDEA: XBRL DOCUMENT

Note 4 - Inventory (Tables)

6 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	December 31,		June 30,
	2019		2019
Raw materials	$	372	$	333
Work in process		166		166
Finished goods		7		31
Total inventory, current	$	545	$	530

Schedule of Inventory, Noncurrent [Table Text Block]

	December 31,		June 30,
	2019		2019
Enriched barium, non-current	$	116	$	117
Raw materials, non-current		11		38
Total inventory, non-current	$	127	$	155

XML 17 R36.htm IDEA: XBRL DOCUMENT

Note 9 - Leases (Details Textual)	1 Months Ended	3 Months Ended		6 Months Ended
Note 9 - Leases (Details Textual)	Apr. 30, 2024 USD ($)	Dec. 31, 2019 USD ($) ft²	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($) ft²	Dec. 31, 2018 USD ($)	Jul. 31, 2019 USD ($)	Jul. 01, 2019 USD ($)	Jun. 30, 2019 USD ($)
Operating Lease, Right-of-Use Asset		$ 1,116,000		$ 1,116,000
Operating Lease, Liability, Total		$ 1,118,000		$ 1,118,000
Operating Lease, Weighted Average Discount Rate, Percent		6.00%		6.00%
Operating Lease, Weighted Average Remaining Lease Term		4 years 109 days		4 years 109 days
Operating Lease, Expense		$ 73,000		$ 147,000
Operating Lease, Right-of-use Asset, Amortization		56,000		111,000
Increase (Decrease) in Operating Lease Liability		$ 55,000		$ 109,000
Lessee, Operating Lease, Renewal Term		5 years		5 years
Asset Retirement Obligation, After Adjustment		$ 555,000		$ 555,000
Gain (Loss) on Change in ARO Estimate				73,000
ARO Original Obligation Amount						$ 704,000
ARO Discount Amount Interest Rate						$ 5.10
Forecast [Member]
Termination of Lease, Penalty	$ 20,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset							$ 1,200,000
Operating Lease, Liability, Total							$ 1,200,000
Operating Lease, Weighted Average Discount Rate, Percent							6.00%
Maximum [Member]
Operating Lease Arrangement, Maximum Early Termination Penalty		$ 40,000		$ 40,000
Applied Process Engineering Laboratory [Member]
Area of Real Estate Property \| ft²		15,000		15,000

XML 18 R32.htm IDEA: XBRL DOCUMENT

Note 6 - Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Share-based compensation	$ 94	$ 97	$ 185	$ 190
Cost of Sales [Member]
Share-based compensation	8	10	16	20
Research and Development Expense [Member]
Share-based compensation	19	18	38	36
Selling and Marketing Expense [Member]
Share-based compensation	24	22	49	44
General and Administrative Expense [Member]
Share-based compensation	$ 43	$ 47	$ 82	$ 90

XML 19 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 20 R23.htm IDEA: XBRL DOCUMENT

Note 9 - Leases (Tables)

6 Months Ended

Dec. 31, 2019

Notes Tables

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Year Ending June 30,
2020 (remaining nine months of the year)	$	145
2021		290
2022		290
2023		290
2024		237
Total		1,252
Less: Imputed Interest		(134	)
Total Lease Liability		1,118
Less current portion		(229	)
Non-current Lease Liability	$	889

Schedule of Change in Asset Retirement Obligation [Table Text Block]

	Six months ended December 31,
	2019			2018
Beginning balance	$	621		$	590
Accretion of discount		15			16
Gain on change in ARO estimate due to lease modification		(73	)		-
Ending Balance	$	563		$	606

XML 21 R27.htm IDEA: XBRL DOCUMENT

Note 4 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Raw materials	$ 372	$ 333
Work in process	166	166
Finished goods	7	31
Total inventory, current	$ 545	$ 530

XML 22 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 118 265 1 true 36 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://isoray.com/20191231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://isoray.com/20191231/role/statement-consolidated-balance-sheets-current-period-unaudited Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://isoray.com/20191231/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://isoray.com/20191231/role/statement-consolidated-statements-of-operations-unaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://isoray.com/20191231/role/statement-consolidated-statements-of-cash-flows-unaudited Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statement of Changes in Shareholders' Equity (Unaudited) Sheet http://isoray.com/20191231/role/statement-consolidated-statement-of-changes-in-shareholders-equity-unaudited Consolidated Statement of Changes in Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Basis of Presentation Sheet http://isoray.com/20191231/role/statement-note-1-basis-of-presentation Note 1 - Basis of Presentation Notes 7 false false R8.htm 007 - Disclosure - Note 2 - New Accounting Standards Sheet http://isoray.com/20191231/role/statement-note-2-new-accounting-standards Note 2 - New Accounting Standards Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Loss Per Share Sheet http://isoray.com/20191231/role/statement-note-3-loss-per-share Note 3 - Loss Per Share Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Inventory Sheet http://isoray.com/20191231/role/statement-note-4-inventory Note 4 - Inventory Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Property and Equipment Sheet http://isoray.com/20191231/role/statement-note-5-property-and-equipment Note 5 - Property and Equipment Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Share-Based Compensation Sheet http://isoray.com/20191231/role/statement-note-6-sharebased-compensation Note 6 - Share-Based Compensation Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Commitments and Contingencies Sheet http://isoray.com/20191231/role/statement-note-7-commitments-and-contingencies Note 7 - Commitments and Contingencies Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Fair Value Measurements Sheet http://isoray.com/20191231/role/statement-note-8-fair-value-measurements Note 8 - Fair Value Measurements Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Leases Sheet http://isoray.com/20191231/role/statement-note-9-leases Note 9 - Leases Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Shareholders' Equity Sheet http://isoray.com/20191231/role/statement-note-10-shareholders-equity Note 10 - Shareholders' Equity Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Contracts With Customers Sheet http://isoray.com/20191231/role/statement-note-11-contracts-with-customers Note 11 - Contracts With Customers Notes 17 false false R18.htm 017 - Disclosure - Note 3 - Loss Per Share (Tables) Sheet http://isoray.com/20191231/role/statement-note-3-loss-per-share-tables Note 3 - Loss Per Share (Tables) Tables http://isoray.com/20191231/role/statement-note-3-loss-per-share 18 false false R19.htm 018 - Disclosure - Note 4 - Inventory (Tables) Sheet http://isoray.com/20191231/role/statement-note-4-inventory-tables Note 4 - Inventory (Tables) Tables http://isoray.com/20191231/role/statement-note-4-inventory 19 false false R20.htm 019 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet http://isoray.com/20191231/role/statement-note-5-property-and-equipment-tables Note 5 - Property and Equipment (Tables) Tables http://isoray.com/20191231/role/statement-note-5-property-and-equipment 20 false false R21.htm 020 - Disclosure - Note 6 - Share-Based Compensation (Tables) Sheet http://isoray.com/20191231/role/statement-note-6-sharebased-compensation-tables Note 6 - Share-Based Compensation (Tables) Tables http://isoray.com/20191231/role/statement-note-6-sharebased-compensation 21 false false R22.htm 021 - Disclosure - Note 8 - Fair Value Measurements (Tables) Sheet http://isoray.com/20191231/role/statement-note-8-fair-value-measurements-tables Note 8 - Fair Value Measurements (Tables) Tables http://isoray.com/20191231/role/statement-note-8-fair-value-measurements 22 false false R23.htm 022 - Disclosure - Note 9 - Leases (Tables) Sheet http://isoray.com/20191231/role/statement-note-9-leases-tables Note 9 - Leases (Tables) Tables http://isoray.com/20191231/role/statement-note-9-leases 23 false false R24.htm 023 - Disclosure - Note 11 - Contracts With Customers (Tables) Sheet http://isoray.com/20191231/role/statement-note-11-contracts-with-customers-tables Note 11 - Contracts With Customers (Tables) Tables http://isoray.com/20191231/role/statement-note-11-contracts-with-customers 24 false false R25.htm 024 - Disclosure - Note 1 - Basis of Presentation (Details Textual) Sheet http://isoray.com/20191231/role/statement-note-1-basis-of-presentation-details-textual Note 1 - Basis of Presentation (Details Textual) Details http://isoray.com/20191231/role/statement-note-1-basis-of-presentation 25 false false R26.htm 025 - Disclosure - Note 3 - Loss Per Share - Antidilutive Securities (Details) Sheet http://isoray.com/20191231/role/statement-note-3-loss-per-share-antidilutive-securities-details Note 3 - Loss Per Share - Antidilutive Securities (Details) Details 26 false false R27.htm 026 - Disclosure - Note 4 - Inventory - Current Inventory (Details) Sheet http://isoray.com/20191231/role/statement-note-4-inventory-current-inventory-details Note 4 - Inventory - Current Inventory (Details) Details 27 false false R28.htm 027 - Disclosure - Note 4 - Inventory - Noncurrent Inventory (Details) Sheet http://isoray.com/20191231/role/statement-note-4-inventory-noncurrent-inventory-details Note 4 - Inventory - Noncurrent Inventory (Details) Details 28 false false R29.htm 028 - Disclosure - Note 5 - Property and Equipment (Details Textual) Sheet http://isoray.com/20191231/role/statement-note-5-property-and-equipment-details-textual Note 5 - Property and Equipment (Details Textual) Details http://isoray.com/20191231/role/statement-note-5-property-and-equipment-tables 29 false false R30.htm 029 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://isoray.com/20191231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Details 30 false false R31.htm 030 - Disclosure - Note 6 - Share-Based Compensation (Details Textual) Sheet http://isoray.com/20191231/role/statement-note-6-sharebased-compensation-details-textual Note 6 - Share-Based Compensation (Details Textual) Details http://isoray.com/20191231/role/statement-note-6-sharebased-compensation-tables 31 false false R32.htm 031 - Disclosure - Note 6 - Share-Based Compensation - Share-Based Compensation Expense (Details) Sheet http://isoray.com/20191231/role/statement-note-6-sharebased-compensation-sharebased-compensation-expense-details Note 6 - Share-Based Compensation - Share-Based Compensation Expense (Details) Details 32 false false R33.htm 032 - Disclosure - Note 6 - Share-Based Compensation - Summary of Stock Options (Details) Sheet http://isoray.com/20191231/role/statement-note-6-sharebased-compensation-summary-of-stock-options-details Note 6 - Share-Based Compensation - Summary of Stock Options (Details) Details 33 false false R34.htm 033 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) Sheet http://isoray.com/20191231/role/statement-note-7-commitments-and-contingencies-details-textual Note 7 - Commitments and Contingencies (Details Textual) Details http://isoray.com/20191231/role/statement-note-7-commitments-and-contingencies 34 false false R35.htm 034 - Disclosure - Note 8 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://isoray.com/20191231/role/statement-note-8-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details Note 8 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 35 false false R36.htm 035 - Disclosure - Note 9 - Leases (Details Textual) Sheet http://isoray.com/20191231/role/statement-note-9-leases-details-textual Note 9 - Leases (Details Textual) Details http://isoray.com/20191231/role/statement-note-9-leases-tables 36 false false R37.htm 036 - Disclosure - Note 9 - Leases - Future Operating Lease Payments and Lease Liability (Details) Sheet http://isoray.com/20191231/role/statement-note-9-leases-future-operating-lease-payments-and-lease-liability-details Note 9 - Leases - Future Operating Lease Payments and Lease Liability (Details) Details 37 false false R38.htm 037 - Disclosure - Note 9 - Leases - Asset Retirement Obligation (Details) Sheet http://isoray.com/20191231/role/statement-note-9-leases-asset-retirement-obligation-details Note 9 - Leases - Asset Retirement Obligation (Details) Details 38 false false R39.htm 038 - Disclosure - Note 10 - Shareholders' Equity (Details Textual) Sheet http://isoray.com/20191231/role/statement-note-10-shareholders-equity-details-textual Note 10 - Shareholders' Equity (Details Textual) Details http://isoray.com/20191231/role/statement-note-10-shareholders-equity 39 false false R40.htm 039 - Disclosure - Note 11 - Contracts With Customers (Details Textual) Sheet http://isoray.com/20191231/role/statement-note-11-contracts-with-customers-details-textual Note 11 - Contracts With Customers (Details Textual) Details http://isoray.com/20191231/role/statement-note-11-contracts-with-customers-tables 40 false false R41.htm 040 - Disclosure - Note 11 - Contracts With Customers - Concentration of Customers (Details) Sheet http://isoray.com/20191231/role/statement-note-11-contracts-with-customers-concentration-of-customers-details Note 11 - Contracts With Customers - Concentration of Customers (Details) Details 41 false false All Reports Book All Reports isr-20191231.xml isr-20191231.xsd isr-20191231_cal.xml isr-20191231_def.xml isr-20191231_lab.xml isr-20191231_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 23 R22.htm IDEA: XBRL DOCUMENT

Note 8 - Fair Value Measurements (Tables)

6 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value at December 31, 2019
	Total		Level 1		Level 2		Level 3
Cash and cash equivalents	$	3,180	$	3,180	$	-	$	-

	Fair Value at June 30, 2019
	Total		Level 1		Level 2		Level 3
Cash and cash equivalents	$	5,326	$	5,326	$	-	$	-

XML 24 R26.htm IDEA: XBRL DOCUMENT

Note 3 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive securities (in shares)	10,790	10,056
Series B Preferred Stock [Member]
Antidilutive securities (in shares)	59	59
Warrant [Member]
Antidilutive securities (in shares)	6,080	6,080
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	4,651	3,917

ZIP 25 0001437749-20-002375-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-20-002375-xbrl.zip M4$L#!!0 ( ="3% 20A]]PG< +BN!P 0 :7-R+3(P,3DQ,C,Q+GAM M;.Q]:W?;1K+@]SUG_P-6$]_KG"/*!-]T)MXCRW*N9AU+*SF3G4\Y+: IX@8$ M�@B?/KMZKQ( "B20 $0)#N.9-$H@AT576]NKH>?__?KPM3>:8.,VSKYS/U MHGNF4$NS=<-Z^OGLMX?.Y\/__-__/U_=3J_ M4(LZQ*6Z\KA2OLT]2Z?.)WM!E?_W\?Z+TE&Z@_?]WMVORF_?KI1>M]?M='L= M5>UT/OS]]=$QC??X;P4@L!C_T?CY;.ZZR_?OWKV\O%S@)Q>V\_2NU^WVWQD6 MPJ#1,__[^;_Y7K,]RW56T1/\VXQJ%T_V\[O@C_"D.NYTU4Y?C1[S' =((7HN M^&O&@SHULI^!/^#7I\FOTU=MGOU]_ L^,$D^8%C/E+G9C_A_PX?ZJ8>8/>BI MXVUD\[^Q?L")O@Q_?'*]+/@K\@?/Y\Q8[$TZ=D[_S4@B>\O%]32X1_WLTF>%,VV7/KJWN.;]#]\ M"J-<^S^J/4YL0__Y3.OTAF#]<+/TVNFGCIYIK?@)\*+:6>?5"[ MG?^;7 3?LG[WM>4:[NH*/G>(>0.ZXO7_T%4A3@%\NO"_<6_2GXS]I3)?NK&F MO5C8UH-K:W\^S(E#V:WG8?R=9Q]&X]&P.QPD(=NR] :8/N/?TZ7MN/#W!Y>XQ3A,'9U]^!=E M"0 R7YI>^@:6<(CF&L\4&(($#Q5:NMO=6#O[K>FUK\&B/0%DOSCVBSL'@BV) M58POQ@E=M>6MZ:7!,%'G"B3@R7:*+0GJ\2N88Z)IU R\0_ZR. B)MZ>7OJ=/ M!@.FM=RO9%%,88*LW3#[GJS.E1M+NX@OF7QK>LV'.37-$@3N=3,(''_9QD(@ M-N9'CQD69<48>'+VP76\Y$+QEZU7>J#@GL*?U=[C-\,UBZDKD!-?,L'I!]$\ M5W[H7H!-]I=-OWF]YC>'H. ^K!:/MED(+U#]8+O]]R?>XK\<_O;^4M, <_V. MK!S;-"\M_9Z:R%C?R"ME61)I)!9::ZM./UAV..P.!D/\8Z2Q @>XXX'O ,:A M#^KT[^_RKKX_K-S,;X.U)X)U,BT+JF-_ A.+1Z#+!?Z;:R4X0-RGS:D1[6%? MH/T1R*':'8F '%ZH(8S;5DT =^L8H*>(>?MH&D_$A2.J_T YT(8BT,;=P9J MXE5CH#%&X3VNX5"TY;$OS@"32_V_/>8N\K+D!IS"?1["%R(X%G&%?ZL_H8=^9Q+) ]H!I/E%F/%F_V\Z?0@S^N'/L)77<%3[F MPC/7?WG&$E?\N$+?YO+58)TK&[QWQ],0KAL+GGB";6:_TL4C=;:0H*L*MZK7 M'4>)J[EYX[MQU\)7C% M&F!#GC(4PP2E3U7_>/ >F:$;Q%D]$)/>SKAOQS&_,JZFA/KB=Y8E_>WU\P%"/*>'K:( M;5^H7M:69"L$I0&=K &=)&PK-QS3X50 F?+*WEN&^?,9NA7AT;@4H>!\DV7; M^?HC561DJUI_LEX_ W^Q] C7!]?1H8313]3_+ZR_S:X699VD81]-A-H.Q"!B MG8(P58A,%GN)D1$Z )W^L$YD'!N4C6U>ORZIQ0I+O*=/_)J++S%-7',U3?J+."5* 9W% Y=* ML/LD,19J%+2L 6HE 15ARCW1V]EO\"H\I,'AT7&-?POU8Q&QG8AV*?1UU'PSN/$>;X^[!D8JNH_B;\ X12!_>X8:4#KLC]>S#G?HO M'P[!2]>KWE-&"7R''ZF>J6GS$]\5>##DT78XB _4>38TRKY2P.&>&HM'SV%T M(SJ0PY$>3@MKD(KARW*TA?&JJ5BMK!7T7@#6N _;-/E0:#R;VX?\ZGTHMI2# M83/[@*$1QZ N<5;97RBJ%E,8;G$;Q^,=*.Z$K0;D"HF1V,?L3W?MWR&0*^+P M#[?8,[7;0N2*"9[0UHTGNS1@,>0PS ;6\C.EVZ)T&=O12X2P!I-=03?!6FM@ M^$4N)OSH>/T%IT<_)KUVJ3ZNUE^!PSY^=/E"'/UVB5]DO_B>I!7D&1##^2H-.=^"CY__8[_Z!21\/6'P9]3W);X$()5BL.LNO"?T:4>3?ET8W+ISZE2[$6+'=; #B^W 5(_* MSAT1NJEJ?]>.%,0E'CK=)_=#* 5AV&O[FF7AVIGG(8YL#C:D,P]$.,RS 4=AGSAIZF)IM"4!)@6P (#2->FK %X628MI*Y&=G^ MY#T%*6"&2X,PE>\MWE/-?K+X6_(XO-UIPB,,4DS662SP;K!+'^\<.J.@:W7^ M%]\U7#^%XLB3FY>VA8@$^2^;CR0N80:B'<^,*;:37IF8QV0G"VV1.CEVM 50 M;9XC4I=Q6[157R!1]=#@Z"A^3UUB6%2_)@YFN;$L;BN4"=4FW+=PS%!X\/SN M."8=]3J,*A=& EK'96)ZE5#EPIRC8T>[K"J?" ^8T[$4S#U5^41T2FX]MVWC M&*';_YUQ3.*P=#BO?-(5>6,MX[)M]"JNRB?JD5BPPFB75.4380K[AZDJ!7,_ M53XIEI_?)MRW<8S8^']O').^J#^,*N^+0E6MXS(QO4JH\O[16+"":)=5Y7UA M7'XZD(*YIRH?'(WCD#^]<#(0&__6#Z4"H;]!@)U:NJCHI+BP#!5I$J1[1B7)]>W .O+=LX%NJ\&K?1 M-&T-+\&YCOR8UI%;*CLW#-F-I=D+&FW;%]O/D B$E;F@S(A),RKO4ZI?7,,P M21(A%^C5H)O!GY6A*TZ)Z1X,WX+;FYTN';Q]-P7$R3?38]GQ/2D@KD8_',\7 MY($':II^HXM?B?,GQ4JRW.B+,QH&Q\( ^Z OSDCL'V@N[@- _&Y\Y![D$YC MJ\K[F(H;7Z5=SD9W+)T.5QV^0F\KG>37WOW=R]>8=H7>5O^0_G6A'=^3 D)O MJW\XGB_( ^7=C:FX7>#@D.YV(0;8!WUQ=XK#V:B"N[^GIS$57K%_F!S.XRS( M GO30'PGT29+L 4#8<8 G!J'+=K&;2B(0UY5[(+E&KIA>L@601-=@[+K5\WT M=*I_=NP%OL)S@]K ,)9X1QV^2$;?4Y&P[KG2QU7V"W8%_K<<)H9Q+9_L"SY, MJ?DJJ-0(X3,T1 L)/SX]PC?,\4%SJ]VDWNR=$/6^[TZZ1TKLAKD\-[&W#!HX M7F(WS-G7BZ5IKRCEJL2OM=])^%%72/C!:*@>*>$;YO)2A%>%A.]/U?&1$KZ( MBSD9]80D4+OCM(MV-#0HXJ-.1OTM-.@.1[73P*$$FW\1\YKA22@L1=[2LS'Z MKM]Z(;O0F6F.L?3!"%_I9R$LEZ;!&])JE+%KZ\FP*'A"UM,7ORV9[:QR](", MRX[G.AWVU\P%@J7.)0+44@00M=TO49D\'8J[6/12NE2T;&GH)KNA$X:FAFEA MJQRZW0?.D?# .4QW;ZB!=CNA$YXE1]U1I=!A#PA:W3E^*&YW-,P'=QJ@RO H M=)@?"B-KZ;N$BO%@V"=WCZ8D6QJ\YF3K& 35P+RSP8)0%'.KL>TPLS*4%+9; M_C"9ICO2\$7R+KRS$X[P&FLZ2%^B"Q?>HZ^-.)@(+)2Q'X(^.[O V$4&<41P MW,_2)=E@7!&&-ROX'\R]>R8F3[MSK^"DN (_8#._-R^5A.S15U,GR%PP5 3V M+JIN&0[4[XT.!/;N=$)5?-$'S]<#=M0I#H=-F3;S'#&C_!%]^2,XE 2_RWN5 M./0O#Z?\'6OT2'<&^84%*'DY+@.A.ND0_?A?!G7PAG/U!>\W MDZ2XL> P?@?U" !O E2"JW[:9"R5SDIX\0KE8Y^6(+T:R5(J:X@>Q'$'QG6 M@*2(?;.<]J)>2=F@0XN5CK@,Z#1(6:O2&92J\3TL06I5.H-",P3B!$E1 UMR M.X;F4CV@5O*#V#=+^)OC+8>)87>\P?2E8:L5S9VQKK'XL-(;3S;]TW:BN?/0 M,Q:G./3[HV-!,\=I0SS]K)]**FH+FG[!Y^:X*HS5\X0RC0]"Q FYU[,9U?:\ M3!F+,\\Z/76P:C*19@U.O7ZFC&8S>P8HT^B,+ M_LK4>F:^IF>HJH(C45,D^H?5^FW M-<1F\9NM5%H41B83DKH?0@U1YW#<)LXPXT'V8Z/D5ES%64?#2:W(VHN%X9=8 MXVD(0 ,I@2Y.LWBN&91H6_4F9P2L[,[(P M3/C0-1: KT5?%,=>$"OX*S/^3=\K:G?IGOW'D_L3OM'%:0;A.W]2$*B.8>F MQWNENWQ-O?8_R&+YTU^>[?[TC2_P%1:XQP76?SA7^)_.%08&?[:Q\$_*@CA/ MAH5OQU\,J_-BZ.[\O0+G,ECO3-&H:;(EP6F=/Y\AJ/R3)='U]2>/MJ-3!W]Y MY9@H"L?%"1&I&FA_$;Z&'J[Q3!W7T(C9(:;Q!/BX]O(G)95AS -=-?M.R'=!O_@KC"USC'2P2KI?U,R?5.UAL3VPXE(2$W5AJ2&I25 D==[I J8-J'YTJ<$.Z<*IC-2"S,15S@X!2J M@]5^LET_QY"!5G+GRC?XWNV26LH_;,-R%7^H2/C@VZ"L!T!1[CW&#/(C .,H M^/)ER"SV3+FBS/ 6G?HQ5OMJ8K=AZ[P9T5QP@'3E<<4!N[%@'US/Y9!]]323 M$D?Y%=!P#/!B+SC&$? DY'1EZ=C/A@ZOB5..DZA^M&R+)M!: ML(K6XUU^:DZF?M64SNSH&9GB@.0=NMI,Y#PL;I#;R(K\.CD /J M 7\W>#B0MD17$5>YO[F\YVY0.SAB<@B.6$O/P ?BO)@(X2:#8E^@8L2? S6Y MWO>Y8WM/3:CP#7I.4YCHRL+6P3\(P7ZV36_!;12)>L0I;.X/+F.'U?2_H7_( MH0S)?ZZ$^;!+Q\#S,^=<'P?&?8*#R55HRYGBT 7O.XBJ?XDAN^:DZ5>RBC;^ M$(+T#P_87@T 2 N1S37I;DD*MQ8EBC5'NTOO"5QG97!@ZO6[F=3CD:ZT7HF1 M<+<7C=)!(C75'$$WE!!8P68]HEXW24N6<*[G1(^$UW>[%^356 "'$K\T[) G MBR4.)G;Q[.-%RA#D [.3* S= MIE\2/^/B>'OJ1 $M_\6-1+1JV/($Y93D;\HV*O#(2YP&L4#Q%I W%Q7^$O\Y M=H=2Z")@\Q(AZ,A\1YQ;A_=MT7F&5EC?F"N!)GD'-)Z*QO-EWJYVNVH2FQT0 M58+"1JK3!@J"E*YZ4>!_99>>.XP% $' M^X 86WT_.'>34ISK4!&#/X,R]R=/A,_P&OB/X/W/5WB<(LN,0OM>(CVBOYD> M >XN12LRF<8I**;1/M3,:)![O-2;"KI):K::-_%#\ B#3V^1HKN8<[#I M.83D5-7OG#D+DQ.X<]- -TG.C$Y)-9#S"DZ@]H(Z(GK^2O[;=L(O!:U]S"LX M&%KV%YO]0ER;<6)^)IIA\G2O3;(.DFTCQ$+?ZX^:8-.-1DBG05X(F/Q )WN=)AR1D0PE(>U2(?RH7#2]0<5W(': M82U2\3"<"&M?X(=! W3-7T@P%([21EC3#FD^6./]EG(IU+#_T9U)+#0/6(# M+VMBDBRP%>D&3.+J_Q@B<0#W UU,V)&X+T^*K&6A*;+-HY%PFT?#O-!$@;#; M67*@'.^RQ:)RU:MJ9M5\\^!LC43],?KPIEMFO8+OV[E MD@X*C?&;?Y['P"G-IV+R[+V0TIAAQ9N!.?XD3 S(XO4BP_A+\'U[Z:?WZ9X3 M7NS6S_WNW*')'+8%?'/.%&IA3MTA\B^R=QK3%NJ'!JU==N[L6\."+;$]!H"P M']^W@AVW [%657&+E+P[[&U<,*J3I;MAW/:_*SR &?0SCS,M82TWGZG=R*PR M:'YAS4:26C^?C7KPJS34-7G*?'M]US!?__8U.. M28!WH-5!!RJ_?1*C3!L M2C*'ZH?=P(S>)&O;N)O?&(#UG\^2A[.6[ U ^.*0Y<]G_G_;P$%M@$%RL3!G MN7O\;%R)21P.N35LT"2VS0R&0U=Y68Z^'KL:!@RE12P'P\FKD.GQJY!V[23<]H P\ES;^_X MN5<>_BJQ?;]0BSK8DP>L']$7AF4PGK'[3*4)3)*TP$7&4>B:0@C5KI(&_<.K MI*Q;&6EEI8"T0T#&)RH@\A!;B2'_9KN\"51V\J>TX?EDO \RKML>)BMN"GF; MKXT*(5*_MIJVX'R1%BQFN"GK* )*Y1(EAD 8DL(#GJW'A90"+*9GXP7F7YR.$Y M]? B(A/^9?F(Y"99/G(:4=8C*!]19-6(S+??G6XX.GR01\8^)1OO'5LX?C:6 MF4.R;*3%,)RZ"NF?0.)].SFG#3">@!]WI&?!MAE 638BM4?1)#Y9,BFY M]WBYMP5)7:VP??+P)\M&9%9\&[+B)RVH9)-E(U) 6BL@TQ8$;&792'L-N2P; MD:GP[4F%5R?#]JDK63"\VTU(#H]B8*%* M"*__-JIW"/B3Y(DJ2WBI#8##K\K+W-#FL+IB,(ZH%F#XF"B+,9I'[6*J)O1! MQ+$K2AQV\=T+C\*\!7QOQ7/VD!W7C&BXT76_XF)ZZ%@ M"^%Q3$E4_0#+:G3I*EBV15^IHQD,B[]PSITO!M198&E0 M6YEE;=[$!4&J+ @Z\6J'0R_<1#)\^ZGP_2TL]_T[KT#%M)^M%( MR8)M7E@:6^F"MH\YI6*N4U"^>CPJ;\^D:I9,>"@FO YNP><. MT5R/F)(-)1L>B@UO@ L-BQE:^YFP=4YLV'%I,'BSD?#&LR1*M=]J-JG9SY/: MS)9H)0>T21NTM]U:_4KCUD\&:H'*D-T")?L69M\[S.&2S"N9]QB9]QMU%LK; M?V&>ZH^2AR4/'R,/_Y.8WK$J8%E,6 M;M*C4$^@GZ[LRE;)^>.?E&$Q,M9QQBN3G^%C>1Z19E">1XZ>@:4=E.>14^!C MJ8CE>>28^5?J87D>D?/A7ZF'18RLCELP'4+VPJT'B&^P^51YP7_5STGU MKV#9&ZP:TC79JS1LVJDKNN?@R#GL6EH_?.[52Q M0#AXIUG^&7:89;-58O>CS9?=?!L5_WXWLV5T Q9L.-Q8.6 %\D(QLI2/[96/TKM]3TZ+Z'.\COH MT]>EX4@W1HJI%-,,(6K(;O8WS6:6Q,YL9T8-5TJKE-904#"@\;V*:FLL:G8X M(+DA]0+*C%:F#ER?BPX0&I)MOJ MQ[19B36P%Y/SWC Y1C(B04,ASDWEV;*8@91=*;NME-W>*"V\#9G3..Q[3SY17]MXRS)_/7,>C9^]J0C43:/@5!$L(\;!]$%_JNH%\0\P[8N@W MUA59HDR%T.M4@Z.0R7X^Z_23N(P$N'Q057!=XHPJ!+])/.^I2T![Z-?$L4#K MLJSM&1]@>[:1>')0$D_7L$X/*.>3WK3V;=F&:G$YG^"NM@WBDG(^Z?=:RX0E MY7S2K]]P;(*]C<2#JDD<(G]'G= ',+1+2_]DF)[+QW47@O?FZ^N&U@(R"[ HM<4%M-.=UQ@+P0^ MA0"+?G-[$6&19R\$WH0 BT%%6$3N<+Y=0("9.E#5T7!T]B'7,25,FG;Y00&O M+1P\*(1'DR@E.KI!\R>XK\>?;TQ&3T].#Y;/-W=]G30M+N!T[>5/6769P9OZ MHUPUE54?C?(0.SS_/=JFWM2=9/]"=%;;.$4FT^P/$0PJ1\0O-F,*"*+"928W MBMMR]+^G2WBND7@,2@^4)0W4D/(63O#L1TY;KMX4_ =$4?/X(5YY7,$S8/,Q M3&11%S9*LQ&#YNXUD\V8@(L34^G''9C :K.Y?=RUDI9VBYH-X.8YLHG MIO%,(QQXK(V"3_A,3'0'+Y1+5T:V.!5#EL(P)) RY,,-Q@CX0#>: %6T[6"* MN4E"QEZ&CJZ_O>?)S7XA#M[D@FS:3I3[XP@^93.0 M%-LS0>I #N'!B,%TCTN8*\I30,DTN8ZT&3]C??J>;#WQD'4!^PU@V,2 M,HUAE6#_<^71./,M%8>U.U;2ZP[J&!V?'[YPB-TV.B)N.M/M;.+ES M-'B38Y.;[03G7YHJ']/'W)Q<<>(M7 K#,#SQSBW#A/')H$>JAT M 0;)O>WG7CF1H1*[=Y45Q)5&3ZJ-#+4Q.N].NL>O.=K)/&V 03+P43#PD1[_ M6FWZ@BM+:?F*!FJ.0K\40JAV-91GIM$!U%!6($H:5RDC!Y&1_OE4'9^HC,BC M:R7V^YL-G+5.+5HGAK HY46:\RS)[H-DZ[:':18GHJNV8U2[LE*[Y^-I"P\6 M:6W5EQ9=BLE!Q:2[:L([FO$_XY%_5]M]U\40-3L)POV)5EY9>0J M&AMV>Z(*R ^#X2!1K9OVCG?OJB@D1+VE<,6E_$H) MJBW>E"8WE0]645@%\KL=H^:[QZL0TR*-A^B4_"W]O=86XB=Z:ED(4!\,DO.W5(V$&+U$TZ3,U>2_.L+AF M_:K"^4R>S%>,8G=2(R9$57\P/,8GW&HN\)UX'/;?S4@"_8X6-*> MP=>78:T/ ,. 1O :C5AN6/ 5@V6Q9MGOM=OV#\^B2K\K;]J^!ZF0@4=YTR;92=ZT288Z3H:2-VV2H>1-F[QI MDS=M,AYVT'C8\+S?:V$1IXSL2DZ6G"PY^;ODY!.XHY!<++GX^+FX'3=M[9M" M]DU4P:@)CB' +(Q/BUQQ8'F M7] 5CV&5)7(<_ +4^I.ZRM(Q-,J$)<[K[@9;.PPDFQ'\0@P+)X3>6O#=< +> M[2PHU\PU:3HV"+A;:C9W01BVSXE.3N<>=873N7O]1*N,K4#L2;,MW2D 0L$( MZ(IIMFV>\,K.X!U9H4>-W*=I8 KT+['N M$_M)[E@HN9UADL'*@5WYZ8)U4)OF!>A M-3!5@%]H0\9"/=*95 _^C?4,GH?M5" K0I734?L[X(Y!L1? Q0@MU$J=884 MW\*YS[GR' <>J$XS;;%]NYA$ %!E>!13/T)N5R?UX''GT"4Q]$_!0+_ 1P'5 MQ=]7Y(0GYBRQ<"K!\5BPB/TQ'MU8.A+VVH=["C=37%8F?V(:[@8AX MJ."9@3UZHRA[U!.1N U$^C/ZCV42".\K&H F69\10?(V#LHAFQ_&M-Y6/EHK MD[C=3!98];H-55C%+_1&_5SF=+-F;%U.EF5(925*JQ-S#Y!Q&]W\.#(ZDPE-TENDC4L@6L\ZK6OAN6>O,#?@"$,8LJZ ME3VS2TB50@C5KG[&AU<^6=$F:5"E?+1"/OKJB0J(/*-68K)Y>T5@ MHR#)YUS1_$1>:;SS27Q6__[)U$G)33)U M\L12)Z\MQ]#P(NV1.(:W.(=#E-61D3F9@9;G0EX]@0MYR<>2C]46W.W*6ZI6 MV,-$*8&TAO(2O=EXNWJJE^A20*2 5"$@_7YP>Z M/%=[+3A7R$P3*2Q'(2S#4TW+:D>FR;[]WJIO7QGG^NQ&< GKK3ATZ5#&!\$X M\5.ZXLZ)J[Q0ARJ<1R_7ZUKJW8CRZ!#Y]MTUM@NV;F*L##?NMD MY65N:'-PJ1@VG+/"O%0^C0;?H1E+@KWH&#'A9?XKX"'#;&+HC&4GW99'WFR: M 0C1_!MB*3A;@KC8'T];:2:]4&ZMY!;7W*'NTGN"#02OD_>H&Y]G\Y>['OZC M\$LHOE.P.P0^MA@P I_0<5).[,^(O_(KU8T_;>=N M3@">SF\.>']?OESAGC]2X#7%2QO8<6#9QW=%I0*^E,N@BRFC$>;0M MP&WMK5ZL_QH;E 1<;0 FQ#17<7YN*&L*.34;.3B84 <$ MT\"A30ZQGOP=6TNB#2>;)EET<-[MBC;"XZW%[5FC=$NT854^ 0RP?R@A]:_N MSD&"$LLWT\B2&:^)51?PO3D#IM5I(WTT-[IZGBLB]>1S:2-@6?8!MD(DM[XL MQ/0W6-PEU7"TBPGFN&$9V:U;UK: V_ Y8:#V*6A]YGL!2\?6/0TG6%THEX=I M'2MF,@H^#WHQ@0>#?W+H(E+E"4OE^QNP&YZ),_$:P&0R'208TV<-8- E$/65 M PX&J7XX1@FUC2SH[S4G"+A#D:CR%KA4L<"M;$*)OE#SF6;HLS6C-B/*D_X@ M6TXV"$1FX',=0 9ZW8N$#(!O [ZZP9JT_TDM&]LCQCSP3S2J$'Y0>)E3G$G M.2FF70)2 OT6AL7]T4,!Q\!&7DV0-3*00(AB8[^["9TV2#=!S]#CE.DOBN*L66 %.48,Z M+-H<^DHU#[8FQRS-;>,E!(,HPHX#OV##@<0("B/7B)#)2#@_8YP:GY&U8EFH MNJ-.O[L-*N&\JWYZW%4!L+Y2MPR)QL+)5,-!>L;->J5B,.PBR%@5PM!/SSG9 M#8-MA=$$$3G^N/,>02Y^1^Y$Q#][5>N7K=AT1,/RAL) ML(A@+84,IVM-R&R9^B>0G3V1R;$S]^3EUS "M1L#\GMBI.,0CH#:&T.6%*+Y'I6R.D._ZXUXV3/$E2T*UT^:( MF:F?'L.6'RKL@8>CIG@'O%+$$K/42* S$VN6A6LGN<2,51(NYJ)'>6-I]H+> M\$ LVW,RZZ@GU-&;(&8M7Q;(0L.$>V(UO"FA54)9:)9<3SS)M6Y:%A@'UQ// M$R]#RR_ J)3>AO<87W!P7#CB;P6B[\$I8?4-[\Y*S('3.C6/@%L7,V_4.:?K MH(/E,R[']KUMRZC4-JQ.5G%V_D2CK!2B<$S;\$V!N^'-65G_HL11KBTDE))5 MPKEY [PK'V /8+(OK$YSB9HSS?!'C/DH;]?!3/@7#3-O>AEYEXTE?"PLP]-*LL@(P%"4#%QJ"*!8.O5.K>UR",'W=_>=%?KE);N M[T[1[LG]/>;]W2F_?;F_Q[R_.^5W4-/^UE7ZD,T&[:I+Z/5WY?KNYI:<=04' M5Q$\QU[J"/3ASGO#7=-DCE)+X''\O7*S6.*%FA(>V:7>J)R#WJJIZ_N:%,,H!C['OS\9S.22$>41P!BF%0PC- M'KA@;4497(17FW#Z+H\+0%,>EV^8'5\*&?&-V![(<'#VP.;%+H6+^ YR'UQ> M[!*8W/-K!-#!M[//!@,/A=\?;@;_FL[8+&W[@:! ME;@99NI 54=CM=[KX>C.=_.*MMX2RYU]N0'4U(TU?A)=9R]??<<^=52HI=([ MY96ECR.NO8P:*4[JJC:OOPPWUO ]#\-EW/'6[F).A0G4\9^W--#8MG73WO'N M7;*$NMSV^9HJ-U&WU8ZW8C#!H6O%XW6R:(ZQ\H(I)%;XI&-C>)I9\KOQ,& M1\ G%TO*<'7\RGJ-1ZJ1!0T+LFV+-Z-IHN;F@2Y=O^@&#C+CC8*;3()@N1P6 MXC8 GSI,%^ J["\/ZV!FE/J5WH:EF9X.W(+F"3[GE3$V* \PH'1)?'HBO\"^ MK;$Y]XO^L9Q_22T&.W,.VZ^9E%A@G.T%?P\!;V'Q:*XP^02/*L'C\.N,[SFP M(:_V!P=+-WPF@4U>+I$= $9RH=PTL8G@G0R3;>RWE,PO;-V8(;"XI?")*]AD MDP=C>$&1_PB\PB\U_,LSG*@NVZ%P-O57^R5$,\AWVR&:7%!TYDM9T^S9\]ESE$1S;4X1 MJ'47%@MO;Z)!0!'4M P!:9\--!Q\ M0<+L'HZ]?5'V"TFJ#H/C$P^6IXK+WZM^2)P/.(JR9ZM M%U[[',V<82(E/]C0\0:OE./^N$B#-L 0/:X[DZU[+J.4=AUM(O)I(/?G_--U M;ZZ E"P\Z?!N8_B51V+RJG\VYV+,SY9F8'@V7"%4ROF@9Q*&5=Z8.Y]!G[NT"1KQQE^TX M]@L2A^ 0'^S_Y0"4_^;-4)@1G%F)P@R0#.+X_A(_O_G" &XT>"C!D<@G>D0K M[)<6/0CZR+(7H)>I]6PXMM]^C+#U$F MJ>W'(/SWX_X#9\(:ZK0T M>I,\T<<;*EVTTI=I=;SOL^W(+FF';&"%X;.T2:.O&'J+:4L4Z\:]M7%_XV#3 MS([]H [&N/0V08]($]U99CIK"TR5^[?OVAR$B,/1P8BHJAM+Z[(MXL$%/L'' M"F9>@6>5D'MTJBC/%D"?(G*U%D2GYS$?;'V6"R,-^@'X>_,>HBG^[DXWEIY) M:]8TCCDX205G-H[PWUZ1EC^QC84/>*YX&]]-'L*T/0;XLQ_?Y][G1N_. MUZD3R2RA#<;9EQ.S.T-L30S:;&2Q[G&1E1(D^T>TH[F#[!^18++ONG_$!E[M M&%(E^T=45'_>TOV5_2-.>W]E_XC3WE_9/Z*5_2,VR=7>.92R?T1U_2..4DO( M_A'MZ1]1J>*0_2/:I3]V]X\X6OTA^T>THW]$60:2_2-:N-^[^T?4IR^"7PXT M +5H15M(@&XWBP3A)XY/][#F-_V2.#]HO%8@JH3$%V<^4\.N;^ 9_;(-8$ZQ MPN#N6##WIBN[=KW !1MB4C:YJ>&R7_Z03C7;KW=[K_!Q=VO*7O)$D7OJAK5; MMX^P HD,9-&;S=+H*>.+WO'7C&())+&"]!MG354[HJKR]O+^]D?\AJT9_#XT M',2U+N0QW-!9,8.J'A9+^;FQ\(K5HG[U3_2T?V&:J!4*1U@UE&^]I;X)<%:T M.0YNU?%.U[^#9LK;DO>J5>]NP'P;0IZZZ^Q,!=V-ON^;V%V^TDY?"AQY -#Z M^6QTMLW2%7%]'HS79')(_(*_*(B%3BCU4*:WC3)AL>JT^ H50S"IE;3%#W\I M[VO<#5S[CU$16I"C4N?YO^U7OZ->W6R/HUUJ09$^YE"$ MY2 RCH9QM.93*;Y/.H^.4ZZV!RM_(>#7@%3Y_C+Z[N@]A].]%3V>,AUW]QN* M:U5Y'9+OU8=CL+?C?F$.J_(V1&[AWEO8:7(##VJ/@^35C_D=V@U4^^$XM_WX M"UZCZ+:'9]\:0]];5VG JQL5UPV;<=_,'=C?],N=W><\U*W KZAB9X_SIN.0 M<5@;&,K +GFIIDA8_,AP6+AG^A4H]'5I.#1L35,_3\ULSW'G";)AOSJ7.GAZ MFO&&OSP)O0%8>EUUE*P5CWK,4$L/,^(C4JZ;G/GE=X9EN 9\OA'DCEQ4I/;, M,\V50O@9D3=O"YN2^45 Z-+Z+XA]V2]7I3K6!398J=FZHK(M_<%X7Z^@STJL M^QS>.8"Z"5I$-L#.1JJ+F]\#P9U[+( QW#[>X^^1SFR';G*,9C.7!5T['FG0 ME07W_]O<8%CR[)G!]06)JCQ#F44."@O,> ?#&3&<=7N3^FGPPW"S^G.M(4.& MS^I6I#QM'/&X\(7RTPSX&07NC19(I\0NUJ#HT/*7;'=ZF6Q6&>N<&':C]/6B M%^MV'NVEOO4NL)E^)3^,NX/-K5[#"M(3DQW/!U^W;4ZW>@S0@ WR1XIWQAP-5.,E@/$W-_%BO5 B$[JC3[VX#H2=L MSC\>% ?ATM(?7"#3W#;!!V?7?WGH-I4@S; O@FLR[?=%<&4NOS^PNX@X% YO MF YZ0B(6 _8JR#\K0%R8SVC+:MN6T93X=BD3J\[R(-+!DS5X5)L7X2#4CJ#[J!? M)S*1N:ML8R;BC5&G_5P2DP%4=<@4V9G15+PSO7%O5!4R-Y9F+^@7F^U+_.$6 MXH_5#4Y:KUL(I$(D'&TAX31E)"L"J3L%,_3'@PO>)OK*5R9XS[0#?D;*/=PZ=43PI\K_\RKWW]5.^6<:#EVUAUQ+^9-8C"5$>BMPJY96]MPSS MYS/7\>C9N\J0RP03?H7CCQ!&D=?2*(R74:3ACA@@)U=DB:Y^%KPB"]PHO/<4 M^XY3_9HXF/+#0D"%6GTHM+8===B=U,;XVT 2CK:K%B2UFU0/AY'%B0C;_?A& MC%P)611:RT9AS"^+0H/8*+R%97$J/'!WU(&ZX2Y6QOC;0!(>P*L$*>$]',XN M3M0Z=/@VY(K+XD2M0U\4AC&W+$Y4T=#51N$M*HL35>RC3M0-E[HROM\"44_L MHE8)4:0TBI.!*,"V']>(D2LAB<))KXW"F%\2A5-V&X6WL"2*)QUW)M-Q M;7R_#2+A'.G2$%T^$\/DL[WM&-,%L=>/A!G:?C"/^EOTV70JAGDW8!5C5<0] M&0W$.A'60Q^R=EC4UK/^!*6Z1P8W1.HB$W[WV1&$NA$'&S-3O*VP?OT3W,?,,?SX/AE<'L7*:8/+6(^2.-@PP^/Z4K:(8?R^7)'+\6SF3@ MF>[^,^L$,#AT.91GB3VNE(7-W+#; ^_4[W$9Y4EB=#;SAV8H_E!2"T>2^8/L M7,!P <#QME8@XTOXW08)7\_9)#.WD:'Z?OHG1:Y??]V?@QY[/$X/?]HVGV_C:S.@YGDB^;*Y-&_#83.%;;XK/MP:V]G!A4[AZ!4PU7 >M%'PE9--@_ 3L^O=N=VJU M\[!Y'RD>'97K:)= *C[[\S[N_,TX7B^@P3*39MR#K_:SKTI1C;;$/9@T[!X MX@D&N,+AG8]VH$ N'0=#%OY-#43N)JCPXWOERB3 3JLP;YXWIR5^;Z:/ MU'VAU&IN6G,2.&X6FUI[U!TEYZ6LI_>A1W6.U3U (G^B/;;N>0))C$:M1Z8$ MJ#:W7[BM 2>+,?#'*']$@R,]5DUH"28@:R;P+99/>0;.5UA40K0PSQU=)ZXS MFR1*TJQ]XS.6P?!'XV-=K'1!$28.3;EY,5^!G2>\O=!XHHGU6V@QFOIZ"]R_ M5!T3[U26\OM2/E_DKT5#XX%#PDEP%.L3_.%0O P-OJKYC@<+S!W0PS3]\;_P M;@,(//.S7H$L++R 8=^CH[$.^MUR:2)K7X%%O@(?I\RI]XA:*S OP(BP"4N; M^:<4;GGX-W6[ :9*3S .#F9K#D(L3*S^\CT9[GFB*#4/&HXOU()Z&DY%HF % MD(/<%S#K>D(:[Y' 3WY9+ I'/QQ7'>"8E(T#C8[&>B&/85&>QILH)RX0?(8X M#-D),(!F+$F"\E:,XGA@=K \*S: +JD;<&*=X8]8]VL.N;X)9M'!7ITK&F%S M9<9[%L+KD!:FS8#?F#!2';^UV?_B)765 ^\(A/>&M3+?;6+HP9(4X414F"O?4:=60%>(]84;#K*HDEM&6!+=IMY\-FRB5)1=TQ?3>ML2.WK0&\(JINVT)&OTZP"O$ M=[UMB1:#<4GP^)U%2>M[\_5S#,)A5YCU_F$LX+WXZB4!W+;!&P"*#:^(@'DA MC*8S9!:G1R9^TV?;6>;5\53 *,_1L%0/Q:*]US=WF:&71+9\70D+K/& MTBG+Q>SS5W44<3\6D3[-)+VKVXOGU]=$RCLX3#_]F'[D5W)-J!W=A53YL-=DKA M,3@T'O?A#&[^QV_46:A;$B#WC_[<#?XE]J=?LH):,92*4"=)V(9_^8AGJLH M(@>_7%KZG7\KS7^]G7T.(T51%C_[%(6 L">(\63Q-KR6&V-#>)]F[),\.Y#) MLS)YMOBMZ8DDS^Y-:LR!YX'TC%: ;7I/Y:7N)^^7U-1DU#=![).A3F+S>X9#C,)=M-]]AEGJ69GA[.:_P=-:#Z*R/4<)7YR#+8"JX:7,S+9=R\94)6S5ZB=.P@L#DFYL MW?0G%J9!^JF/L *V=@5 P!]<-' /I2;ZZ77^3[1?86Y?,\T+8ZE]ZE2H^C>4 MQD:'\;]]YO_;Q_Y7=_]](.AXTJV5GW_7X@7BN22HHL"?9A[J$=!5/.W7,VG( MZ$^>&63]!@+\0.$\[N<.XS>N7X-^H%C/93#&I\4]7%_]&!O^MO[I*DB(,:P9 M\@.707Q+*$CQ6\J 9NG37'G!UYD&?:;^-32N',>=\'0!^I>'J0&AD,:IUOR=-> &6A3VV 1%"K3; MGI(B934#NI#]@>LP0X4G1&&.F9<43(=J6*$/UMWW'X#G<.-#\8QF0O/GD^8E M;G+]%(S,Y("(I38RFIM0_PNR*E[O52DO\[[-.I]!\QPTR$6I]>LH#D"!1[K. MQ.'%$KR[.+?*F7HTGENSSB4)4UI8T+4<-QZ1PS.\87FH[Z*K< 4T#0M4%$]' MB[F3%G@RFU\,2W>5&9S4 Q9.IN^A2TQCF=H\==LEKWXCWE1V8"/IOSU!HVN> M<_?81.9/MVA?X*8C/*GX$F;:\9 JV^N>8"B^E593_7XSERP)U:Z.L.+;:'54 M#JIJ6N>*LV[2ERK9:Y8&;&<+72'!QH/B@-V1%6?3V]DG W.H+9TE&\CX/ X? M4/#?^"?[MM/=N "Q0GI:.#7"6B[0,E6@C+.[$GNHBG!^DZE IUJMVRVWYL!Y4'N:V MX^*EB-]^V#_[Y;Z@".$NU7:M)"S%*"K,5)GTAM/M),T")X5!0N(C1> G"T4> MQ(V?@;QGBZ(MN8$+ J 5"4RA1+8Q$WDVX%,(?W3%V9K#5N!3+$48*&\U(/, M'7%N'?Y]_9\X=>2..@]S#-3DB(@*H* MD0T'<0,1@>O:!"+\"^S2@].[PZ<4E=F)1.NQ),!\2H&8E=++[POJ3EH/-G,Z M#@3J'ATEMR+8$R(X/,!>U(!@OSD$;_Q:N 9W;S-5)T)NVAT-MZ/F@[L/6G7M MV; )M&X]EU&\&Z-F_< (+<8%6^:_'Q6:6ZZ.8$WTA37> M N7:J):I5J8EP6F M&$V% 93!(%7XDP^>#1RRZ;Z^"RN=S3Q2F\EF5N+IS HF(=?<*&IGTC. FDI[ MQD^BQ.?E:R+U.42D:J#76;NYY!QGUGDPVA;CI_ M=PW)VS@H?HLOCP%([,?WA]K/VIERK>:X15^7!FU4#:6KB@*0? PZC@]"K_MF M4XWMK1V74S_8)LDQ\6H<_VJYK+S(M=2W:/+4SF7:F^84U&[?6 MXK6+ 1#Q7IQ8<$B=VIRZ8!L;M'@!0GRUN&K*Z0A(SO@N.",T$^WDBG?QDDVI MWXZ#BP,#V_&W!;ZV?%5XBJSB/#V^!8\$___C(9B=NT*'870E<#/B5)'<)+FI M.6XJI$LWJV\XN7O= 1PH^A/XUW#X8R,:-PP^C')5B%?)@ZZ]#$-Q_@DW&02Q M[!>'+'\^\_][=KC=.C /M0$&R<5V,#AD)N_!FU@V^Q>9NS[^S5^A6$X M>5UQ/AGWCU];M)-YV@##=\# O>'Q,_"1'OG:9NYXHS\<@(W#'QP3UO/Q70!>"F88F'U25X>#H"XZ/?I(@'[ M!!/0EK8_/O:]W^+/>(8G-K85#/9Z@*DJ2A"1)KSH#:#/TR/5<9$XTS5MX?M-[G2X=JAD;DRF^ M7Z,H7?A:-=3;\?E@,#X"%27.G&RRY.E'*912*)L0ROZX*X6R$J&41_E*[A.R M#^[GV,]>ZL1\2J4/2D6W/2QEW=0J;I1/1_W6YC3FM:%?1F:E^+2 M"G$9=5L8A*A$7+:UYCC0?,2F+\E3Q#E(CX_#$J!^"1+F(42TO_''J#%EB:VR M4AU.ZH

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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 3 - Loss Per Share (Tables)
6 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

December 31,

2019

2018

Series B preferred stock

59

59

Common stock warrants

6,080

6,080

Common stock options

4,651

3,917

Total potential dilutive securities

10,790

10,056

XML 27 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 4 - Inventory
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Inventory Disclosure [Text Block]

4.

Inventory

Inventory consisted of the following at
December 31, 2019
and
June 30, 2019 (
in thousands):

December 31,

June 30,

2019

2019

Raw materials
$
372
$
333

Work in process

166

166

Finished goods

7

31

Total inventory, current
$
545
$
530

December 31,

June 30,

2019

2019

Enriched barium, non-current
$
116
$
117

Raw materials, non-current

11

38

Total inventory, non-current
$
127
$
155

Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will
not
be consumed within an operating cycle. On
August 25, 2017,
the Company entered into a Consignment Agreement and related Services Agreement with MedikorPharma-Ural LLC to begin utilizing our enriched barium-
130
carbonate inventory. The Company originally anticipated obtaining enough Cesium-
131
under this arrangement to obtain over
4,000
curies of Cesium-
131.
During the
three
and
six
months ended
December 31, 2019,
the Company obtained
no
and
31
curies, respectively, of Cesium-
131
under this agreement which has been used in production. At
December 31, 2019,
the Company estimates that the remaining enriched barium will result in
894
curies; approximately
60
of which will be obtained in the next
twelve
months and
834
will be obtained after
December 31, 2020.
There is
no
assurance as to whether the agreement will be terminated before this full amount is obtained and other supply sources are used, nor is there assurance that the agreements with the
third
-party Cesium-
131
suppliers will be executed.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 1 - Basis of Presentation
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

1.

Basis of Presentation

The accompanying unaudited interim consolidated financial statements are those of Isoray, Inc., and its wholly-owned subsidiaries, referred to herein as “Isoray” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form
10
-K for the year ended
June 30, 2019.

The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information
not
to be misleading.

Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented
may
not
be indicative of those which
may
be expected for a full year. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year
2020
will be
0%.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares

Dec. 31, 2019

Jun. 30, 2019

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized (in shares) 7,000,000 7,000,000

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 200,000,000 200,000,000

Common stock, shares issued (in shares) 67,388,047 67,388,047

Common stock, shares outstanding (in shares) 67,388,047 67,388,047

Series B Preferred Stock [Member]

Preferred stock, shares authorized (in shares) 5,000,000 5,000,000

Preferred stock, shares issued (in shares) 59,065 59,065

Preferred stock, shares outstanding (in shares) 59,065 59,065

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 8 - Fair Value Measurements
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Fair Value Disclosures [Text Block]

8.

Fair Value Measurements

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands):

Fair Value at December 31, 2019

Total

Level 1

Level 2

Level 3

Cash and cash equivalents
$
3,180
$
3,180
$
-
$
-

Fair Value at June 30, 2019

Total

Level 1

Level 2

Level 3

Cash and cash equivalents
$
5,326
$
5,326
$
-
$
-

The Company’s cash and cash equivalent instruments are classified within Level
1
of the fair value hierarchy because they are valued using quoted market prices.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 9 - Leases - Future Operating Lease Payments and Lease Liability (Details) - USD ($)
$ in Thousands

Dec. 31, 2019

Jun. 30, 2019

2020 (remaining nine months of the year) $ 145

2021 290

2022 290

2023 290

2024 237

Total 1,252

Less: Imputed Interest (134)

Total Lease Liability 1,118

Less current portion (229)

Non-current Lease Liability $ 889

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 32 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 6 - Share-Based Compensation - Summary of Stock Options (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
6 Months Ended

Dec. 31, 2019

USD ($)

$ / shares

shares

Outstanding (in shares) | shares 4,651

Outstanding, weighted exercise price (in dollars per share) | $ / shares $ 0.64

Outstanding, weighted average contractual term (Year) 7 years 167 days

Outstanding, intrinsic value | $ $ 418

Vested and expected to vest, Options (in shares) | shares 4,651

Vested and expected to vest, weighted exercise price (in dollars per share) | $ / shares $ 0.64

Vested and expected to vest, weighted average contractual term (Year) 7 years 167 days

Vested and expected to vest, intrinsic value | $ $ 418

Vested and exercisable (in shares) | shares 2,956

Vested and exercisable, weighted exercise price (in dollars per share) | $ / shares $ 0.74

Vested and exercisable, weighted average contractual term (Year) 6 years 259 days

Vested and exercisable, intrinsic value | $ $ 172

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 33 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 34 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 11 - Contracts With Customers - Concentration of Customers (Details)
6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Revenue Benchmark [Member] | Customer Concentration Risk [Member] | El Camino, Los Gatos, & Other Facilities [Member]

Concentration Risk, Percentage 23.60% 22.26%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=isr_ElCaminoLosGatosOtherFacilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 5 - Property and Equipment (Tables)
6 Months Ended

Dec. 31, 2019

Notes Tables

Property, Plant and Equipment [Table Text Block]

December 31,

June 30,

2019

2019

Land
$
366
$
366

Equipment

3,873

3,825

Leasehold improvements

4,143

4,143

Other
1

801

645

Property and equipment

9,183

8,979

Less accumulated depreciation

(7,447

)

(7,370

)

Property and equipment, net
$
1,736
$
1,609

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 11 - Contracts With Customers (Tables)
6 Months Ended

Dec. 31, 2019

Notes Tables

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

Six Months Ended December 31,

Facility

2019
% of
total

revenue

2018
% of
total

revenue

El Camino, Los Gatos, & other facilities

23.60

%

22.26

X

- Definition
Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592
+ Details

Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 4 - Inventory - Noncurrent Inventory (Details) - USD ($)
$ in Thousands

Dec. 31, 2019

Jun. 30, 2019

Total inventory, non-current $ 127 $ 155

Enriched Barium Inventory [Member]

Total inventory, non-current 116 117

Raw Materials [Member]

Total inventory, non-current $ 11 $ 38

X

- Definition
Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(d))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=isr_EnrichedBariumInventoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=isr_RawMaterialsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 10 - Shareholders' Equity (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended

Jul. 11, 2018

Dec. 31, 2019

Dec. 31, 2018

Proceeds from Issuance of Common Stock $ 7,381

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 5,830,000

Private Placement [Member]

Stock Issued During Period, Shares, New Issues 11,000,000

Shares Issued, Price Per Share $ 0.75

Proceeds from Issuance of Common Stock $ 8,250

Payments of Stock Issuance Costs $ 750

Class of Warrant Or Right, Authorized, Percentage 50.00%

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 5,500,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.75

Private Placement [Member] | H.C. Wainwright & Co., LLC [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 330,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.9375

X

- Definition
Represents for percentage of unregistered warrants to purchased up to the number of common stock of Investors'
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightAuthorizedPercentage

Namespace Prefix: isr_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=isr_HCWainwrightCoLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 8 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands

Dec. 31, 2019

Jun. 30, 2019

Cash and cash equivalents $ 3,180 $ 5,326

Fair Value, Inputs, Level 1 [Member]

Cash and cash equivalents 3,180 5,326

Fair Value, Inputs, Level 2 [Member]

Cash and cash equivalents

Fair Value, Inputs, Level 3 [Member]

Cash and cash equivalents

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 6 - Share-Based Compensation (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 454,000 $ 454,000

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 332 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 0 0 0 0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 30,000 155,000 40,000 237,500

Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value $ 11,000 $ 52,000 $ 14,000 $ 87,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 0 0 8,250 10,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 0 32,000 26,250 70,750

X

- Definition
Fair value of the options grants in period.
+ References
No definition available.
+ Details

Name: isr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 42 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 3 - Loss Per Share
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Earnings Per Share [Text Block]

3.

Loss per Share

Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding and does
not
include the impact of any potentially dilutive common stock equivalents. At
December 31, 2019
and
2018,
the calculation of diluted weighted average shares did
not
include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company’s net loss position.

Securities
not
considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of
December 31, 2019
and
2018,
were as follows (in thousands):

December 31,

2019

2018

Series B preferred stock

59

59

Common stock warrants

6,080

6,080

Common stock options

4,651

3,917

Total potential dilutive securities

10,790

10,056

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (1,713,000) $ (2,922,000)

Adjustments to reconcile net loss to net cash used by operating activities:

Depreciation expense 77,000 65,000

Gain on equipment disposals (23,000)

Amortization of other assets 20,000 25,000

Accretion of asset retirement obligation 15,000 16,000

Gain on change in ARO estimate due to lease modification (73,000)

Share-based compensation 185,000 190,000

Changes in operating assets and liabilities:

Accounts receivable, net (255,000) 85,000

Inventory 13,000 53,000

Prepaid expenses and other current assets (190,000) (20,000)

Accounts payable and accrued expenses (51,000) (195,000)

Accrued protocol expense (109,000) 36,000

Accrued radioactive waste disposal 15,000 18,000

Accrued payroll and related taxes 114,000 (35,000)

Accrued vacation 21,000 (19,000)

Net cash used by operating activities (1,931,000) (2,726,000)

CASH FLOWS FROM INVESTING ACTIVITIES:

Additions to property and equipment (204,000) (225,000)

Proceeds from sale of equipment 23,000

Proceeds from maturity of certificates of deposit 4,418,000

Purchases of and interest from U.S. Treasury Securities (8,259,000)

Net cash used by investing activities (204,000) (4,043,000)

CASH FLOWS FROM FINANCING ACTIVITIES:

Preferred dividends paid (11,000) (11,000)

Proceeds from sales of common stock, pursuant to registered direct offering, net 7,381,000

Net cash (used) provided by financing activities (11,000) 7,370,000

Net increase (decrease) in cash, cash equivalents, and restricted cash (2,146,000) 601,000

Cash, cash equivalents, and restricted cash beginning of period 5,507,000 2,781,000

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD 3,361,000 3,382,000

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:

Cash and cash equivalents 3,180,000 3,201,000

Restricted cash 181,000 181,000

Total cash, cash equivalents, and restricted cash shown on the consolidated statements of cash flows 3,361,000 3,382,000

Non-cash investing and financing activities:

Recognition of operating lease liability and right of use asset 1,228,000

Warrants issued to placement agent of registered direct offering $ 163,000

X

- Definition
The amount of gain (loss) related to the change in ARO estimate.
+ References
No definition available.
+ Details

Name: isr_GainLossOnChangeInAROEstimate

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the amount of increase (decrease) in accrued payroll and related taxes.
+ References
No definition available.
+ Details

Name: isr_IncreaseDecreaseInAccruedPayrollAndRelatedTaxes

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in accrued protocol expense.
+ References
No definition available.
+ Details

Name: isr_IncreaseDecreaseInAccruedProtocolExpense

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in accrued vacation.
+ References
No definition available.
+ Details

Name: isr_IncreaseDecreaseInAccruedVacation

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of warrants issued in a non-cash financing activity
+ References
No definition available.
+ Details

Name: isr_NoncashFinancingActivitiesWarrantsIssued

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: isr_ReconciliatoinOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheetsAbstract

Namespace Prefix: isr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848
+ Details

Name: us-gaap_AssetRetirementObligationAccretionExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in current liabilities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 44 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 6 - Share-Based Compensation
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

6.

Share-Based Compensation

The following table presents the share-based compensation expense recognized for stock-based options during the
three
months ended
December 31, 2019
and
2018
(in thousands):

Three Months
ended December 31,

2019

2018

Cost of sales
$
8
$
10

Research and development expenses

19

18

Sales and marketing expenses

24

22

General and administrative expenses

43

47

Total share-based compensation
$
94
$
97

The following table presents the share-based compensation expense recognized for stock-based options during the
six
months ended
December 31, 2019
and
2018
(in thousands):

Six Months
ended December 31,

2019

2018

Cost of sales
$
16
$
20

Research and development expenses

38

36

Sales and marketing expenses

49

44

General and administrative expenses

82

90

Total share-based compensation
$
185
$
190

As of
December 31, 2019,
total unrecognized compensation expense related to stock-based options was approximately
$454,000
and the related weighted-average period over which it is expected to be recognized is approximately
.91
years.

A summary of stock options within the Company’s share-based compensation plans as of
December 31, 2019
was as follows (in thousands except for exercise prices and terms):

Weighted

Weighted

Average

Number of

Exercise

Contractual

Intrinsic

As of December 31, 2019

Options

Price

Term (Years)

Value

Outstanding

4,651
$
.64

7.46
$
418

Vested and expected to vest

4,651
$
.64

7.46
$
418

Vested and exercisable

2,956
$
.74

6.71
$
172

There were
no
stock options exercised during the
three
months ended
December 31, 2019
and
2018,
respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.

There were
30,000
and
155,000
option awards granted with a fair value of approximately
$11,000
and
$52,000
during the
three
months ended
December 31, 2019
and
2018,
respectively.

There were
no
stock option awards which expired during the
three
months ended
December 31, 2019
and
2018,
respectively.

There were
no
and
32,000
stock option awards forfeited during the
three
months ended
December 31, 2019
and
2018,
respectively.

There were
no
stock options exercised during the
six
months ended
December 31, 2019
and
2018,
respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.

There were
40,000
and
237,500
option awards granted with a fair value of approximately
$14,000
and
$87,000
during the
six
months ended
December 31, 2019
and
2018,
respectively.

There were
8,250
and
10,000
stock option awards which expired during the
six
months ended
December 31, 2019
and
2018,
respectively.

There were
26,250
and
70,750
stock option awards forfeited during the
six
months ended
December 31, 2019
and
2018,
respectively.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 10 - Shareholders' Equity
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

10
.

Shareholders’ Equity

On
July 11, 2018,
the Company completed the closing of a registered direct offering with several institutional and accredited investors (each an “Investor”) for the sale of a total of
11,000,000
shares of common stock of the Company (“Shares”) at a price per share of
$0.75,
for aggregate gross proceeds to the Company of
$8.25
million. Cash expenses relating to this offering were approximately
$0.75
million.

In a concurrent private placement, the Company sold to each Investor, at
no
additional consideration, unregistered warrants to purchase up to the number of shares of common stock of the Company equal to
50%
of such Investor’s Shares or a total of
5,500,000
shares, with an exercise price of
$0.75
per share, exercisable from
January 11, 2019
until
January 11, 2024 (
the “Investor Warrants”). The Company also issued warrants to purchase up to
330,000
shares of common stock of the Company, at an exercise price of
$0.9375,
exercisable from
January 11, 2019
until
July 10, 2023,
to representatives of H.C. Wainwright & Co., LLC (“Wainwright”), the placement agent for the registered direct offering, as part of its compensation (the “Placement Agent Warrants” and together with the Investor Warrants, the “Warrants”).

The aggregate number of shares of our common stock issuable upon the exercise of the Warrants is
5,830,000
shares relating to this offering. We will receive gross proceeds from this offering solely to the extent any Warrants are exercised for cash.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Document And Entity Information - shares
6 Months Ended

Dec. 31, 2019

Feb. 11, 2020

Document Information [Line Items]

Entity Registrant Name IsoRay, Inc.

Entity Central Index Key 0000728387

Trading Symbol isr

Current Fiscal Year End Date --06-30

Entity Filer Category Non-accelerated Filer

Entity Current Reporting Status Yes

Entity Emerging Growth Company false

Entity Small Business true

Entity Common Stock, Shares Outstanding (in shares) 67,650,547

Entity Shell Company false

Document Type 10-Q

Document Period End Date Dec. 31, 2019

Document Fiscal Year Focus 2020

Document Fiscal Period Focus Q2

Amendment Flag false

Title of 12(b) Security Common stock, $0.001

Entity Interactive Data Current Yes

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 47 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 7 - Commitments and Contingencies (Details Textual)
1 Months Ended

Dec. 31, 2015

Purchase Agreement Period 1 year

X

- Definition
This element represents the period of purchase for which the entity is enabled to purchase.
+ References
No definition available.
+ Details

Name: isr_PurchaseAgreementPeriod

Namespace Prefix: isr_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 48 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands

Dec. 31, 2019

Jun. 30, 2019

Property and equipment, gross $ 9,183 $ 8,979

Less accumulated depreciation (7,447) (7,370)

Property and equipment, net 1,736 1,609

Land [Member]

Property and equipment, gross 366 366

Equipment [Member]

Property and equipment, gross 3,873 3,825

Leasehold Improvements [Member]

Property and equipment, gross 4,143 4,143

Other [Member]

Property and equipment, gross ^[1] $ 801 $ 645

[1] Includes plant and equipment not placed in service which are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at December 31, 2019 and June 30, 2019 are costs associated with advance planning and design work on the Company’s new production facility of $207,000.

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=isr_OtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 9 - Leases - Asset Retirement Obligation (Details) - USD ($)
3 Months Ended 6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Beginning balance $ 621,000 $ 590,000

Accretion of discount 15,000 16,000

Gain on change in ARO estimate due to lease modification (73,000)

Ending Balance $ 563,000 $ 606,000 $ 563,000 $ 606,000

X

- Definition
The amount of gain (loss) related to the change in ARO estimate.
+ References
No definition available.
+ Details

Name: isr_GainLossOnChangeInAROEstimate

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849
+ Details

Name: us-gaap_AssetRetirementObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848
+ Details

Name: us-gaap_AssetRetirementObligationAccretionExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 50 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 7 - Commitments and Contingencies
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

7.

Commitments and Contingencies

Isotope Purchase Agreement

In
December 2015,
the Company completed negotiations with The Open Joint Stock Company (located in Russia) for the purchase of Cesium-
131
manufactured by the Institute of Nuclear Materials. The purchase agreement provided the Company with
one
year’s supply of Cesium-
131.
The original agreement was due to expire on
March 31, 2017,
but in
December 2016
an addendum was signed extending it until
December 31, 2017.
On
October 23, 2017,
the Company, together with The Open Joint Stock Company, signed an addendum to the contract to include Cesium-
131
manufactured at RIAR and extending it until
December 31, 2018.
On
December 24, 2018,
an addendum was signed extending the term of the supply contract through
December 31, 2019
and modifying the volume of additional shipments of Cesium-
131.
Under the addendum, current pricing and volumes for Cesium-
131
purchases remained in place until
May 31, 2019.
On
July 11, 2019,
another addendum was signed extending the pricing terms until
August 4, 2019.
On
July 30, 2019,
a new supply contract was signed with The Open Joint Stock Company for a term of
August 2019
to
December 2020
as the Company had purchased the maximum amount of Cesium-
131
permitted under the prior agreement.

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands
3 Months Ended 6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Sales, net $ 2,206,000 $ 1,904,000 $ 4,521,000 $ 3,466,000

Cost of sales 1,095,000 1,139,000 2,174,000 2,177,000

Gross profit 1,111,000 765,000 2,347,000 1,289,000

Research and development:

Proprietary research and development 277,000 395,000 510,000 789,000

Collaboration arrangement, net of reimbursement 19,000 45,000

Total research and development 277,000 414,000 510,000 834,000

Sales and marketing 666,000 702,000 1,481,000 1,351,000

(Gain) on equipment disposal (23,000) (23,000)

General and administrative 1,071,000 1,101,000 2,168,000 2,074,000

(Gain) on change in estimate of asset retirement obligation (Note 9) (73,000)

Total operating expenses 2,014,000 2,194,000 4,086,000 4,236,000

Operating loss (903,000) (1,429,000) (1,739,000) (2,947,000)

Non-operating income:

Interest income, net 6,000 15,000 26,000 25,000

Non-operating income 6,000 15,000 26,000 25,000

Net loss (897,000) (1,414,000) (1,713,000) (2,922,000)

Preferred stock dividends (2,000) (2,000) (5,000) (5,000)

Net loss applicable to common shareholders $ (899,000) $ (1,416,000) $ (1,718,000) $ (2,927,000)

Basic and diluted loss per share (in dollars per share) $ (0.01) $ (0.02) $ (0.03) $ (0.04)

Weighted average shares used in computing net loss per share:

Basic and diluted (in shares) 67,388 67,331 67,388 66,743

X

- Definition
The amount of gain (loss) related to the change in ARO estimate.
+ References
No definition available.
+ Details

Name: isr_GainLossOnChangeInAROEstimate

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of research and development expense during the period related to the collaboration services, net of reimbursement.
+ References
No definition available.
+ Details

Name: isr_ResearchAndDevelopmentCollaborationServicesNetOfReimbursement

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of research and development expense during the period related to the proprietary research and development.
+ References
No definition available.
+ Details

Name: isr_ResearchAndDevelopmentProprietaryResearchAndDevelopment

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 11 - Contracts With Customers
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

11.

Contracts with Customers

We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms, and in most cases, prices for the products that we offer. However, these agreements do
not
obligate us to provide goods to the customer and there is
no
consideration promised to us at the onset of these arrangements. For customers without separate agreements, we have a standard list price established for all products and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is
not
controlling. Our performance obligations are established when a customer submits a purchase order or e-mail notification (in writing, electronically or verbally) for goods, and we accept the order. We identify performance obligations as the sale of our products and services as requested from our customers. We generally recognize revenue upon the satisfaction of these criteria when control of the product has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are
not
affected by contingent events that could impact the transaction price. We do
not
offer price concessions and do
not
accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do
not
have any material performance obligations where we are acting as an agent for another entity.

Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are
no
further performance obligations.

Sources of Revenue

We have identified the following revenues disaggregated by revenue source:

1.
Domestic – direct sales of products and services.

2.
International – direct sales of products and services.

During the
three
months ended
December 31, 2019,
the Company did
not
have any international revenue and had a nominal amount during the
three
months ended
December 31, 2018.

During the
six
months ended
December 31, 2019,
the Company did
not
have any international revenue and had a nominal amount during the
six
months ended
December 31, 2018.

For the
three
months ended
December 31, 2019
and
2018,
respectively, prostate brachytherapy comprised
89%
of our revenue while other revenue comprised
11%
.

For the
six
months ended
December 31, 2019
and
2018,
respectively, prostate brachytherapy comprised
89%
of our revenue while other revenue comprised
11%
.

Contract Balances

We incur obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate.

Warranty

Our general product warranties do
not
extend beyond an assurance that the product delivered will be consistent with stated specifications and do
not
include separate performance obligations.

Returns

Generally, we allow returns if
not
implanted and we are notified within a few weeks after satisfying our performance obligations of a return. Returns after shipment
may
result in a
50%
restocking fee.

Significant Judgments in the Application of the Guidance in ASC
606

There are
no
significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

Commissions and Contract Costs

We expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do
not
incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.

Practical Expedients

Our payment terms for sales direct to customers and distributors are substantially less than the
one
year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Shipping and Handling Charges

Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of sales.

Taxes Collected from Customers

As our products are used in another service and are exempt, to this point we have
not
collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities.

Concentration of Customers

One group of customers, facilities or physician practices has revenues that aggregate to greater than
10%
of total Company sales. While the aggregate members of the group aggregate to more than
10%
of total Company sales,
no
single member of the group has revenues greater than
10%
of total Company sales. These facilities are serviced by the same physician group,
one
of whom is our Medical Director:

Six Months Ended December 31,

Facility

2019
% of
total

revenue

2018
% of
total

revenue

El Camino, Los Gatos, & other facilities

23.60

%

22.26

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 2 - New Accounting Standards
6 Months Ended

Dec. 31, 2019

Notes to Financial Statements

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

2.

New Accounting
Standards

Accounting Standards Updates Adopted

In
February 2016,
the FASB issued ASU
2016
-
02
Leases (Subtopic
842
), which requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update was effective for annual and interim reporting periods beginning after
December 15, 2018
and early adoption was permitted. The ASU became effective for, and was adopted by, the Company in the
first
quarter of the fiscal year ending
June 30, 2020.
The Company elected the transition option to apply the new guidance at the effective date without adjusting comparative periods presented.

Accounting Standards Updates to Become Effective in Future Periods

In
November 2018,
the FASB issued ASU
2018
-
18,
Collaborative Arrangements (Topic
808
): Clarifying the Interaction Between Topic
808
and Topic
606,
which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic
606.
The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after
December 15, 2019,
with early adoption permitted. The Company is in the process of evaluating the impact the standard will have on its financial statements.

Other accounting standards that have been issued or proposed by FASB that do
not
require adoption until a future date are
not
expected to have a material impact on the consolidated financial statements upon adoption. The Company does
not
discuss recent pronouncements that are
not
anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 11 - Contracts With Customers (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2019

Restocking Fee, Percentage 50.00% 50.00%

Prostate Brachytherapy [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]

Concentration Risk, Percentage 89.00% 89.00%

Product and Service, Other [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]

Concentration Risk, Percentage 11.00% 11.00%

Geographic Distribution, Foreign [Member]

Revenue from Contract with Customer, Excluding Assessed Tax, Total $ 0 $ 0

X

- Definition
Represents the percentage of the item price which will be used as a restocking fee in the case of a return after shipment.
+ References
No definition available.
+ Details

Name: isr_RestockingFeePercentage

Namespace Prefix: isr_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=isr_ProstateBrachytherapyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�"-$AN1$N;WZRU/VJ[8^\>CVY+OKB\*\--W3N'U>77Y-=GG1E.?AEW++Z\_UUO\!4$L#!!0 ( M 9"3%"P_ 3ZLP$ -(# 8 >&PO=V]R:W-H965T&UL M;5/;;MLP#/T501]0)4YZ66 ;:%H4'; !08>MSXI-VT(ET97DN/O[2;+CN:E? M+)+F.3RDJ+1'\V8; $<^E-0VHXUS[8XQ6S2@N+W"%K3_4Z%1W'G7U,RV!G@9 M04JR9+6Z88H+3?,TQ@XF3[%S4F@X&&([I;CYNP>)?4;7]!QX$77C0H#E:$/P)Z.[-)Z.2(^!:<[V5&5T$0 M2"A<8.#^.,$#2!F(O(SWD9-.)0-P;I_9GV+OOI-Y:K G9IA]R\,5KW>)GTT1@G$4\9\7;WWTE*^O;U)V"D1C MSG[(2>8Y4P;S[%.)9*G$/OD"3Y;AFT6%FPC??%)XNTRP72381H+M)X*[BQ:7 M&PO=V]R:W-H965T&UL;5-A;YPP M#/TK47Y [EK.YT J==IVJ1-.G7:]CD'!J(FA"7AZ/[]G,!1=N,+L8W?\[/C M9*.QKZX%\.1-J\[EM/6^/S#FRA:T<'>FAP[_U,9JX=&U#7.]!5%%D%:,)\D# MTT)VM,AB[&2+S Q>R0Y.EKA!:V'_'$&9,:9-/Z$&!%UHL&OH/_T9\L M>FQAJ:2&SDG3$0MU3I_2PW$?\F/"3PFC6]DD='(VYC4X7ZJ<)D$0*"A]8!!X M7. 9E I$*./WS$F7D@&XMJ_LGV+OV,M9.'@VZI>L?)O3#Y144(M!^14DMSA"K7X MP!9'0>V#^8BVG=9L5-2VX)VSO5'QFS5@>+V!GO0_J9!H[CSIFF9[0WP.I*49,EN=\L4%YJ6>?2= M39GCX*30<#;$#DIQ\_L$$L>"[NF[XT6TG0L.5N8];^$;N._]V7B++2JU4*"M M0$T,- 5]V!]/6,O$Q*I0VKJ0:K$,UJ_A4%'^;=J'C/DXW:3+3M@G)3$@6PGV,PZ9 ,?,G M[GB9&QR)F7K?\_#$^V/B>U,%9VQ%O//)6^^]EOO;-&?7(#1C3A,F66,6!//J M2XAD*\0I^8^>;-/3S0S32$_7T0]WVP+9ID 6!;)_2LP^E+B%.7P(PE8]56#: M.$V65#CH.,DK[S*P#_$1V5_X-.U?N6F%MN2"SK]L['^#Z,"GLKOQ(]3Y#[88 M$AH7CG?^;*8QFPR'_?R#V/*-RS]02P,$% @ !D),4")TMZ.W 0 T@, M !D !X;"]W;W)K&UL;5/M;ILP%'T5RP]0)X0F M401(3:MJDS8IZK3MMP,7L.H/9IO0O?VN#66LXX_M>WW.N1^^S@9C7UT+X,F; MDMKEM/6^.S'FRA84=W>F XTWM;&*>S1MPUQG@5>1I"1+-IL]4UQH6F31=[%% M9GHOA8:+):Y7BMO?9Y!FR.F6OCM>1-/ZX&!%UO$&OH'_WETL6FQ6J80"[831 MQ$*=TX?MZ9P&? 3\$#"XQ9F$2J[&O ;C)*RMYYHR853$7QMW$7.N[#>+-+)]HZ(9D(R4PXQCAL#!0S?^*> M%YDU [%C[SL>GGA[2K W97#&5L0[3-ZA]U9L]_N,W8+0A#F/F&2)F1$,U><0 MR5J(<_(?/5FG[U8SW$7Z;AG]_K ND*X*I%$@_:?$PX<2US#'#T'8HJ<*;!.G MR9'2]#I.\L([#^Q#$M_D+WR<]J_<-D([7S;VOS;& Z:RN<,1:O&#S8:$ MVH?C <]V'+/1\*:;?A";OW'Q!U!+ P04 " &0DQ02\C\][*"TW+//HNILQQ M<%)HN!AB!Z6X^7,&B6-!=_3-\2S:S@4'*_.>M_ =W(_^8KS%%I5:*-!6H"8& MFH(^[D[G+. CX*> T:[.)%1R17P)QI>ZH$E(""14+BAPO]W@":0,0CZ-W[,F M74(&XOK\IOXIUNYKN7(+3RA_B=IU!7V@I(:&#](]X_@9YGH.E,S%?X4;2 \/ MF?@8%4H;5U(-UJ&:57PJBK].N]!Q'Z>;0S;3M@GI3$@7PD.,PZ9 ,?./W/$R M-S@2,_6^Y^&)=Z?4]Z8*SMB*>.>3M]Y[*W?W'W)V"T(SYCQATC5F03"OOH1( MMT*3.CU#G/]AB2&A< M.![]V4QC-AD.^_D'L>4;EW\!4$L#!!0 ( 9"3% .P(1M@$ -(# 9 M >&PO=V]R:W-H965T[EG',_N*2#L<^N ?#D5:O6 M9;3QOCLRYHH&M' WIH,6;RICM?!HVIJYSH(H(TDKQC>;6Z:%;&F>1M_9YJGI MO9(MG"UQO=;"_CV!,D-&M_3-\2CKQ@<'R]-.U/ +_._N;-%BLTHI-;1.FI98 MJ#)ZOSV>DH"/@#\2!K M,L$8A5$NKJ3HG3=Z4L%4M'@==]G&?1AODOU$6R?PBU,$9VQ%O,/D'7JO^?; 4W8-0A/F-&+X$C,C&*K/(?A: MB!/_C\[7Z;O5#'>1OEM&WQ_6!9)5@20*)!]*W'TJ<0V3? K"%CW58.LX38X4 MIF_C)"^\\\#>\_@F[_!QVG\*6\O6D8OQ^+*Q_Y4Q'C"5S0V.4(,?;#845#X< M#WBVXYB-AC?=](/8_(WS?U!+ P04 " &0DQ0)0.N);8! #2 P &0 M 'AL+W=O;$]XW/.7#S.!F-?7 O@R9N2VN6T M];X[,N;*%A1W-Z8#C3>UL8I[-&W#7&>!5Y&D)$LVFUNFN-"TR*+O;(O,]%X* M#6=+7*\4MW].(,V0TRW]<#R)IO7!P8JLXPT\@__9G2U:;%:IA +MA-'$0IW3 M^^WQE 9\!/P2,+C%F81*+L:\!.-;E=--2 @DE#XH<-RN\ !2!B%,XW72I'/( M0%R>/]2_QMJQE@MW\&#D;U'Y-J=WE%10\U[Z)S,\PE3/GI*I^.]P!8GPD G& M*(UT<25E[[Q1DPJFHOC;N L=]V&\V:<3;9V03(1D)MS%.&P,%#/_PCTO,FL& M8L?>=SP\\?:88&_*X(RMB'>8O$/OM=@>]AF[!J$)*K!-G"9'2M/K M.,D+[SRP]TE\D[_P<=I_<-L(['S9V/_:& ^8RN8&1ZC%#S8;$FH?C@<\ MVW',1L.;;OI!;/[&Q3M02P,$% @ !D),4,^Q*PFX 0 T@, !D !X M;"]W;W)K&UL;5/M;ML@%'T5Q ,4QTF;++(M-:VJ M3=JDJ-.ZW\2^ME&!ZP&.N[4/T7EVIP>**F@YKUTSSA\AJF>6TJFXK_"%:2'ATQ\C!*E MC2LI>^M032H^%<7?QEWHN _CS?9NHJT3THF0SH1#C,/&0#'S1^YXD1D&UL;5/;;MP@$/T5Q >$-=XTJY5M*9LJ M2J566J5J^\S:8QL%C MXG?Y]!^PX;NH78(9SSEP8LM'8%]<">/*J5>=RVGK? M'QES90M:N!O30X#1MPUQO0521I!7CN]TGIH7L:)%%W]D6F1F\DAV< M+7&#UL+^.8$R8TX3^N9XEDWK@X,562\:^ [^1W^V:+%%I9(:.B=-1RS4.;U/ MCJ=]P$? 3PFC6YU)J.1BS$LPOE0YW86$0$'I@X+ [0H/H%00PC1^SYIT"1F( MZ_.;^F.L'6NY" J"D@EH,RC^;\0GF>FXIF8O_"E=0" ^98(S2 M*!=74@[.&SVK8"I:O$Z[[.(^3C?I8:9M$_A,X OA$..P*5#,_+/PHLBL&8F= M>M^+\,3)D6-ORN",K8AWF+Q#[[5(#DG&KD%HQIPF#%]C%@1#]24$WPIQXO_1 M^38]W&PO M=V]R:W-H965T$M%$$2$VK:I,V M*>JT[;<#%[#J#V:;T+W]K@UAK../[7M]SKD?OLX&8]]<"^#)NY+:Y;3UOCLR MYLH6%'=WI@.--[6QBGLT;<-<9X%7D:0D2S:;>Z:XT+3(HN]LB\ST7@H-9TM< MKQ2WOT\@S9#3+;TY7D73^N!@1=;Q!KZ!_]Z=+5IL5JF$ NV$T<1"G=/'[?&4 M!GP$_! PN,69A$HNQKP%XW.5TTU(""24/BAPW*[P!%(&(4SCUZ1)YY"!N#S? MU%]B[5C+A3MX,O*GJ'R;TP,E%=2\E_[5#)]@JF=/R53\%[B"1'C(!&.41KJX MDK)WWJA)!5-1_'WRVVAS1CUR T84XC)EEB9@1#]3E$LA;BE/Q'3];I MN]4,=Y&^6T;?/ZP+I*L":11(_REQ_Z'$-ATG>>&= M!_8QB6_R%SY.^U=N&Z$=N1B/+QO[7QOC 5/9W.$(M?C!9D-"[N.C-FR M!<7M#7:@_4V-1G'G3=,PVQG@520IR9+-YA-37&A:9-%W-D6&O9-"P]D0VRO% MS>\32!QRNJ7OCF?1M"XX6)%UO('OX'YT9^,M-JM40H&V C4Q4.?T?GL\I0$? M 2\"!KLXDU#)!?$U&%^JG&Y"0B"A=$&!^^T*#R!E$/)I_)HTZ1PR$)?G=_6G M6+NOY<(M/*#\*2K7YO1 204U[Z5[QN$S3/7<4C(5_Q6N(#T\9.)CE"AM7$G9 M6X=J4O&I*/XV[D+'?1AOTKN)MDY()D(R$PXQ#AL#Q-%9G @9NQ]Q\,3 M;X^)[TT9G+$5\X^!&&+GBHP39PF2TKL=9SDA7<> MV/LDOLE?^#CMW[AIA+;D@LZ_;.Q_C>C I[*Y\2/4^@\V&Q)J%XY[?S;CF(V& MPV[Z06S^QL4?4$L#!!0 ( 9"3%!PL>E7L@$ -(# 9 >&PO=V]R M:W-H965T,;N@E\"CKQH4 R]-.U/ 3W*_N:+S'9I92:FBMQ)88J#)ZM]D?=B$_ M)CQ)&.S")J&3$^)+<+Z5&4V"(%!0N, @_'&&>U J$'D9OR=..I<,P*5]87^( MO?M>3L+"/:IG6;HFHY\H*:$2O7*/.'R%J9\/E$S-?XE/@:!2H;OZ3H MK4,]L7@I6KR.IVSC.4S\%]@Z@$\ ?@5@8Z&H_(MP(D\-#L2,L^]$N.+-GOO9 M%"$81Q'_>?'61\_YYG.2LG,@FG(.8PY?YLP9S+//)?A:B0/_!\[7X=M5A=L( MW[Y3^)_ZNU6"7238O2/@5RVNY6ROBK#%3#68.FZ3)07V;=SD171>V#L>[^0M M?=SV'\+4LK7DA,[?;)Q_A>C 2TEN_ HU_H'-CH+*!?.CM\VX9J/CL)M>$)N? M&PO=V]R:W-H965T MA=!5B%)<)*L5M=$4"9QD87841>9ZBUG$HX:F5X(JC\.P-60 MXS7^##RSIK4^0(JLHPW\!/NK.VJW(C-+Q01(PY1$&NH)R_LG^$&IWM9RH M@3O%?[/*MCG>851!37MNG]7P"%,]*493\3_@#-S!O1.G42INPA>5O;%*3"S. MBJ#OX\AD&(=Q)]U,:?&$9$I(YH1=T"&C4'!^3RTM,JT&I,>S[ZB_XO4^<6=3 M^F XBK#GS!L7/1?K;]N,G#W1A#F,F&2)F1'$L<\224SBD/R3GL33-U&'FY"^ M^>+P/_K;*,$V$&R_$*07)<8PUW&1-"J21@AN+D1BF-V%"%ES8F']$\V@[ D2\Q:^@_O1GXVWV()2"P7:"M3$0%/0 MN]WQE(7X&/!3P&A79Q(JN2 ^!N-+7= D" ()E0L(W&]7N \S V. MQ$R][WEXXMTQ];VI@C.V(MYY\=9[K^7N<,C9-0#-,:&UL=51A;]L@$/TKB!]0'!)W6V1;:EI5 MG=1*4:=MGXE]ME'!N(#C[M\/L.-Y&?L2N/.[]]X!EVQ4^LVT !9]2-&9'+?6 M]GM"3-F"9.9&]="Y+[72DED7ZH:87@.K0I$4A";)+9&,=[C(0NZHBTP-5O . MCAJ904JF?QU J#''&WQ)O/*FM3Y!BJQG#7P#^[T_:A>1A:7B$CK#58_DI-2;#[Y6.4Z\(1!06L_ W'*&>Q#"$SD;[S,G7B1] MX7I_87\,O;M>3LS O1(_>67;''_&J(*:#<*^JO$)YGY2C.;FG^$,PL&]$Z=1 M*F'"+RH'8Y6<69P5R3ZFE7=A'6?^2UF\@,X%]*J 3$+!^0.SK,BT&I&>SKYG M_HHW>^K.IO3)R5"5A3V>GK+4V!5/X\I6?XKBM]02P,$% @ !D),4)N,'NJT 0 MT@, !D !X;"]W;W)K&UL=5-M;YLP$/XKEG] M39QT;2- :CI-F[1)4:=UGQTXP*K-,=N$[M_/-H2QC'[!=\?S//?B;4- M@"-O6K4VHXUSW9XQ6S2@A;W!#EK_IT*CA?.NJ9GM#(@RDK1B/$D^,"UD2_,T MQHXF3[%W2K9P-,3V6@OS^P *AXQNZ"7P+.O&A0#+TT[4\!W43,U_ MA3,H#P^5^!P%*AN_I.BM0SVI^%*T>!M/V<9SF/0OM'4"GPC\BL#&1+'RC\*) M/#4X$#/.OA/ABC=[[F=3A& <1?SGB[<^>LYYR8S8Q@7GU. MP==2'/A_=+Y.WZY6N(WT[3+[PSOY=ZL"NRBP^Z?%^ZL6US /5TG88J8:3!VW MR9("^S9N\B(Z+^PCCW?R%SYN^S=A:ME:T)LV8)D]DIWH/Q.K8UDSB]-0VQG@%4Q20I"D^2:2,85+K(8.YHB MT[T37,'1(-M+RM7\+B>Y7C)!@" :4+#,P/9[@'(0*1M_$Z M<>)9,B0NY^_LWV+MOI83LW"OQ3.O7)OC&XPJJ%DOW*,>'F"J9X?15/P/.(/P M\.#$:Y1:V/A%96^=EA.+MR+9VSAR%<=AW+F^G=+6$^B40.>$FZA#1J'H_"MS MK,B,'I 9S[YCX8K3/?5G4X9@/(JXY\U;'ST7-$TR<@Y$$^8P8N@"D\X(XMEG M";HF<:#_I=/U],VJPTU,WRS5;S_1WZX2;"/!]I\2TXL2US"?N-RMBNQ6"#87 M(FN8[84(65R<3+[G6 MVH&WDEQY+ZWOXGDAH'9A^L7/S?B6QX73W=2F9/Y7%'\!4$L#!!0 ( 9" M3%">8==#MP$ -(# 9 >&PO=V]R:W-H965T[ F"T:T,+>8 >MOZG0:.&\:6IF.P.BC"2M M&-]L[I@6LJ5Y>GDZ?8.R5;.!EB>ZV%^74$A4-&$WIUO,BZ<<'!\K03-7P% M]ZT[&6^Q6:64&EHKL24&JHP^)(?C+N CX+N$P2[.)%1R1GP-QJUG(6%1U0_9.F:C-Y34D(E>N5> M5'PJ6KR-NVSC/HPW^RMMG< G M I\)]Y' QD Q\R?A1)X:'(@9>]^)\,3)@?O>%,$96Q'O?/+6>R\Y3VY3=@E" M$^8X8O@"D\P(YM7G$'PMQ)'_0^?K].UJAMM(WRZC?_A/_-VJP"X*[/XJ\>Y= MB6N8_;L@;-%3#::.TV1)@7T;)WGAG0?V@<&UL;5/M M;ITP#'V5* _00&Z_=@5(O:VJ3=JDJT[K?N>"@:@)84FX=&\_)U!&6_X0VSG' M/C9.-AK[XEH 3UZUZEQ.6^_[/6.N;$$+=V%ZZ/"F-E8+CZYMF.LMB"J2M&(\ M2:Z9%K*C119C1UMD9O!*=G"TQ U:"_OW ,J,.4WI6^!)-JT/ 59DO6C@)_A? M_=&BQY8LE=30.6DZ8J'.Z5VZ/^P"/@*>)8QN99/0R@5$B$,O[,.>E2,A#7]EOVQ]@[]G(2#NZ-^BTKW^;TEI(*:C$H_V3& MKS#W%""-4JC7/R2Z#D+2M'B=3IE%\]QNKFZF6G;!#X3 M^$+ VJ&7J5!4_B"\*#)K1F*GV?BYX>INQV.FS 0?!7$ YR)^0HG M@G1)5;52*T57M?WMD$U 9V-J.^'Z]K4-(0E8U_P)]C(S.P/QDG=R;)CO,WL_FZ7_F!,0042F44B+Z<80.4 M&B%MX\^@Z8\M#?%V?5'_;+/K+#LB8?8$A3^Q[ M0_AO< :JX<:)[E%R*NVO5YZDXFQ0T588>>^O=6.OW:!_H;D)>"#@D:![?T0( M!T)X)40V?._,1OU$%"ERP3M/]"^K)>8_L7@.]<,L3=$^.WM/IY6Z>BXP7N3H M;(0&S+K'X!O,%8&T^M@"NUJL\8R.[QMLYH@E=G<(G2%"RX_N0DQZK'M,;#%- M'R)(LV#BQ(4*XL1M)G*:B69FDLS-CYW\^($P\)7IY_-W(HYU([T= M5WJTV %PX%R!]A@\:7N5_B2,&PH'99:I7HM^,/8;Q=MAYJ/QPU/\ U!+ P04 M " &0DQ0@&$ S^0! G!0 &0 'AL+W=OCT);>,W2] P&V?,A$- >T.=H7V5&;P4O/4QRLP],)R?. M7XWQO3F@T !A5J9#$0O5ZB 4I-(8_Q=[3O/)+EW"_ 'Q$A"O ='' ":SK7XABI2%X%,@YC]K)&8FHGVB M+[,V3GMW]DQW*[7W6L9Q5N"K2;1HGF9-O-7<*JI[19*O$JP!5HK82Q';^/2& M(G#1)X@=)O"")!V3G@,R:;%,DRAW8ZF/-#4CJ!4D]((\. M2'I7Q$&M[A5)Y*?(O!29A^*30Y'=W7F6.A-4>31)Z(#@S=^D,&) M*SW]=D9;SA7H?.MCI5VLU*+3*;'=Z+^9O=S84'Y=G":]O8_D?4$L#!!0 M ( 9"3%#%==F3W $ "$% 9 >&PO=V]R:W-H965TSCF>@T@V B&\@)?H/Z,QR$KO"B4G<,>MGQWA/0Y.@NV)>)P5O WPY&N9I[)LF1\U=3 M_*ASY!M#0*%21H'HX0(E4&J$M(VW61,MKS3$]?Q#_=%FUUF.1$+)Z4M7JS9' MM\BKH2%GJI[Y^ 1SGAAY<_B?< &JX<:)?D?%J;1/KSI+Q=FLHJTP\CZ-76_' M<5I)TYGF)H0S(5P(P>Y+0C03H@T!3\YLU >B2)$)/GIB^E@#,623)AX[3)(-DE&PO=V]R:W-H965TV$[=_7%Y8EX-WV);;'YYPY M,\&3]XP_BQI >B^4M*+P:RF[#4*BJH%B\< Z:-7-F7&*I3KR"Q(=!WPR)$I0 M& 0IHKAI_3(WL0,O&HNM=0!5.8=OL!W MD#^Z U]:'+Z?"#[0A M(%!)K8#5", MKT0^L?XS#/4DOC<4_Q5N0!1<.U$Y*D:$^?6JJY",#BK*"L4O=FU:L_;V)@T' MFIL0#H1P)*C<'Q&B@1"]$>(/"?% B&<$9$LQO=ECB(42/ZC&HM))C[?\9@Z4Z2.%)E;(',*9 Z!] M K^8@2*\BEU;J;^=272<68_F'<_BV]5F9T?/FXP=A-\POS2M\(Y,JB=I'LZ9 M,0G*9?"@>EVKV3L>")REWF9JS^T$L@?)NF&XHG'"EW\!4$L#!!0 ( 9" M3%"$,Q&PO=V]R:W-H965T-6+F%E.W2\\2^H#413ZREC5HY,EX3J8;\Y(F6 M4W(P1G7E!;X?>S4I&S?/S-PSSS-VEE79T&?NB'-=$_Y[32O6K5SD7B=>RE,A M]8279RTYT>]4OK;/7(V\TTW"*L#8SB1TD[,7EW="@[ MQM[TX,MAY?J:B%9T+[4+HAX7NJ%5I3TICE^#4W?<4QM.WZ_>/YG@53 [(NB& M53_+@RQ6;NHZ!WHDYTJ^L.XS'0**7&>(_BN]T$K)-8G:8\\J87Z=_5E(5@]> M%$I-WOMGV9AG-_B_FL$&P6 0/&H0#@;A:-!G\ZX!'@RP9>#UH9C<;(DD><99 MY_#^\[9$GR*TQ"K[>SUIDFW65'J$FKWD0;C(O(MV-&@VO2:8:FX5V[DBC$>) MIP!&B@"D"(P]GNZ ?8NBU\1&TQC- J6A!3(7I8MD :.$($H(H" +I==$DUT^ M)!@G%@ND"A,?AL$@#)[!8"OB#9[M@I))\GL40!3[=](2@201D)8 =A"##N(' M/G$\PPQC.Y1_:VY $A D 4!"V$$*.D@?B"2=4Z:)?5@A41#!* L090&@8-@! M\N'_O_] -(-H2HJ1?1*W_U/=XMPI1VB.*R1H417;80#7QD1WU M7!3C.Q\1V27G=A6N 6A>!&:H:U!DY\V;-(6:\I-IN,+9LW,C=3F^\[][]0+)VN)EXX_4H_P-02P,$% @ !D),4!,%',&; @ MD D !D !X;"]W;W)K&ULC99MKYHP%,>_"N$# MW/)408,D5W39DBTQ=[G;ZXI5R 7*VJIWWWYM041:96^D+;_S\&^/],070C]8 MCC&W/JNR9DL[Y[Q9 ,"R'%>(O9 &U^+-@= *<3&E1\ :BM%>&54E\!QG!BI4 MU'82J[4M36)RXF51XRVUV*FJ$/V[PB6Y+&W7OBZ\%<>E_>HN-G/)*^!7@2]L,+:DDATA'W+R;;^T'9D0+G'& MI0FH=V(_F5@])UX0QN L'77,JF6\ 1.Y]\A:1VX$$ GT67BF M+%:>9N[=!TAU(AHAZTDGFZ=.[M+TC9OE*_O@;K.BT6:US$PQM6("&#B.,TIV M$KM+)S"F$QC2F8_B&!CX( @T!H$&!Z/37[4,'(@9R4TGB?4DL7E&W F9&87, M#$)&!;*::2%\1SN[5*=<"/4CUK% =[;1*<\/X:-""(W20H,T?R0MU K.=75I M.@4]79G!EU[B&YV*PH<5'AF%109AP4A8-%E\D\1:)Z+AWZ35HT.N\U#/W*AG M;M #1WKFDWITPC<K??OP MZLGK:+2^I:UA?BW:C[0YN[MM>Y0>BQZ)FUHYP<0FJJ^I ",>=%Y)V+ M]JB?E/C Y3 48]HV">V$DZ;K?T#?A"7_ %!+ P04 " &0DQ0C7ZR_I8" M ")"0 &0 'AL+W=O9RYR+X&WXI +%?#FTP8?R$\B MWILUDSVO9]D5%:EY06N'D?W,?463#.D$C?A5D#,?M!TE94/IA^I\V\U<7U5$ M2K(5B@++UXDL25DJ)EG'GX[4[<=4BP2PF='B+J$R!C!:[5K,U=8X/F4T;/# MVO708+7LT"22T[5503T[^IOTD\OH:1Y$\=0[*:(.LV@QP0"3H%O(RH9<$9XL MH*\B@*I8!%9Z<#O TD8D!F3U7Y+L($-O\,]^,1Y[).RY> M94FI\MYJULBU7RK5KH) 'DI:$_G$6]KH?TY[421\XMB54-WPI.7NB;B[Y8RWJU]Y-\.7JISJ>(*>UOX&K;8H,@96\:NBG9RL/9/*GO-7L_EZ7/NAB8@R M>E#&!=&?*WVFC!E/.HX_@U-_9!K#Z?KF_;--7B>S)Y(^<_:[.JIR[6>^=Z0G M="@U>>N_56._W>#_ M9@8;X,$ CP:+U.;2@VSDGX@B12YXYXG^\EMB:HQ66-_-P1S:J[#_Z>"E/KT6 M.$%Y<#6.!LVVU^")YET1:.\C D.(+7XPQPF&'2S &!?6073G8.'$V&MBJVFL M)DKBF3 CD!(!E,BA])IL0@F?)J([2@Q28H 2.Q1(D\"0!(0D@(/4@?2:9'IA M*(,A*0A) 4CF0-(/5"4#*1E 63J4[ -568*4Y2,E#1T*H)FK"@KAMQ8"F(?' M%OY_8=#,FT8 ![L<]% ;O(SG$@)?]@9A .2^S$%T7YYTICP([@ (: &I^SA! M43S#@7L II FKBVYTF/ -NL3YXKJ6,(G7;]2C^-QP^A)F66JUZ*?2?U&\7:8M\$X M](M_4$L#!!0 ( 9"3% V/MVHK0$ )4# 9 >&PO=V]R:W-H965T MM/ =PH_^XM!C"TLM-1@OK2$.FH(^[$[G?<0GP$\)HU_9 M)'9RM?8Y.E_J@F91$"BH0F00>-S@$92*1"CC]\Q)EY(Q<6V_LG]*O6,O5^'A MT:I?L@Y=08^4U-"(084G.WZ&N9][2N;FO\(-%,*C$JQ16>73EU2##U;/+"A% MBY?IE":=XW1S?YC3MA/XG,"7!*P=>YD*)>4?11!E[NQ(W#3[7L1?O#MQG$T5 M@VD4Z0[%>XS>2GXXY.P6B6;,><+P_S#'!<.0?RG"MXJ<^0;!AVV"_:;*?2)X MMR8X9F]4;F%V;XJPU5@TN#8MA">5'4Q:QE5TV;D'GL;Z#SXM[#?A6FD\N=J M/R>-L+$V $K)[G +.GPCBZ.@"=$\H.VF39F<8/OY$;#E)99_ 5!+ P04 M" &0DQ0O!+A4.T! #I!0 &0 'AL+W=ORW&(NBAI:()]9#I^Y4C+=$JI(?L>@Y MD-*06HI]UXUQ2YH.Y:GI[7F>LI.D30=[[HA3VQ+^[QDH&S+DH4OCK3G64C=P MGO;D"#]!_NKW7%5X5BF;%CK1L,[A4&7HB[?=)1IO +\;&,1B[^@D!\;>=?&M MS)"K#0&%0FH%HI8S[(!2+:1L_)TTT?Q(35SN+^JO)KO*#P\6/U1/\3WC90+[/03?/N MS#V55JCN.?<3/\5G+31AGD>,O\1\1NS6B"">(5@9F%WX5A>^X8=+?G)E8H3$ M!M*-$"]QKWRL05'@WW 26)T$*R=^$M@%0JM ^#C*"(GN1UF#;D>)K$XB2Y30 M+A!;!>+'4=:0,+H*&PO=V]R:W-H965T!]J!\$2C/.7U[>TL=7UGY7ATIY=9'GA75Q#YR?AHY3K4]TCRIGMB) M%N+-GI5YPL5C>7"J4TF371V49PY!*'#R)"WLZ;@N>RVG8W;F65K0U]*JSGF> ME/]F-&/7B8WMSX(?Z>'(98$S'9^2 _U)^:_3:RF>G%N679K3HDI9895T/[&? M\6A#/!E0$[]3>JU:]Y9LRAMC[_)ALYO82"JB&=URF2(1EPN=TRR3F82.ORJI M?:M3!K;O/[.OZL:+QKPE%9VS[$^ZX\>)'=G6CNZ3<\9_L.N:J@;YMJ5:_XU> M:"9PJ434L6595?]:VW/%6:ZR""EY\M%8F$^$NLC21+\(1(F]*":1T1DP54:BI@!A-Z0)B8DWJ@#RK 7E> "9&768- M,5K7;2"&P)WG@L/LU@F\3@)7Z[R&"6JF:,8'XP A3?!R(+RY:PSX MT;VZ"&Q(Q+018SM=@U#/7DE@KR& U^"^+T_8&PC@#5CW3@6UN\5#IEL]Q+J" MX&5-@&6->RR8P,N5 ,L5ZQ:LH,Y&"#CP0ZP1Y+0.)3DM#_4IM[*V[%QP^>': M*KV=I)^)/-1HY7,\6F"@?(E'J^80])6^.;9_3\I#6E36&^/B*%4?>/:,<2K4 MHR>A^TB3W>TAHWLN;T-Q7S;'Y>:!LY/Z*\"Y_1\Q_0]02P,$% @ !D), M4 P-,I\W @ 2@< !D !X;"]W;W)K&ULC95O MKYL@%,:_BO']+H)_VUB3MX;!7S. M^3U'/5 .C+^(FA 9O+:T$YNPEK)? R".-6FQ>&(]Z=23,^,MEFK*+T#TG."3 M"6HI0%&4@18W75B59FW/JY)=)6TZLN>!N+8MYG^WA+)A$\+POO#<7&JI%T!5 M]OA"?A#YL]]S-0-SEE/3DDXTK LX.6_"CW"]@R; *'XU9!"+<:!+.3#VHB=? M3YLPTHX()4>I4V!UNY$=H51G4C[^3$G#F:D#E^-[]L^F>%7, 0NR8_1W=2+YMV99ZI:H59O50S3$MQTHDFS'35HH4&/BIVKB+-9 I2!V07RND F/GEP MD5DN1DUF-)W1P"3U0V(O)/9 <@LR:M(%!*TB/R3Q0A(/I+ @R?LAJ1>2>B K M"Y*^'Y)Y(9D+09$%R5Q(G/LAN1>2.Q 8VY7D#@2B%/DIA9=2>$J!%J5P*!]@ MG/@I*R]EY:%8C;)=N;7 Q?_Q0(&1OV,C#R>V6S9RRT%H9;>MF^JMEH)O;!_0 MR9#:WV_2+#NW*!PK;B+'"EAL:OJ4^8[YI>E$<&!2[8]F%SLS)HG*%SVITFMU ML,T32LY2#W,UYN/N/DXDZZ>3"\S'9_4/4$L#!!0 ( 9"3%#%I-;?30( M $0' 9 >&PO=V]R:W-H965T:-'SMED*T*P!X4>(:\0?:XD9^.5!6(R&W[ AXRS#::U)-0.!Y$-2H M:MPTT;$GEB;T)$C5X"?F\%-=(_9W@PGMUJ[OO@>>JV,I5 "D28N.^ 6+G^T3 MDSLPJ.RK&C>\HHW#\&'M/OJK+51X#?A5X8Z/UHZJ9$?IJ]I\VZ]=3QG"!!=" M*2#Y.N,,$Z*$I(T_O:8[I%3$\?I=_8NN7=:R0QQGE/RN]J),#.A'Q M3+NON*\G=IV^^._XC(F$*R M$/2$8"#(W+<(84\(+X3H)B'J"=%',\0](9YD *9VW5R%"NK3T=]D/[F,GM,PB!)P5D(]9F,PP0BS]*\AN0VY(( T,+@(YEQL M HL>7"?(;,1R LGOBFQOBES9#&>;%6I^=-6L>.+"8*#&-!H# ]_SO(D5&Q9_ M]L:P*SO1K)UHQ@Z)3'CVTW,RCX7S/QK)G8,N/[D_YO;$PT:5]V'Y+' MEME/B]"NZ:;254%PMB XT]W%I"!HGR*TK60V#'K0@N4?4]O>53/%@=$(J#$[ MZGG,G8*>&J%^\%%T&/F/@1HAD_C&7V7^3#R75X29Z!=Y<[_\0.Q8-=S942$' MEQXO!TH%ENZ]!WDNI;S2A@W!!Z&6"[EF9K";C:!M?V>!X>),_P%02P,$% M @ !D),4.6N#U%F @ ?0@ !D !X;"]W;W)K&ULE5;;CILP$/T5Q ?$F$N B" UB:I6:J5HJ[;/3N($M("I[83MW]X@MGYIP99FR2AO%7D5$JK;>RJ,3:SJ2L5PB)8T9+(A:LII5Z4DKD;/*XO2\MC_@U0[[VL @?N2T$8.Y MI4,Y,/:J%Y]/:]O1BFA!CU*[(&JXT2TM"NU)Z?C5.;5[3FTXG-^]?S3!JV . M1- M*W[F)YFM[E)22O+5C7IFQZ?S?S6 #MS-P>X,V.;,&7F?@/6O@=P;^R "UH9C<[(@D M:<)98_'V]=9$5Q%>^2K[1[UIDFV>J?0(M7M+/3=*T$T[ZC";%N,^8.)'S':* M<1\1NRDB^@M!2F2OU 65NL;>'ZKPG)&**<8/1C):R-) *@,)O0C#0CQ0B <( MP:.4M9A@P!)$GJ-^,)$/$OD T4S* M!! #CP1DJ#B5*,'6=>ZA)D6@),_HBI MQ40#)F<1!C!+"+*$_RZ!33AYOY$;S,02@2P1P#*JHDTTK:(YDA@DB0&2Y8@$ MPH0P"7;@[G:>J-4.]%"LP3L5@&=.$@QP38X2_!]%@.&# $,G03SC FYA_$P/ MXVD3>^_T,(:;&$-=/$E+"XH?TA)[D\2@P;&N+^:OA%_R2E@')M4-8<[Q,V.2 M*I_.0@G/U+= ORCH6>IIJ.:\O1#;A61U=]FC_HLC_0-02P,$% @ !D), M4/V#<&HN @ \08 !D !X;"]W;W)K&ULC571 MCILP$/P5Q ><$R"$1(!T"3JU4BM%5_7Z[)!-0&=CSG;"]>]K&T("\:&^8'N9 M&<\N>!TWC+^+ D ZGY14(G$+*>LU0B(O@&+QQ&JHU)LCXQ1+M>0G)&H.^&!( ME"!O-@L1Q67EIK&)[7@:L[,D904[[H@SI9C_W0!A3>+.W6O@M3P54@=0&M?X M!+] _JYW7*U0KW(H*52B9)7#X9BXS_-UMM)X W@KH1%WSZ_J+R9WE"]@R\J<\R")Q(]GT MKS0[P>L(7D]0>T\1_([@WPC!)"'H",%H!]2F8FJ388G3F+/&X>W7K;'^B>;K M0%4_UT%3;/-.E4>HZ"7U@UF,+EJHPVQ:C'>'B>9#2/8(N2&0,M"[\&PN-MX# MW1MNL'U$1"-(-B4R\.!;*^$;>C"HQ"C-C07C+T5_9&+#A*-,IC$#(Y'52&01^.*C MKJP"*XM -,JDQ80&4QG,Z"1F4XC6!+H[^!3XR315X>3L7$E]..ZB?=]^]G3C M&,4W\_6V;;\WF?8R^(GYJ:R$LV=2M273/(Z,25 &9T_JGRG4_=,O"!REGB[5 MG+==N%U(5G<7#.ION?0?4$L#!!0 ( 9"3%")WLK]TP$ &($ 9 M>&PO=V]R:W-H965T:L]DSIDYXYFFH](OI@&PY%6*SF2T ML;;?,V:*!B0W#ZJ'#K]42DMNT=0U,[T&7GJ0%"P*@G=,\K:C>>I])YVG:K"B M[>"DB1FDY/K/ 80:,QK2J^.YK1OK'"Q/>U[#=[ _^I-&BRTL92NA,ZWJB(8J MHT_A_IBX>!_PLX71K.[$*3DK]>*,+V5& U<0""BL8^!X7. (0C@B+./WS$F7 ME ZXOE_9/WGMJ.7,#1R5^-66MLGH(R4E5'P0]EF-GV'6LZ-D%O\5+B PW%6" M.0HEC/\EQ6"LDC,+EB+YZW2VG3_'F?\*VP9$,R!: )C[?X!X!L1O -]--E7F MI7[DEN>I5B/1TV/UW,U$N(^QF85S^M[Y;ZC6H/>2Q\F'E%T&POZ>T3=Y7K RB?Y1\K.T3(J_?C48 M#;YB7Y9QDO_UJT51K+Y^^S8/%GSIYYUTQ1-X,T^SI5_ /[.GM_DJXWZ8+S@O MEO';?K<[?KOTH^2K;[_)HV^_*;X]3X-RR9."S9*0721%5*S952)&B-*$';-\ MX6<\_^9M\>TW;[&/Z#=F'].D6.30)^3AYMMS'G38H.>Q?K=WLOGRDC]V6(]> M]KN-G@H>$XB?/D0)9U<%7^;_N]E!PGS'GZ*\R'SH>>TO^6:KJSR]\]<>C!IT M'"./J;QYMLHSS8? MG959AHN\C/( IOP;]S-$)#OWBP;HQ\?=\?&@@2@)]644\XR=0;^G-&N ?)TF MQWX0<&@#+4+1VK5^"=,=7Z590-Z8I\A*5T>8:PF4NR>:93=E MD1=^0GMS&"62E(]<&69U$:.K=7LE/ M-F;1PYBD<@D/&\AIY2;96\)B[?]#?_/)#+J&HGOL/S6(/BIBSM(YZ_4/'X_8 M/0_*#-#8('6Q,;G8F(-NI]OM.3;@*BF 3H,B>N:(*E^19'/()$_C*"22/O5C M/PDX[AXO'!T?L@ $Q/"S2,@?B:"#B^S*! M'>G:A9<:WL]SF.[KQFL_7S 8E 7XA?^CC)[]&-HW)ID% 8KSG&4\X-#H,>8> M2WACK5?),W2WL/9MQE=^%#+^!81^#L2.LZ;% J1!4(.QL6]I 930WN8V U62 MP9;@H+B*%9*!%<"[Z&E1(!F4.1>C43-V>)T6G)UL,AMJKJ_SE1_POWX%JBGG MV3/_ZEO6&)6#,(\"W&#$I!,K,!>(N,!.)S>$#;%" 12 ">*P7)8QT8Z_1$GW M"RD9.YKLZ%%$$$?^8Q1'1<2;E* W>.6O<7<)E3 YB+!JTS8[?> ^8%$-NW8A M$0>G<599"GR5QFI 5SO43ZGDK!<_AS'#*%^EN=]05GID?YVE( X1ZHP+=!7^ MER;(JL.S'[3@,6ABK+'V-'DZ!@&P;$7K=;7=3&#K@\)6 S+<.P"^B#).4BQ] MC*.G%B!;@$,I%A4XBF"T (P?T"H\":"QW*9)8YM(#2W2..19_M_$1\6Z*3+J M A+E(V _ X3&)7\'0JCK=<6/U%_,+XM%FD6_\/ =&T^\P73J=8<3]3;*<]P/ M$@>5_FL@)P2I")B 9:,8.0:!&/BKJ+!2A&:8D,^C(&HPFD!?;EGM5D03G+OT MO =Y#LU/&0B^.0<""(6R9S]]Y,M'GC4,PZH=H?8W4B*'MSZ^60!5@4+-4:L< ML+<.(WD#!*_:5S)'0F P/P,) 5**!F@04&. !@6TV35URMIW[GKO7S%QG2[W M[9;N9L.Y,+5]5E?/'2>NT1%:S%Q("5 U-RLTNX')@**L=HB"L<48&>SL9TT; M' .61V[5V6=I3KHPQQ:;+\%XSW/4+/,FHX-:!OLS$"9.R)]YG))ET!!J:$ MOQ9^MF:9HU,3*B#)QU2@C/D9.'-/7-L="&_&H^5CF>71E M&ZC1!A9I V*#&P'ASU'(+8RA!F#^:A6#+$83JTA!,0L98FB4S9ZG?AX%@CZB MN$2VI7&T)-Q1/G[F:/FBIGV&I<)&2FX&.SC$305(5B5A(%&@ZL$::&W"]#J1 M0_['99R^.$1.8ZC9_7?L\L/-YWMV>7?SD=W<7MS-'JZNW[/9V3 IV$.!?+Q2>XG=R@@@?CVN#/,D0M9MWYQR<@B 2Y.XP M:I&![%S9-$X- Q_1DQH>@ZP*G8>79W4[%T6!)=QF2K+M,P @O* M.@X9B\>//J(+:0>6;FUW1O.0UC!02DLB FJUGG?9E&TTX[["&#?2M!B^+T\NIZ=GVV!:>5;-12 MD8SW[8BD)09U.))-[0U)G"V>U?V" M.$H02\+(B M(]^V0QZC?;KXX=/5C[,/%]W5PRD)U7-^=- MFTF(QTA+H3T6B;L#,@O]S4KD/TIOA:+Z32:7'O<>D^2+](5D6&.JO*9=J/$< MM8O5+<>W!O'#1#9J:,"+"'I*(BVC*R-E(QI"H#?"30V]3)9CH4U_E#^Q'P@Q M#GHZD::DB^1WT[:D;"M)7/?T+\B#=1C][<%'EW>[M_MK!L2=C8PHP*V, IR) M*("SRQT8]5$"TU_X&7)0[FQ)=-@T=(AV<].^87[!S*!KPY/1G;8UO,I1I@5\ M4]SM(^W:+*_?8OQ=,7+/5[MA9+>&&Z.W>H[FZ*T-;^3" !DYACI?CX5;?ZW8 M2BDW83EH=Z#5HM].5(U(OHNHW U;-JAU]-T:MFQ0Z^BM##9/@M M>LA)834ML349;)=";H,8J-R+QMYG3WXB;6M0E%I*DO,.NV=.A!/;QF3G41Z MQU!F(CY^'X$B0,L-$](B@([4=0LC4Z#UIP?^I6"G,;#+;!].4BIA+>S :%G7A',-OJ$3T5LL%FE. N$J3S.58Q9Z-H(F+T"S\?H8 M%"P2[[\1H](_>.Y9FI)OE.YFC ME"\[;!8#5 ;J: %R:;3(4L6M,4.>HRY&RWP!GBN80AQL &C: M@371TW05)7([EW[BJ_ ,YFQ]PRE,.-!FCK&?N01\[D<96VU01,/:L.*X@A)L MQK@$.[.#FP)H02]A(5"Y:6X"+*@7<@ 2-! M,D_3(B$>@GU$!Q*67RP42HU=ZTW>8<^DI(@5YMMA\!A& !@NTVS)>EV425Q+ M#5JRL>!]T+;"3"&2F2F>$:"L5#$P$-88X2>JD!M3.3S4XN*+]&\I$Y+G%(ZZ MOS@[ZK S<+?0!XZ,B@TR_B0VT#V73 ZD@4V (?1F(G:L"]!@(UL #6SV>V1@2' 9HB1AA#Y M+%U&1=' %O*X%5](_?"Z?%JP%QPNCO@S"@60S#BSN7:4%GX(UCC&!11GF%@# M;&ELPB*@A?!-,%%9UC<5-&H,YB]PO) ?L 0<1_L+,H$A^FN2,SE0D!0\*&-A MW:=5N%H!)[KK?ARCI6L"$W]CQ0'KOFD4U)#2Z8/2N>8OIAB_QW"ZG]EB>;5V MX+\F\#TP.,PPM6L-]4;OKQGZ'2=\]H>?5B&1SRQ,B>) )E[RQZQ$.0<\.B9. M';-NGTV'?53+9!:SWDC83D#E65Z8;-WO=MIG@LT\Y1@]91=@.XGT+6#@LBQ0 M8=[*S0$XKM-G,1E.)*?#+]/NE'[&78 ./CH-L$X\)M/D%2"Y!H3(V!# PJ-" MNLS252KC'9>S^U/1,DR)-HP?*VD,@#0^8)@05B \I\UFVK?0+5ZQP8..F&6E MQVA&6;F:Z!#CED=&$!A_ C\.9.83UDEVJ8KGBJBVZN8_^U'<$H+&[LA/+YLQ MXZ2DS3#!-2786U?XIBT]N.;XS1'9;4_MSICW,U48(?G2"_YO).?:B M?.RQUYUVY6>M!; (29*A-Q[UV, [Z4V8"$RL@ 2 SN ;;0+2=%X!WNMZDY,N M_NJ.QHVR$"*?(9"/LRQ&OS!-R_UI9]BIIC"^H=I%KR946G(.QEWZ0KMD0WA- MA[/#>HOZ2_JX\U\PD@D[X<(ZJ&AFE#0[8:#C"ST%W*R@7218%"XHV95&YK!7:P! ]D'3X M.:G#7&_6@YV?-L'9&*D_P<_1B-FK>M! $NHG9UD-/R1S7L!P!HD4*FEDH4U?%K!")B+N&,!7)5&8PX,Q0+.(&!@%4,40 MT"D"8Q?9:U8^@<'+^D*.3CS6 ZSV /U#JM6 ;QV ,.- WM&7)FW@&G&SL(?E MY?1D" *;%2\\!@:9#H:;C5!Y)*CLHRS$0:RL,@)6J=5R7;1$TZF5QVYC7R)! M-_YUO#3J.&!@]C*SWYW+/N!TP%;CL?RL(!IXT\D /_LC45Z$ IQ%2PQQ2W-D MZ/6& _DI5&L3OL,C).M6.U-4Z)STV(SEY7*)?@0NL68_ MH;OKB!\X 5B!!*<0A&UJINL6])>9-$:OM3%Z\85G093CG'@H(BA*.AA1P/ZA M!>U8%;N10(-?!I[Z ]9R'F+!.EC(/U+EF5F0+RS# ]89#]FD,\0-'<)._\A) M\I.T [13D@H4.6:5=NI"@!/]]KV3$3;I3$"5=B;8L0?VU .&VH390/K3S>&> MV78@2C#!3J'?![V>^#WJT^^=Q]EG3K00]A_>S5NUED.QH/Y@XHUH08(>#Z9" M,^PXRM3KCX2YOGN?_I@Z3<#4'[5WLJJG":BGS7K<,[,>=UOQ;JWQK[-M)IUV M4# H7( "9ZK8@,V>8"?E":=JW;#V8 IZFFS'CR37)$(F7JWMN($Q .0F M*%)Z/Z@LTJ9M.35B /VAY_0)"08%RS&-6:J0B,/HL(1#?0 MR;K#9O;)*(Y1A0K%$- ???",@UVI_1\<&M:)@E9,"3(^2E9E(1PM ,;,,,^^MI$K]6$%RKU TW;D[_[\O> .4_5H/T.MG77^'U,/_7Y MZL;OZ^<:>8/^V/@MYGJPT$#@& 40"E9%666/C*V1.RP!LS+'"4;.T"VQG!R! M[><>JTH\1;M7< .PL>QKK(SAJ5'TI0%L#$*$ISVX@-5_=R!'PXV2^BQSX N:%:H\#0VJ>9X MY(&_Y%6@FL(*F%XME&3I@ASL"0TM1"H*0@ HBV(5= 62DUXU:AX26%)84:N^ M:#6N_HU/A*G$P;B3:A.EHO##^QV*]PK!J,T[UNOTJQ&&Z'%AOPX;OW$$YX:= M ;ST,/]C^!Z.V,'!9"#-D"&I:W@R&BO#I&>8#*[^VHSIGFQKW;$ >ZC/K.*F MUF+:[!!D ! *14KQW.Y2&//2EU]#/RR"Z8&[C+O!^B==0J/Z,E!?AFB;2&[M M@<70)]_Y:W:%=;44?Y?E>H>]P1 \9<77M4-!T+,')B)YW3HI@D6AZ&SW^R?0 MK^5($;IOTQ,A6L'7T-6@-U5-MLDCH."!Z=M+N&=W-T?8(D677W*]E*22RJ-" M01JO10U43@G8($T2;N0I25XWRDK1! Y*FVTA+#N<#!A62$EJ.M7SCL8#G+T[)BRG602@ MP197,H?&>L%D*X8JRUCX"N W .95[F^>EJBIT6KJN-AACEX>\(1D"LE<#FXX MF'2%J3SJ]!S)+_#WCZTU88WP"3I[FW5C-,2O,DMA_DYM?JF8U PW2445@ MFGFH&L ]&77?@ (=F9.Q[_V$TFC*L-QX *+@D T&NL?) %L=J(E"3$T\$2% MQQ.8VT\(:I5I42F6.67Z:V5*0L_Z;,5,7J&9I" MRK:>4R(10P6J&CC'TU?1:D6V-HXFZV@2$!@Y%1UC$^IC)*F%-:+S :+0K,.^ M UOVF6=$FE@L6JU+YRDWTY7T(_="3("E+7H"*O=9K_#D7[PV(UXRV0^2CIL@ MD[J"O$($ M'MH$(L-]Z& FG71QHHRR/?N?;PVXBORF_>6T-H SUU)87Z'G5[.W7)&(ZLK%2Z@S)9 &#\&LRIN).5U M!LAJ!$7+D52H*UG4ORGC09\=3R8;FRH$]JDJ>:*DR>\@J MJ$96:40>$\':0>2!I(X*N0/2:9YK%#GPH)@3M:DX48):*=.WG,@2&P!0KX-% M/>SCG.33%;G6N)*P2YKIE\WED\1?UB#*)D.S/0(>,YX40/# M\[0B?BZL"@T^AN_+K#ZX.K7H)^*,G)3.(AN2D1VT7*&91RGG7/*FD@!4N ;F M(4^*2L)4$]X KI_ V%@1K.JQIPQYY!4T!1;K/ )# HL M-MP&Z>X@/F= W[J2QB@!NO@BR47:E.@UZ[VQ%EB1Y;NWD?F'*B=R[H:)<:-. M15T4\9L@[]];$+3CBJ\K+_#W6O2_H?1HS^H9)YFTE]'\7@C[PQ:T[%V>XN;? M]CH5CVP/*@$GTT@<@D/?SF,S*KY^]>;]DE)=!A MH:]?7,?.H'(Y_Z425O@3#N M=+)6G#%[[5[^D;.C6_*8SFUQ)#2]*CGCL8_JTH?7(OX_*8G51O=G5YW!ID=GN.- M N#=X!I!036OY]5GGZ[$H9L'_PN8_C!H_6H-#YW9@(PYZ]4#>/7LFUV]\F.G M7ZW@/=)W8^]RCUMM-,-!;;EL0(89G?9W7:P#N M/FJ'OW7KVMS339YRWP!FWKCE8!SA%+HO&J&2)A'_!<0!2$\9:BIGA\JYDJ'G MNRI), N?20*C^YRHD.@YQ\HS"GGLBPEP%:O2ZBW8VN>6%KL/^Y19KK1K=9 ; MC7%$%^:,2(*C1>7B7YDNOJOY3[W&HRL19TRSY00A:#?1L[I*0)V?EL>L]!A5)S/3*DY-KF*N MCYR+\2@DO>:4(7CD%<#P3QW6UJ9<*.]=-)-6=+&2D8&=IQFG\UJAY7HZBE&K M,]DR(8Q7,N2I$;&W6?4X?-WVIH) XHC- B%?LL7*9(M0L,4+2M2T?D8 U33^ MJ'K$A+]8J_9@X>HLD+V2I3W8LKN8V:JL0#H_"P=0NM(45@ 8:"?O-&I5/,8A MJW[#>>3EOYB@,:ZHVIQP,.@##:V;(?H=H@F[!A.4'T\FQJWUNK+?Q];PMZ:[;V<=45!H$16RQTK+"A "84-,$\U<0J+VN31#I& M*:H\ +K-]BT!1J_:QQVPUCK0;XC%W>;9$ZNM@^Z+Q2KFNC?>=-??#V6V*?;$ MUEC28']T8J5!UWP[('*WDVG;@QV]G>]['S6W[?ALE:G; M ?M#IY/>U![SXB]_[DVF[]K:3AWC?5_&C?&L;;K;VACW)CK:- +X]!>#CM/Y M\2>D5=L5KFTQ?WN$8K-#(REVK@+&&#C4D<*&@+"%"+\W][OF)*O.%WX6KYD)LPO2W8[\.>\A!CH4=>U8!4J7 M %;!NG\REZC;E+7'ZFJTS<5)ATRJKHWTV/Z^TJX90DN_QKE.S!I:G@TLSX8V M5FRF$NT!ZQVX>C.WN!W=;=E""UHW!VPD_"P,T,SY-8/L9N[.GGURG<=J"V'9 M?;]M?SLP[NA359:HL7$OOWF7M'E9=\,QQQ/"V$CE@S >A3+?,RH]C/S4F4]5 M[X_KZJR2ZF&)8XMS7+?Z@G2G_T[^\96X %">MU#1(?'7-CVZ3I%:V$-%N>SN MR<(2Y^U_FENU7ZYQ1?F"K1BZT1B:Z;]7I74^*.R&=K*F!EL0KPMKQ$JJ-J_" M-4BX[SIG>*X@2E[$!?%GD!=1GF[PAYKV>#Y3U/GP!G"W QS]4I!C*"T*# (+\[(+?UX* G M2\%Q(U%@YQ@)>_"_.&SI'6CJN*W87\M]%ZA63.I3CBVHA&9M50EBZRZKJ@07 MSJA:H;$%5+M@/'V;Y\6W_P=02P,$% @ !D),4&H+GYM% @ X H T M !X;"]S='EL97,N>&ULU59M:]LP$/XK0AFCA5';:9.RU39LA<)@*X7FP[X5 MQ3[; KUXLIPY_?63++\D'NO6K!O+E^CN.=USCUZ<4UCI+8/[ D"CAC-11;C0 MNGSG>552 "?5F2Q!F$@F%2?:N"KWJE(!22N;Q)DW]_VEQPD5. Y%S6^XKE B M:Z$C?#% R.5?RQ0B_'#R^FLM]=4KY,;9F]G,?SB]FN(G;> 4(\?Q,8UPL+S MWN^3GOG^SXEM<$*^>";Y4]P3ZN5S=3\M?$I_:>F];O_C,)-B/(9S[ !3GW! M&\(B?$T872MJLS+"*=LZ>&Z!1#*ID#;G;_0%%JD>73APGKT:'0^G0JJVMJO@ M?M?=]$F@]ZQ RM@@<(X=$(V%'+TK-!K24W1DI)+@5I-?09G6%H$V#LWGXW M7[(][B9#;HX]$A\CJZ(WS:H[:7WN<>2VW^5 MJ> 7U&B[X!&(7!R#R.4QB/S;=]+KVLY.;]OK; .*UC5EFHI.;D'3%)P>^[2( M\*U]V;"]_C(V.$.OR=H\-_?X36X*&:F9OK-+;(,1'NU/5GBP'&:M!HH(C_9G M2&G-W[8%QS=M_!U02P,$% @ !T),4+:_@8O: P $AP \ !X;"]W M;W)K8F]O:RYX;6S%F5MOVR 4@/\*\LNZARXQ=M*+FDI=NDNDK:O6JGN"/]JGZ_Z0,"CPP*_9[2P;9X1U3K\7TG%SSAS_8'2W$NINEN49 M60ICW96O.Y1LA1*M^,WK<&0;_?A1&_%;*\?D566TE.$N?R'^=F4;L;(94:SELVQ3A)RIFKQ3#FC(0JT?!67]NT#5BWK] M7@XB]@1+S+& "V91YQY\>Y!S.-92U%![3=XRR53%20BY)7OS+H*D""3=(>1W M&D$6"&21$/+*0_@;+-%+\F7%3019(I#ESB#GS#81Y 2!G.P",C V3-U%D%,$ MXSE[7$" ML@F0@:1;MDS //)#&MBXC;$PK>1;]LHZ98\WG;'1LN;&O@J#QO4&-N:5/(E8 M\M 7E3,PP[;DFW -F7?6Z3;&Q-22IW#+OVF;[,%47?;;')-+GL(NO02^(7P= M(V**R5,X9BB3]V:W%!,.32&Q\2$0U,(9RA%]C'1%4T*X3RER)F@*]3S'O-"J6I/&F)AZ: KU#.;U(L;$]$-WJI\RWES!]%/L M5#]Q- M,/\4NUSO]:&+Z*5+H9Q!S$F.B6VHI+#2T+.MO_&$6*E)8:'#.T>N; MF(6*%!:*YQSGW#$A+;GF/UW'8DS,0D4*"T68$-;.02C#-BJ+TWN!6:A(8:$> MYIFU4-=7[@2T>XR)6:A(8:'!16\\0RHP"Q4I+#0XWXR'4(E9J$QAH4',.+V7 MF(7*8*'1YAM4S9="\?H"JK!POF*RNC3$_ZPWQLJ)7Z N.RGG<.Z+^J19^&KD MG['Y''?Z!U!+ P04 " '0DQ03!)+6JH! !P&0 &@ 'AL+U]R96QS M+W=O8D$9>8+@0]+W+S;*@UEV_BB[/SL7%>-WT9%"-VK M,3XK;)WZE[:S3?_-L75U&OI;EYLNS4YI;@W'\<*X\8QHMQG/G.T/V\CM#Q3- M/E.7V["-S+DRWZT[^<+:X,WP02_]@OXGE\[^9WU[/):9?6NSK]HVX4;%WX+( MW [BZ2"&!\ETD,"#DNF@!!XTGPZ:PX,6TT$+>-!R.F@)#UI-!ZW@0>OIH#4\ MB&)%QAB?I&&-UYH4K@GO-2E@$UYL4L@FO-FDH$UXM4EAF_!NDP(WX>4FA6[" MVTT*WH37FQ6]&:\W*WKS$\[:VF$;KSC->;U;T9KS>K.C->+U9T9OQ>K.B M-^/U9D5OQNO-BMZ,UUL4O06OMRAZ"UYO4?26)[PKT5Z6X/4616_!ZRV*WH+7 M6Q2]!:^W*'H+7F]1]!:\WJ+H+7B]$T7O!*]WHNB=X/5.1GK[(G7V\!%3^ MT257P^_6C.#VX5+9QV<,4^_N'RD=^BW6#->'/Y9AZF^$N?J#9?<#4$L#!!0 M ( ="3%#AC\E6JP$ +<9 3 6T-O;G1E;G1?5'EP97-=+GAM;,V9 MWV["(!2'7\7T=K$(./P'6'BVQ+030Z=N/5ETRTR4N:O*[*84# MYWQ0\MUT_+&UY'N;JJS])"E"L(^,^:R@2OG46*IC9&YB')DI)XFRMM29"MK4;%WG1TG[^X2IH[*= MXPMM_4V-C&+CV.3)$9]PDZH<+RPZ<=U;VMR3N?T+S0SG^N,F7'A554S,-B7[-2&]'D?8EM0-T$8N63G$ M:T%=I=K [LG/*GBX#9EQU+,DM4G-U
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end XML 56 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 5 - Property and Equipment (Details Textual) - USD ($)
6 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Jun. 30, 2019

Depreciation, Total $ 77,000 $ 65,000

Other [Member]

Depreciation, Total 0

Construction in Progress [Member]

Capitalized Costs Related to Advance Planning and Design Work $ 207,000 $ 207,000

X

- Definition
The amount of costs capitalized related to advace planning and design work.
+ References
No definition available.
+ Details

Name: isr_CapitalizedCostsRelatedToAdvancePlanningAndDesignWork

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=isr_OtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 6 - Share-Based Compensation (Tables)
6 Months Ended

Dec. 31, 2019

Notes Tables

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

Three Months
ended December 31,

2019

2018

Cost of sales
$
8
$
10

Research and development expenses

19

18

Sales and marketing expenses

24

22

General and administrative expenses

43

47

Total share-based compensation
$
94
$
97

Six Months
ended December 31,

2019

2018

Cost of sales
$
16
$
20

Research and development expenses

38

36

Sales and marketing expenses

49

44

General and administrative expenses

82

90

Total share-based compensation
$
185
$
190

Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]

Weighted

Weighted

Average

Number of

Exercise

Contractual

Intrinsic

As of December 31, 2019

Options

Price

Term (Years)

Value

Outstanding

4,651
$
.64

7.46
$
418

Vested and expected to vest

4,651
$
.64

7.46
$
418

Vested and exercisable

2,956
$
.74

6.71
$
172

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note 1 - Basis of Presentation (Details Textual)
6 Months Ended

Dec. 31, 2019

Effective Income Tax Rate Reconciliation, Percent, Total 0.00%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2019	Jun. 30, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	67,388,047	67,388,047
Common stock, shares outstanding (in shares)	67,388,047	67,388,047
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065

Note 9 - Leases - Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
2020 (remaining nine months of the year)	$ 145
2021	290
2022	290
2023	290
2024	237
Total	1,252
Less: Imputed Interest	(134)
Total Lease Liability	1,118
Less current portion	(229)
Non-current Lease Liability	$ 889

Note 6 - Share-Based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Dec. 31, 2019 USD ($) $ / shares shares
Outstanding (in shares) \| shares	4,651
Outstanding, weighted exercise price (in dollars per share) \| $ / shares	$ 0.64
Outstanding, weighted average contractual term (Year)	7 years 167 days
Outstanding, intrinsic value \| $	$ 418
Vested and expected to vest, Options (in shares) \| shares	4,651
Vested and expected to vest, weighted exercise price (in dollars per share) \| $ / shares	$ 0.64
Vested and expected to vest, weighted average contractual term (Year)	7 years 167 days
Vested and expected to vest, intrinsic value \| $	$ 418
Vested and exercisable (in shares) \| shares	2,956
Vested and exercisable, weighted exercise price (in dollars per share) \| $ / shares	$ 0.74
Vested and exercisable, weighted average contractual term (Year)	6 years 259 days
Vested and exercisable, intrinsic value \| $	$ 172

Note 11 - Contracts With Customers - Concentration of Customers (Details)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| El Camino, Los Gatos, & Other Facilities [Member]
Concentration Risk, Percentage	23.60%	22.26%

Note 4 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Total inventory, non-current	$ 127	$ 155
Enriched Barium Inventory [Member]
Total inventory, non-current	116	117
Raw Materials [Member]
Total inventory, non-current	$ 11	$ 38

Note 10 - Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Jul. 11, 2018	Dec. 31, 2019	Dec. 31, 2018
Proceeds from Issuance of Common Stock			$ 7,381
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,830,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	11,000,000
Shares Issued, Price Per Share	$ 0.75
Proceeds from Issuance of Common Stock	$ 8,250
Payments of Stock Issuance Costs	$ 750
Class of Warrant Or Right, Authorized, Percentage	50.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Private Placement [Member] \| H.C. Wainwright & Co., LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	330,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.9375

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Dec. 31, 2019	Feb. 11, 2020
Document Information [Line Items]
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	0000728387
Trading Symbol	isr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		67,650,547
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common stock, $0.001
Entity Interactive Data Current	Yes

Note 1 - Basis of Presentation (Details Textual)	6 Months Ended
Note 1 - Basis of Presentation (Details Textual)	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%